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Abstract
Neisseria meningitidis is an important human pathogen and a major cause of septicaemia and 
meningitis worldwide. The immunodominant antigen of N. meningitidis is the highly variable 
OMP, PorA and detection of serum anti-PorA antibodies (IgG) is classically performed through use 
of the enzyme-linked immunosorbent assay (ELISA). Whilst sensitive and reliable, these methods 
are labour and reagent intensive particularly for detection of multiple anti-PorA antibodies within 
a single serum sample.
This thesis describes the development and evaluation of an assay for simultaneous detection of 
antibodies directed to eight serosubtypes of PorA. A panel of purified meningococcal proteins 
were developed including seven serosubtypes of PorA along with a variable regions 1 and 2 
deleted mutant; three serotypes of PorB and five variants of FetA. PorA proteins were conjugated 
to  fluorescent microsphere sets and assessed using serum from a range of sources including 
preclinical and clinical trials and carriage and seroepidemiology studies.
No evidence of microsphere interference was observed between monoplex and multiplex assays 
over a range of dilutions. The multiplex assay was specific; sensitive, with low limits of detection 
(<176.88 pg/ml); and reproducible for the measurement of serotype specific anti-PorA antibodies, 
with low intra- and inter-assay variability.
Increases in serum IgG against specific PorA serosubtypes were detected using the assay in serum 
from a range of sources. However with the complexity of adult serum, it is difficult to distinguish 
between pre-existing and induced responses and may result in what appear to be non-specific 
responses. Lack of a suitable human standard has hindered the quantification of antibodies and 
an arbitrary concentration was assigned for each PorA serosubtype. However, advantages of 
small sera volumes, high throughput of sera, simplicity o f the assay, and the ability to extend the 
assay, make the PorA multiplex assay a viable alternative to the standard ELISA.
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Chapter 1 Introduction
1.1 Meningococcal Disease
Neisseria meningitidis is an important human pathogen and is a major cause of septicaemia and 
meningitis worldwide. Symptoms of meningitis, characterised as inflammation of the meninges, 
the membrane surrounding the brain and the spinal cord, include a rash, severe throbbing 
headache, stiff neck, photophobia, and fever, leading to confusion and coma(87). Symptoms of 
septicaemia, characterised as an uncontrollable multiplication of bacteria in the blood, include 
rash, fever, chills, severe muscle pain in the back or thighs, joint pains and breathlessness(130).
Meningococcal disease can appear as either meningitis, septicaemia or a combination of both. 
This disease is known to develop rapidly and death in previously healthy individuals can occur 
within 24 -  48 hours from the onset of disease. High case fatality rates are associated with 
meningococcal disease (5 -  15 %) even with rapid diagnosis, and the prompt administration of 
antibiotics*117'159'293*. Mortality can be reduced with optimal intensive care and disease 
treatm ent*29*, however up to 2 0  % of disease survivors are often left with severe debilitating tissue 
and neurological sequelae including mental retardation, loss of limbs and neurosensory hearing 
loss*81'219*. Age specific attack rates are highest in infancy and decline during childhood with a 
second peak in teenagers and young adults, conversely the rate of meningococcal carriage is 
lowest in infants and young children and highest in teenagers and young adults*109'256*. The three  
main causative pathogens of bacterial meningitis were Haemophilus influenzae type b (Hib), 
Streptococcus pneumoniae and N. meningitidis{270). However, the introduction of the Hib 
conjugate vaccine and the 5. pneumoniae conjugate vaccine has resulted in declines in meningitis 
caused by these bacteria and N. meningitidis is now the leading cause of bacterial meningitis in 
the world*223'58*.
Onset of meningococcal disease may occur 1 - 1 4  days following acquisition of the  
meningococcus, and it is only when the bacterium crosses through the mucosal epithelium into 
the blood stream that illness occurs*17'356*. Invasive infection with N. meningitidis can result in
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various forms of disease including meningitis, severe sepsis and septic arthritis, pneumonia, 
purulent pericarditis and conjunctivitis, although the latter four presentations are rare(356). 
Survivors of a meningococcal infection usually remain protected from further infection for life*163*.
1.2 Meningococcal Carriage
The only known reservoir of N. meningitidis is the human nasopharynx and colonisation by 
meningococci, resulting in asymptomatic carriage as opposed to disease, is essential for 
meningococcal survival and the first step of pathogenesis*46'356*. N. meningitidis may be carried 
asymptomatically by as many as 5 -  25 % of the population at any time*49* with the rate of 
nasopharyngeal carriage lowest in young children (2 %) and highest (up to 25 %) in adolescents 
and young adults*109'43'286'302*. Carriage rates in the older population are less than 10 %*43,46*. 
Increased rates of meningococcal carriage have been found in closed populations such as military 
recruits and college and university students as a consequence of closed, crowded living conditions 
and mixing with new communities*43'287'36*. Other risk factors for meningococcal carriage include 
co-infections such as influenza and other respiratory viral infections, smoking and damage to the 
upper respiratory tract*288,36'183*. Social factors including attendance at pubs/clubs, and intimate  
kissing were all found to be highly associated with the risk of meningococcal carriage in British 
teenagers*183*. Carriage may be prolonged (lasting a few months), interm ittent (lasting days to 
several weeks) or transient*35'286*.
Carriage is an important part of the transmission of pathogenic strains of meningococci, where 
infection is usually from within the healthy population rather than from individuals with the  
disease*113'46'36*. Thus, an understanding of transmission of meningococci isolates is important for 
understanding the best way to manage the disease. Transmission of meningococci is via direct 
contact or inhalation of meningococci through very close and prolonged contact with droplets 
shed from the nose and the throat*87*.
Carriage is itself an immunising event*114* leading to the development of bactericidal antibodies 
against capsular and noncapsular antigens*113*. Several studies have reported a correlation
21 | P a g e
between the detection of carriage and an increase in the detection of bactericidal antibodies 
against the colonising strain*152'153*. High levels of protective antibody may be produced for 
several months following clearance of the carriage strain*114'152*. However, whilst colonisation is 
beneficial in the induction of an immune response, carriage is not protective against colonisation 
with heterologous strains and is not always protective against invasive disease *8*.
1.3 Microbiology
N. meningitidis is a Gram negative aerobic diplococcus*137*, classified as a proteobacteria belonging 
to the kingdom Bacteria. It is further classified in the Neisseriales and Neisseriacaeae order and 
family respectively. Gram negative bacteria have a thin peptidoglycan cell wall situated in the  
periplasmic space between the inner and outer cell membrane (Figure 1.1). Gram positive 
bacteria have a thicker peptidoglycan cell wall but do not have an outer cell membrane. The 
outermost structure of meningococci is a polysaccharide capsule and is the target for mucosal and 
humoral immunity*113,114*. The polysaccharide capsule is used both as an epidemiological marker 
and a vaccine target*292*.
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Figure 1.1 Surface structure of N. meningitidis. Source: Chiron Vaccines 
(h ttp ://m en ing itis .ave nu e -e .de /? idca tl= 50 ).
The polysaccharide capsule is an im portan t viru lence fac to r o f the  meningococcus. Disease 
associated capsules have antiphagocytic properties essential fo r bacterial survival in the  blood 
stream (145) a ffo rd ing  the  bacterium  p ro tection  against environm enta l factors, the re fo re  a llow ing 
g row th  and spread(310). Conversely, expression o f the  capsular polysaccharide inh ib its 
colonisation o f the nasopharynx by masking meningococcal adhesins/invasins, suggesting th a t 
capsule expression may be dow n regulated during the  in itia l stage o f in fec tion (131). W hile  the  loss 
o f capsule enhances the  capability o f meningococci to  colonise the  human nasopharynx and to  
avoid human defence systems, reports o f disease caused by unencapsulated meningococci are 
very rare(132'337).
1.3.1 Capsule structure
The biochem ical com position o f the  polysaccharide capsule is used to  classify the  species into
tw e lve  serogroups (328) o f which five have been extensively studied. The serogroup A capsule is
composed o f repeating units o f (a lH >6)-linked N -ace ty l-D -m annosam ine-l-phospha te  (291). In
contrast, serogroup B, C, Y and W  capsules are composed of, o r contain polysialic acid (291) and are
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biochemically similar. Serogroup B and C capsules are polysialic acid homopolymers, but whilst 
the C serogroup contains both the N-and the O-acetyl groups, the B serogroup contains only the 
N-acetyl groups(177). Serogroup Y and W  capsules consist of sialic acid linked to D-glucose and D- 
galactose, respectively*308*. Serogroup B capsular polysaccharide is poorly immunogenic in 
humans and is structurally similar to the certain human glycoproteins. As a result, the perceived 
risk of autoimmune response is greatly increased if this capsular polysaccharide were to be used 
as a vaccine*221,231*. Notably however, no autoimmune disorders associated with antibodies to the 
serogroup B capsule polysaccharide have been reported*284,363*. Whilst increased titres of 
antibodies reactive to the serogroup B capsule have been observed following colonisation with a 
serogroup B meningococci, these responses have been transitory, and the subsequent decline in 
anticapsular antibodies was not accompanied by a corresponding decline in bactericidal 
activity*153*. This corresponds to previous studies where PorA is the major antigen associated with 
the production of a bactericidal immune response(347).
1.4 Epidemiology
Meningococcal disease is a significant worldwide health problem occurring as either a sporadic 
disease, affecting mainly children and adolescents, or in pandemic waves*223*. There are an 
estimated 500,000 cases per year, resulting in at least 50,000 deaths and a similar number of 
cases of neurological damage(22). Epidemiology of meningitis is variable with morbidity ranging 
from 0.2 to 4.7 cases per 100,000 inhabitants in industrialised nations. In sub-Saharan Africa and 
the countries of the meningitis belt, epidemics involve from 1 0 0  up to 1 ,0 0 0  cases per 1 0 0 ,0 0 0  
population*134*.
Although meningococci can be classified into twelve different serogroups, only six serogroups are 
associated with 90 % of severe meningitis and septicaemia, i.e. serogroups A, B, C, Y, W  and 
x(226,257,28). Five of these serogroups have been studied extensively; however the emergence of 
serogroup X as a disease causing strain, and its ability to cause epidemics is a more recent 
discovery(28,72).
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The different serogroups, whilst having a similar mode of action, have been shown to have 
differing effects, and have variable prevalence in different parts of the world(244). Serogroup A is 
thought to be responsible for 80 - 85 % of meningococcal disease cases found in the sub-Saharan 
meningitis belt and Asia. Outbreaks of serogroup A disease tend to occur in irregular 8 - 1 0  year 
cycles, and last 2 - 3  years, predominantly peaking in March -  April, at the end of the dry season, 
and dying out with the outset of the rainy season(133,22). More than half the cases occur in 
individuals younger than 15 years of age. China, India, Nepal and Mongolia have also seen 
epidemics due to serogroup A meningococci(142'52'338). Since World W ar II, large outbreaks of 
meningococcal disease caused by serogroup A have not occurred in Europe or the United States 
(245) and this strain is now rarely seen to cause disease in Western countries(127,134). However, 
serogroup A meningococci have been associated with several epidemics within Europe since the  
1960's. An epidemic in Russia from 1969 onwards was found to result from a spread of an 
epidemic strain of serogroup A meningococci from China and was associated with migration(6). 
This strain persisted in Russia into the late 1990s. A serogroup A epidemic associated with an 
identical clone to that of the Russian epidemic was also experienced in Finland in 1973 -  1977(224), 
and in western Norway in 1969(138). Serogroup A epidemics have also been reported in Greece in 
1968(327) and Romania in 1970, with a second epidemic in Romania from 1985 -  1987(202). An 
epidemic of serogroup A disease was reported amongst the indigenous population of central 
Australia from 1987 -  1991, and was found to closely resemble outbreaks in sub-Saharan 
Africa(220). Serogroup B and C outbreaks are more common in Europe, the Americas and 
Australasia although incidence of serogroup C disease has decreased due to the use of the 
meningococcal serogroup C conjugate vaccine (MCC). Serogroup B accounts for 30 -  40 % of 
cases in North America, and up to 80 % of cases in Europe(273'244). Serogroup C is responsible for 
the majority of the remaining cases. The case fatality and incidence of serogroup B and C disease 
are higher for young children and adolescents, than in newborns and the elderly in all 
countries(22). The highest specific incidence of meningococcal disease occurred in infants <1 year 
of age(256), with a higher proportion of serogroup B disease observed in this age group in
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comparison to cases due to other serogroups (Figure 1.2). However, a shift in the age distribution 
of meningococcal disease towards higher age groups (> 2 0  years of age) can be observed during 
outbreaks and epidemics(225,71). Serogroup B isolates are responsible for severe persistent 
epidemics, many of which occurred in Latin American countries (Cuba, Columbia, Chile and Brazil); 
Norway and New Zealand. In many cases these have lasted for more than 10 years(45,262'16,22). 
These periods of hyperendemicity are a helpful way of distinguishing between serogroup B 
infection activity and infections due to other serogroups, e.g. serogroup A. Disease caused by 
serogroup B meningococci is rarely seen in Africa and other developing countries.
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Figure 1.2 Incidence of meningococcal disease in Europe in 2006. Data is representative of 27 
countries participating in EU-IBIS(134).
Serogroup Y meningococci have recently emerged as a causative agent, initially mainly in North 
America, since the 1990s(256). Throughout 2006, enhanced surveillance has also revealed an 
increase in disease incidence due to serogroup Y in England and Wales(165), and northern 
Europe(136>. Whilst serogroup W  organisms are a relatively rare cause of endemic disease, these 
have been associated with outbreaks, for example with the Hajj in 2000(7), and an epidemic in 
Burkina Faso in 2002(69). Serogroup X meningococci were identified as the disease causing strain 
following a large epidemic of meningococcal disease in Niger in 2006(28).
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1.5 Immunological Typing
Im m unological approaches were the  firs t m ethods to  be w ide ly accepted fo r  meningococci 
typ ing (101). These included the  iden tifica tion  o f the serogroup, based on the meningococcal 
capsule13281, serotypes and serosubtypes, based on the o u te r m em brane proteins (OMPs) PorB 
and PorA, respectively*981. For example a strain w ith  serogroup B, serotype 2a and serosubtype 
P I.5,2 w ou ld  be designated B:2a:P1.5,2. The im m unotype, based on the  lipopolysaccharide (LPS) 
can also be used fo r fu rth e r strain resolution*3061 how ever th is is now not com m only used (Figure 
1.3).
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Figure 1.3 Surface structures of N. meningitidis including those used for serological 
classification*2631.
1.5.1 Outer membrane proteins
The ou te r m em brane o f the meningococcus consists o f a lipid bilayer, em bedded w ith  a complex 
range o f m em brane proteins essential fo r selective perm eab ility  and fo r m ain ta in ing  the 
structura l in teg rity  o f the m em brane. In early studies meningococcal OMPs were categorised in 
five main classes, designated class 1 to  class 5, based on d ifferences in m olecu lar w eight*305,991.
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The class 1 and class 2 /3  proteins are the most abundant and immunogenic OMPs in pathogenic 
Neisseria species, and are found in all Gram negative bacteria*1431. PorA, previously known as the 
class 1 protein, and PorB, previously known as the class 2 /3  protein act as selective channels, 
allowing the passive passage of ions across the cell membrane*101'1431. Although the function of 
the class 4 Reduction modifiable protein (Rmp) is not known, it is suggested that RmpM is 
involved with peptidoglycan binding, acting as a bridge to anchor the peptidoglycan to the outer 
membrane through the formation of stabilized heterooligomeric complexes with PorA and 
PorB*1431. RmpM is also associated with iron regulated proteins, lactoferrin binding protein (LbpA), 
transferring binding protein (TbpA) and FetA (also known as FrpB), again resulting in the 
formation of oligomeric complexes*2431. Antibodies directed against this protein are not 
bactericidal*2101. The heat modifiable class 5 opacity proteins, Opa and Opc play an important role 
in the adhesion and entry of both N. meningitidis and N. gonorrhoeae to endothelial and epithelial 
host cells*334,333,681. Opc proteins have been shown to bind different members of the 
carcinoembryonic antigen receptor family, present on endothelial, certain epithelial and 
polymorphonuclear cells*335,3361. Opa proteins in comparison have been shown to interact with the 
serum glycoprotein vitronectin, using this protein to attach to heparin sulphate proteoglycans 
present on the endothelial cells*681. Expression level of Opc varies between meningococcal strains, 
with high-level or intermediate-level expression observed in some strains and no Opc expression 
observed in others*2681. Whilst the opc gene is found in gonococci, Opc is only expressed in 
meningococci*3611. In contrast, Opa is expressed in most meningococcal and gonococcal isolates, 
with up to four distinct Opa proteins expressed by the meningococci and up to 11 distinct Opa 
proteins expressed by gonococcal isolates resulting in a heterologous population of bacteria 
expressing none, one or multiple Opa proteins*1641. The outer membrane also contains LPS which 
helps to confer serum resistance and is involved in the pathogenesis of meningococcal disease*2081.
1.5.1.1 PorA
The immunodominant antigen of N. meningitidis is the highly variable OMP, PorA*323,641. PorA is a 
4 4  -  4 7  kDa cation-selective transmembrane protein which forms a trimeric pore in the outer
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membrane of meningococci. A transmembrane 16 strand (3-barrel conformation has been 
proposed for PorA based on known Escherichia porin structures*3181 with eight surface exposed 
loops (I -  VIII). Two distinct variable regions (VR), VR1 and VR2 corresponding to loops I and IV, 
respectively, are located on the longest of these loops (Figure i .4 ) (198'188'3181 and form the basis for 
serosubtyping of N. meningitidis.
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Figure 1.4 Proposed structure of the PorA protein w ith a P 1 .2 1 ,16 serosubtype. The top part of 
the model show the surface exposed regions, whilst the central part indicates the transmembrane 
regions*3181.
The PorA protein, is assigned the "P I." prefix and is expressed as a pair of numbers corresponding 
to the subtype on the two variable regions (VR1 and VR2) located on the surface exposed loops of 
the PorA protein*261,2581. The reaction of monoclonal antibodies (MAbs) with specific regions of 
VR1 and VR2 have previously been used to serosubtype N. meningitidis{2), however meningococci 
were frequently only partially serosubtyped or classified as non-serosubtypeable. This was due 
mainly to a lack of a comprehensive panel of PorA MAbs*2581. Nowadays molecular methods are 
used to subtype meningococcal isolates (http://.pubmIst.org/Neisseria/). The amino acid 
sequences of VR1 and VR2 deduced from nucleotide sequence data are used rather than relying
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on reactivity with specific MAbs*2581 Amino acid sequences with >80 % similarity to each other 
were grouped into VR families, with the VR epitope recognised by an existing MAb raised against 
PorA, or the first defined amino acid sequence of a VR family designated as the prototype VR for 
thatfam ily(258).
A third region of variability (VR3), located on loop V, has a lower level of genetic variation*611 but 
this region is not thought to be as immunologically important as VR1 and VR2. Loop V is a shorter 
loop than either loops I and IV and therefore maybe less exposed to the immune system and thus 
selection pressure, however bactericidal antibodies to this region have been produced*61'621. A 
number of VR3 genosubtypes have been described*511 therefore VR3 may be sequenced along 
with VR1 and VR2 to allow for further characterisation of PorA.
1.5.1.2 PorB
The second major porin is PorB and is expressed by all meningococci*1011 and makes up the vast 
majority of water-filled channels within the Neisserial outer membrane*3561. Pores formed by the  
PorB protein are thought to be anion-selective*1431. Topology models have been constructed for 
PorB based on nucleotide sequence data*188,3181 and three dimensional homology models have 
been generated using structural similarity between Escherichia coli porins and Neisserial porins*741. 
Like PorA, the 37 -  42 KDa PorB protein is predicted to consist of a transmembrane (3-barrel 
conformation with eight surface exposed loops. Whilst some serotypes can be assigned to 
particular peptide sequences*311'3121, the PorB serotype epitope is largely discontinuous, and made 
up of several of the eight surface exposed variable regions which, when the protein is in its native 
conformation, are in close proximity*3571.
Serotyping was previously based on the reactivity of MAbs against immunogenic regions within 
the PorB protein; however, as for PorA, sequence based typing is more commonly used to reduce 
the number of non-typeable meningococci*2,3'261,801. PorB genotyping is most commonly used 
where further resolution is required, however this is not used in the recommended nomenclature 
of N. meningitidis{u9'180).
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1.5.1.3 FetA
Iron acquisition is a well defined determinant of bacterial pathogenesis, with the production of 
several ligand-specific iron transport proteins involved in the acquisition of iron from the host 
binding compounds. Neisseria acquire iron through direct interaction between the iron binding 
glycoproteins such as lactoferrin, transferrin, haem, haemoglobin, and haemoglobin complexed to 
the serum glycoprotein haptoglobin and the bacterial ce||(37'355'209'173) via receptors specific for 
human lactoferrin and transferrin on the meningococcal surface*307,831. One such iron binding 
protein is FetA (also known as Frbp), a member of the TonB dependant class of OMPs *60).
Meningococcal FetA is a 70 kDa iron-regulated OMP with a predicted j3-barrel configuration 
located in the outer membrane with 26 membrane spanning domains and 13 surface exposed 
loops*1621. As wjth PorA, the longest loop (loop VII) contains the immunodominant region 
corresponding to a single hypervariable region of the protein*2961. FetA was not routinely used as 
a serological typing target, as it is only expressed under conditions of iron limitation, and so whilst 
it will be expressed in the human host, in vitro expression is dependent on iron limitation*1491. 
However, FetA is a major component of the outer membrane and th e fe tA  gene is found in most 
meningococcal isolates. Following on from the introduction of sequence based typing schemes, 
antigenic sequence typing of FetA is part of the molecular typing scheme for N. m e n in g itid is ^ .
1.5.2 Typing at a population level
The clonal nature of relationships among N. meningitidis isolates has been demonstrated, and 
whilst some clones have been repeatedly isolated worldwide, others have rarely been isolated*2411. 
Meningococci associated with epidemics and outbreaks generally belong to distinct clonal groups, 
whereas sporadic meningococcal disease is caused by more diverse meningococci*41. A number of 
techniques have been used to investigate genotypic relationships among meningococci. These 
include pulsed-field gel electrophoresis (PFGE)*8'2411, amplified fragment length polymorphism 
(AFLP)*1221, multilocus enzyme electrophoresis (MLEE)*471, and multilocus sequence typing 
(MLST)*1851.
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MLEE can differentiate between isolates by identifying the variation in the electrophoretic 
mobility of nine cytoplasmic enzymes using starch gel electrophoresis*441. Electrophoretic types 
(ETs) are assigned based on the multilocus profile of the isolate, with only isolates that are 
marginally different assigned to the same clonal group or complex. Several hypervirulent, 
hyperendemic ETs have been identified using MLEE and include ET37, ET5 and the A4 
complex*338'1221.
MLST was developed as an alternative to MLEE, with nucleotide sequences used to characterise 
isolates of bacterial species using seven housekeeping gene fragments*1851. Housekeeping genes 
are used in MLST as they encode proteins required for bacterial growth, and so are constantly 
expressed, and are under non-diversifying selection*2441. Alleles are assigned to each 
housekeeping gene, within a bacterial species, based on different nucleotide sequences, and the 
seven loci are used to assign a sequence type (ST) to each isolate. This provides unambiguous 
sequence data allowing for high levels of discrimination between isolates and for the rapid 
identification of hypervirulent meningococci without the need for culturing of the organism*841. 
The number of nucleotide polymorphisms is not important in MLST, instead sequences are given a 
different allele number whether they vary at a single or multiple nucleotide sites. The MLST 
database is then used to analyse sequence data unambiguously against a large central database 
(http://pubm lst.org/A/e/sser/o/)*1501. The majority of disease causing isolates fall into distinct 
clonal complexes and are monitored across Europe by the European Centre for Disease 
Prevention and Control.
The analysis of six to eight housekeeping gene fragments, as utilised for MLST is not always 
suitable for the resolution of closely related organisms*51. Extended MLST (eMLST), which uses an 
increased number of housekeeping genes, in addition to dispensable genes sequences can help to 
further resolve genotypic differences within clonal complexes. However, many variations 
between the genotype and phenotype occur at a level other than at the level of clonal complex, 
and cannot be resolved using eMLST*751. In addition, due to the diversity of bacterial organisms, a
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separate MLST scheme is required for each group of related bacteria, and MLST typing schemes 
are limited to bacteria belonging to the same genus(184).
With the introduction of rapid nucleotide sequencing schemes, the number of whole bacterial 
genomes available for analysis has greatly increased*2011, allowing for analysis o f genetic variation 
across the whole domain at selected shared loci*1481. Using the Bacterial Isolate Genome 
Sequence Database (BIGSdb)*151) a combined taxonomic and typing approach has been introduced 
for the whole domain bacteria. Ribosomal MLST (rMLST) indexes the sequence of ribosomal 
protein-encoding genes, into a MLST scheme providing increased resolution of the whole domain 
bacteria to the species or subspecies level*1481.
1.6 Vaccines
A major task for vaccine manufacturers is to design a meningococcal vaccine that is safe, 
addresses individual or public health issues, and is effective in the age groups most susceptible to 
disease. There are many different types of meningococcal vaccine available, but none currently 
offer protection against all serogroups in all age groups. A problem in the development of 
vaccines is due to the peak incidence of meningococcal disease being in children under 1 year of 
age*971 and the poor immunogenicity of carbohydrate antigens such as the capsular 
polysaccharides in the very young*1711. Whilst polysaccharide vaccines offer protection in older 
age groups, protection is serogroup specific*1071. Conversely, whilst protein vaccines are more 
immunogenic than carbohydrate vaccines, the immunogenic meningococcal surface protein 
antigens are also highly antigenically variable, thereby limiting the cross protection afforded by 
the vaccine.
1.6.1 Polysaccharide vaccines
The first meningococcal vaccines, based on purified capsular polysaccharide were developed in 
the 1960s and shown to protect against meningococcal infection in humans*1191. Plain 
polysaccharide vaccines are safe and systemic reactions are rarely seen*111,1101. Both the 
serogroup A and C polysaccharides are good immunogens in humans and the first successfully
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developed capsular vaccines targeted these polysaccharides*1191. The efficacy of the group C 
capsular vaccine was initially shown in military recruits and later used to prevent an outbreak of 
group C meningococcal disease in the US Army*971. Immune responses to both vaccines were age- 
dependant with short term efficacy levels of 85 -  100 % observed in older children and in adults. 
However, neither vaccine was found to elicit protective antibodies in younger children and 
infants, with no response detected to the serogroup A vaccine, and a low level response to the  
group C vaccine in infants immunised at three months of age*1101. This is thought to be due to the  
poor immunogenicity of the capsular polysaccharides in children under two years of age.
1.6.2 Conjugate vaccines
Conjugate vaccines consist of the saccharide antigen covalently bound to a T-cell dependant 
carrier protein, such as tetanus toxoid or CRM197*1121. There are several benefits of conjugate 
vaccines over polysaccharide vaccines. These include: the induction of herd immunity; longer 
lasting protection through the induction of immunological memory; the induction of high avidity 
antibodies; effectiveness in infants and young children; and the ability to boost the immune 
response with repeated doses of vaccine with less risk of a hyporesponsive immune response 
(124,26) conj Ugat e vaccines have been found to be effective in reducing the acquisition of carriage 
and disease across all age groups, including children less than two years of age, with vaccine 
efficacy demonstrated in infants as young as two months of age*1241. The first conjugate vaccine 
developed was the Hib polysaccharide-tetanus toxoid conjugate vaccine and has been 
implemented into routine infant immunisation schedules in over 30 countries*3521.
Following the success of the Hib vaccine, a number of meningococcal group C conjugate (MCC) 
vaccines have been developed and have considerable advantages over polysaccharide vaccines. 
There are three MCC vaccines licensed globally*2501. All three vaccines, were found to induce 
bactericidal antibodies and immunological memory in UK toddlers after one dose*2501, and in 
infants following three doses*251,181. The MCC vaccine was introduced into the UK infant 
vaccination schedule in 1999, with a simultaneous two-dose catch-up programme offered to
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infants aged between five and eleven months, and a single-dose catch up offered to children aged
1 - 1 7  years of age in order to induce widespread immunity(205). Introduction of the MCC vaccine
led to a dramatic reduction in disease cases caused by serogroup C strains of N. meningitidis 
(Figure 1.5)(18,39). By 2006, the MCC had been introduced into routine immunisation schedules 
across Europe, with a resulting 10-fold reduction in the incidence of meningococcal serogroup C 
disease(105).
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Figure 1.5 Incidence of invasive Serogroup C meningococcal disease in England and Wales 
following introduction of the MCC vaccine in 1999 (adapted from epidemiological data reported 
by the Health Protection Agency (HPA))1.
As with the Hib vaccine, the effectiveness of the MCC vaccine began to wane over longer periods 
and the age at which the final dose of the vaccine was given, was found to be important in vaccine 
effectiveness. The effectiveness of the vaccine remained high in children targeted in the catch-up 
campaign (five months to 18 years), however, direct protection was not found to persist for 
longer than one year in children immunised at a younger age(299). As a result, the MCC vaccination 
schedule was changed in 2006, to two doses at three and four or five months, with a booster dose 
at 12 months of age(38). In order to afford greater protection to teenagers and to make the make 
the overall MCC vaccination programme more effective, the vaccination schedule was again 
changed in 2013. A single priming dose at three months of age was found to be sufficient to
http://www.hpa.org.uk/Topics/lnfectiousDiseases/lnfectionsAZ/MenineococcalDisease/EpidemiologicalDat
J Z _______________:_________________.  ' ______________________
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provide protection against meningococcal serogroup C disease in the first year of life(89). A 
booster dose given at 12 months of age, and a second booster dose at 14-15 years of age will 
provide higher levels of antibody that persist for longer(299'31) and persisting herd protection will 
maintain disease control for a number of years(301'31,105). Despite the concern of capsule switching, 
where the type of capsule expressed by meningococcal clones changes, no evidence has been 
found with the use of this vaccine(39).
Several conjugate vaccines have also been developed for serogroups A, W  and Y in a range of 
formulations. Quadrivalent vaccines, targeting serogroups A, C, Y and W, have been developed 
and are currently in use in the US, Canada and Europe(227,248'218). A bivalent vaccine (Menhibrix), 
targeting both serogroup C and Y meningococci in addition to Hib has been licensed in the US for 
use in infants as young as two months of age(212) 
(http://ww w .cdc.gov/m m w r/preview /m m w rhtm l/m m 6203a3.htm ). In 2010 Burkina Faso was the 
first country to introduce a new serogroup A conjugate vaccine (MenAfriVac) to eliminate 
epidemic meningitis in Sub-Saharan Africa(76).
With the availability of vaccines against serogroups A, C, Y and W, the greatest challenge is now 
the development of a serogroup B vaccine, however there is an increased risk of the induction of 
autoimmune antibodies due to the poor immunogenicity of the serogroup B capsule and the  
antigenic similarities with human neural cell adhesion molecule(233'9:l'231,. For this reason, vaccines 
based on capsular polysaccharides do not offer any protection against serogroup B meningococci.
1.6.3 Outer Membrane protein and vesicle vaccines
As the feasibility of a serogroup B capsular polysaccharide vaccine has been questioned(125), the  
use of other vaccine targets has been considered, and the focus for the development of vaccines 
offering protection against serogroup B organisms has for many years been non-capsular 
antigens(97,237'231'140). A number of OMPs, shown to induce bactericidal activity against different 
meningococcal isolates have been investigated(269,97,295) and the PorA protein was the most 
immunogenic(253). The use of LPS-depleted OMPs was considered a good approach for the
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development of an effective serogroup B meningococcal vaccine and led to the development of 
several vaccines from single strains of serogroup B meningococci(147). However, the efficacy 
and/or the effectiveness of these vaccines have not been completely satisfactory*147'115* with 
vaccines limited by poor immunogenicity in infants*204*, and the short duration of immune 
response*27*. The poor performance of these vaccines was largely attributed to the loss of tertiary  
structure that accompanied precipitation and recent research into serogroup B vaccines has 
concentrated on the development of outer membrane vesicle (OMV) vaccines with proteins 
displayed in their native confirmation(208).
1.6.3.1 Outer membrane vesicle vaccine
Outer membrane blebs, released naturally by many Gram negative bacteria during bacterial 
growth, are small particles of a Gram negative cell wall. These blebs consist of OMPs, LPS and 
phospholipids (PL) as well as periplasmic proteins as they would normally be situated in a 
bacterium, on a much smaller scale*314*;*24,314*. Outer membrane blebs have a range of functions in 
bacterial survival including mediation of bacterial envelope stress, biofilm formation, virulence 
and transformation*55*. Outer membrane vesicles (OMVs) produced as a result of detergent 
extraction of OM blebs, have reduced levels of LPS and are ideal candidates for vaccine delivery 
due to their immunogenic properties, ability to be taken up by mammalian cells and potential for 
recombinant engineering*55*.
OMV vaccines based on single strains of serogroup B meningococci have been developed for use 
in areas with clonal meningococcal outbreaks, including Cuba, Norway and New Zealand*255'86'217*. 
These vaccines were shown both to elicit serum bactericidal antibody (SBA) responses and to 
protect against the development of meningococcal disease in clinical trials*65'27'276,231*. Overall 
efficacy of these vaccines was between 50 -  80 %, however, in some studies no protection was 
observed in young children*65'213*. The PorA protein is considered an important candidate of 
meningococcal vaccines*317* as the immunodominant antigen PorA proteins are a major inducer of 
SBAs*295*. However, PorA is highly variable among isolates, with the low cross reactivity of
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antibodies between serosubtypes limiting the use of PorA as a cross protective antigen*253'324'161*. 
In order to produce a vaccine providing widespread coverage across a diverse range of organisms, 
a number of PorA proteins representing the most common variants must be included*297'330*. In 
spite of the variable nature of FetA, this protein also has potential as a vaccine candidate due to 
its ability to induce high levels of bactericidal antibodies*347,161*. O M V vaccines include FetA along 
with other antigens such as PorA and PorB as vaccine components*100*. These vaccines have been 
shown capable of inducing bactericidal responses in people, including infants, however this 
response is strain-specific*192* and can probably be attributed to PorA as this is the 
immunodominant antigen in OMVs. Limitations of OM V vaccines include waning immunity, 
protection falling after eight months to one year following a two-dose immunisation schedule 
with no booster, and strain/serosubtype restricted immunity in infants*295*. OM V vaccines based 
on single meningococcal strains are beneficial in the fight against clonal disease outbreaks, but 
are not beneficial for sporadic endemic disease caused by differing meningococcal strains.
Two of the most extensively studied vaccines were produced in the 1980's in response to 
meningococcal outbreaks in Cuba (VA-MENGOC-BC®) *276* and Norway (MenBvac™)*27*. The Cuban 
OM V vaccine, produced at the Finlay Institute from a B:4:P1.15 strain of N. meningitidis, is a 
bivalent vaccine composed of serogroup C capsular polysaccharide and serogroup B OMVs with a 
. P I .19,15 serosubtype*276,208'309*. VA-MENGOC-BC® was licensed for use in 1989 and has been used 
successfully to control epidemics in Cuba, Brazil, Columbia and Uruguay*65,34'280*. The efficacy of 
this vaccine was found to be age dependent, with estimated efficacies of 37 % (95 % Cl: 100-73) in 
infants under 24 months of age, 47 % (95 % Cl: 72-84) in children aged 24 -  47 months and 74 % 
(95 % Cl: 16-92) in children aged over 48 months*204*. A high level of efficacy (83 %) was 
demonstrated in a large clinical trial following a two-dose schedule of the vaccine in school 
children aged between 10 -  14 years of age. The vaccine was not found to have any efficacy in 
children less than 24 months of age*204*. The presence of antibodies to cross-reactive epitopes 
was detected following immunisation with the VA-MENGOC-BC vaccine*203*.
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The high incidence of serogroup B meningococci disease observed in Norway during the 1970s 
and early 1980s motivated the development of an OMV vaccine against a strain representative of 
the epidemic (B:15:P1.7,16)*102'253'208*. The MenBvac vaccine was produced at Norwegian Institute 
for Public Health (NIPH), is safe, immunogenic and confers protection against group B 
meningococcal disease*27,253*. The efficacy of this vaccine, as for the Cuban vaccine, was found to 
wane and studies of a two-dose regime in teenagers over 29 months from 1988 -1 9 9 1  estimated 
the efficacy at 57 %*208*, although a three-dose regime gave a longer, more cross-protective 
response*295,267*. Vaccine efficacy among children (from 12 to 16 years of age) was found to be too 
low for general use of the vaccine*27*. A combination of the MenBvac vaccine with a MCC vaccine 
was demonstrated to be immunogenic with regard to both serogroups B and C meningococci in 
adult volunteers*1*.
An epidemic of systemic serogroup B meningococcal disease in New Zealand caused by a single 
serosubtype (Pl.7-2,4)*191*, accounted for an estimated 80 % of all meningococcal disease cases at 
its peak*274,172*. A similar approach to vaccine development was adopted as for MenBvac, and a 
tailor-made vaccine was developed by the Norwegian Institute of Public Health (NIPH) in Norway 
and Novartis, in partnership with the New Zealand Ministry of Health and the University of 
Auckland*216*. MeNZB is a meningococcal serogroup B OM V vaccine administered in a three-dose 
regime. With a seroresponse, defined as a four-fold rise in serum bactericidal antibodies, found in 
96 % of adults, 76 % of children, 75 % of toddlers and 74 % of infants receiving three doses of 
MenZB, the vaccine was safe and efficacious in adults and children of all ages and licensed for use 
in 2004*216*. In order to achieve rapid epidemic control, a large randomized controlled efficacy 
test was not undertaken for the vaccine, following satisfactory safety and immunogenicity profiles 
demonstrated in phase I and phase II trials and following experience of other group B OMV  
vaccines extensively used elsewhere, however, a prospective observational study demonstrated a 
vaccine efficacy of 73 % (95 % Cl 52 -  85)*156’. The vaccine was found to be particularly effective in 
the younger population with efficacies of 83 % (95 % Cl: 59.4 -  94.3) in children between 0.5 -  3 
years of age and 80 % (95 % Cl: 52.5 -  91.6) in children between 0.5 -  5 years of age*104*.
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As with other OMV vaccines, the protective response was not long-lasting and poor 
immunogenicity was observed in young infants aged between six to eight months with four doses 
required to produce a protective response*217'172*. The use of an intensive immunisation 
campaign, offered to all young New Zealanders under the age of 20 years of age (2004-2006), 
with three doses of vaccines affording 80 % coverage has led to the effective management and 
control of New Zealand's meningococcal epidemic*172*. OM V vaccines such as MenBvac and 
MeNZB have been found to reduce meningococcal carriage and may therefore induce herd 
immunity*70*.
To overcome serosubtype restricted protection afforded by single strain OMV vaccines, the  
National Institute for Public Health and the Environment (RIVM), Netherlands, developed a 
multivalent vaccine comprised of PorA proteins from six different prevalent pathogenic 
isolates*319,323,50*. Hexamen is a recombinant, hexavalent vaccine composed of two OMVs 
produced using two genetically engineered variants of the H44/76 vaccine strain, each expressing 
three PorA serosubtypes. The first strain, PL16215 encodes for the P I.7,16, Pl.5-1,2-2, P I .19,15-1 
serosubtypes and the second strain, PL10124 for the P l.5-2 ,10, P I.12-1,13, P 1.7-2,4*50,323*. The six 
PorA proteins in the vaccine were represented in over 80 % of UK and western Europe 
meningococcal case isolates in 1996 to igggf323-50'42'208). Hexamen was safe, well tolerated and 
induced bactericidal antibodies against strains expressing each of the six PorA proteins in 
adults*222* and following a three-dose immunisation schedule in infants*42*, toddlers and 
children*64*. As for the previous OMV vaccines, bactericidal response in infants quickly waned, 
however a fourth dose at 12 months boosted serum antibody titres to protective levels*42*.
To provide an even broader range of protection, Hexamen was expanded to include a third 
trivalent vaccine strain, HP1416, making up the nonavalent PorA OM V vaccine, Nonamen. The 
serosubtypes included in this vaccine are the P I.7,16; P l.5-1,2-2; P I.19,15-1; P l.5-2,10; P I .12- 
1,13; P I.7-2,4; P I.22,14; P l.7-1 ,1  and Pl.18-1,3-6*316*. Together the nine PorA proteins in the  
vaccine represent the most frequently occurring serosubtypes in industrialised countries*316*. 
Nonamen has been showed to be immunogenic in mice and rabbits. A Phase I trial was carried
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out in Spain in 2007 and as with HexaMen, NonaMen was found to be safe and well tolerated, and 
on the basis of European PorA subtype data from 1999 to 2004, is predicted to have a potential 
coverage of 80 % based on European PorA subtype data from 1999 to 2004*304*.
Traditionally, OM V vaccines are prepared using detergent extraction to remove LPS, and increase 
vesicle release. However, whilst selective removal of LPS in this way reduces endotoxicity, the PL 
and lipoproteins, such as factor H binding protein (fHbp) that contribute to immunogenicity, are 
also removed*160*. Immune responses resulting from detergent extracted OM V vaccines are 
therefore directed against specific PorA subtypes and do not provide cross-protective 
responses*324,208*. A number of methods have therefore been investigated for the detergent-free 
purification of OMV. Vaccines produced using detergent-free OMVs have shown promising 
results in animals and humans with cross-protection against a panel of serogroup B strains but are 
limited by the high LPS content to intranasal administration*139* and the low yield of OMV  
following purification*88*. A new generation of OMV vaccines has been developed utilising 
meningococcal strains with genetically attenuated*283* or detoxified LPS*320*. This allows native 
OMVs (NOMV) to be used without detergent extraction needed to remove LPS*321*, reduced OMV  
aggregation, and comparable yield and toxicity to detergent extracted OMVs*315*. Retention of 
membrane associated lipoproteins in the NOMV allows proteins such as fHbp and transferring 
binding protein, to be present in the vaccine*363*. An advantage of using a vaccine with multiple 
antigens is the potential for a synergistic bactericidal action of antibodies induced to the different 
antigens*353,351*. Vaccines produced using NOMV have been shown to produce a broad based 
bactericidal antibody response against serogroup B meningococcal strains in mice and 
humans*315,232*. The bactericidal antibody response induced by a trivalent NOMV vaccine in mice is 
also effective against serogroups C, Y, and W, epidemic serogroup X, and certain serogroup A 
strains of meningococci in mice*232*. An improved next generation Nonamen has also been 
produced and studies in rabbits and mice have found the vaccine to be safe and have the 
potential to enduce a protective immune response*154*.
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1.6.4 Reverse vaccinology
Reverse vaccinology is a method of using a bioinformatic approach to screen the entire genome, 
to identify and investigate meningococcal proteins as putative vaccine candidates*247* and was 
developed following publication of the genome sequence of the virulent MC58 strain of 
serogroup B meningococci. DNA fragments were analysed to reveal open reading frames (ORFs) 
and up to 600 novel genes predicted to encode surface exposed or exported proteins were 
identified. These genes were amplified and cloned into E. coli for expression as fusion proteins. 
Recombinant protein was successfully purified from 350 of these genes and used to immunise 
mice. The resulting sera were analysed to confirm the surface exposure of the proteins and the 
ability of the protein to induce bactericidal antibodies. Of these, 85 proteins were found to be 
novel surface-exposed proteins, of which 25 proteins induced bactericidal antibodies. Finally, 
seven proteins were selected for further analysis*233'247*.
One such antigen identified through reverse vaccinology is the fHbp*195'95*. This is a surface 
exposed lipoprotein expressed by most meningococci. Factor H is an important regulator of the 
alternative complement pathway and fHbp recruits human factor H to the bacterial surface to 
help it to evade complement-mediated killing*272*. Expression of fHbp may vary between strains, 
but the genetic sequence for this protein appears to be present in almost all strains of 
N. meningitidis(195'95,20'289). Other antigens discovered by reverse vaccinology include Neisserial 
adhesion A (NadA) and Neisserial heparin-binding antigen (NHBA)*108*.
The first vaccine produced using this approach is the four component formulation (4CMenB), 
known as Bexsero®, and was licensed for use in Europe in January 2013 and more recently in 
Australia. This vaccine is made up of four components, fHbp (variant 1.1), NadA (variant 3.1), 
NHBA (variant 1.2) and a single serotype OMV (expressing PorA P1.4)*289*. Bexsero® was found to 
be safe, well tolerated and immunogenic in adolescents, adults*157*, and in infants*90'279'331*. More  
than 95 % of infants aged six to 12 months generated a SBA response as early as one month post- 
second dose against strains representing multiple antigens included in the vaccine*279*. Although a
decline in the level of protective antibodies was observed in infants, six months following the 
third dose, a booster dose resulted the restoration of protective levels in 93 % of 
participants*289,331*. Bexsero has a predicted vaccine coverage of 78 % (95% Cl 66-91) of 
meningococcal B strains in Europe*77* 76 % (95% Cl, 59% to 87%) of strains in Australia*118* and 66 
% (95% Cl: 46-78%) of strains in Canada*23*.
1.7 Vaccine Evaluation
Immunity against invasive meningococcal disease is dependent on bactericidal activity by serum 
immunoglobin G (IgG), together with complement*113'144*. The importance of IgG in protection 
against meningococcal disease is highlighted by the inverse relationship between antigen specific 
serum IgG levels and incidence of invasive disease*113*. Conversely, antigen specific serum IgG 
levels remain low until adolescence and then increase steadily, while carriage rates of 
meningococci rise rapidly in childhood before steadily falling with increasing age*163*. The 
bactericidal antibody response produced in response to carriage, provides high levels of 
protective antibodies, specific to the carriage strain and also cross-reactive to heterologous 
strains*249* through shared antigens including PorA and PorB. However unlike the immune 
response elicited by invasive disease, meningococcal carriage does not always elicit a protective 
immune response against meningococcal disease and any protection may be short lived*8*. 
Bactericidal activity against meningococci is dependent on the IgG class of antibodies*120*.
Various serological methods have been used to measure IgG responses to capsular 
polysaccharides including capillary precipitation*121*, bactericidal antibodies*113*, opsonisation*252*, 
immunofluorescence*113*, passive hemagglutination*121*, solid-phase radioimmunoassay*362*, 
solution-phase radioimmuno assays*155* and enzyme-linked immunosorbent assay (ELISA). Of 
these, only the radioimmunoassay and ELISA were found to accurately determine total anti­
polysaccharide antibody levels using the small volumes of sera typically obtained from young 
children*40*
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1.7.1 Serum Bactericidal Antibody Assay
Correlates of protection are used for the evaluation of vaccines when a low sample population is 
available, due to low disease incidence, previous vaccination of subjects, or where vaccine 
challenge may be unethical. The correlate of protection used for evaluation of meningococcal 
vaccines is the SBA assay. This assay is considered to be the gold standard for determining 
meningococcal vaccine efficacy with standardised SBA assays developed for serogroups A, B and 
£(196,32) ability of SBAs to confirm protection against meningococcal disease is widely
accepted, and, for purposes for licensure of meningococcal vaccines, regulatory agencies 
generally accept induction of these antibodies as evidence of vaccine effectiveness*32'207*. 
However, this is a complex method with a number of variables that have to be considered in the  
design o f the assay, including the use of live bacteria and the source of both complement and 
serum. It has also been suggested that the extent of meningococcal immunity in the population, 
in addition to the potential effectiveness of new meningococcal vaccines are being 
underestimated due to the reliance on SBA assay results*350*.
Extrapolation from measurement of total serum anticapsular antibodies to predict bactericidal 
antibody titres may be limited(123). For example, serum from young children and infants 
vaccinated with a meningococcal polysaccharide vaccine were found to have high serum antibody 
responses to the serogroup C polysaccharide, however, no bactericidal antibodies were 
detected*176'197*. Although the immunogenicity of some meningococcal vaccines have been 
described in terms of the presence of polysaccharide binding antibody concentration, only 
bactericidal titres measured using SBA assay are associated with protection from meningococcal 
disease1113'204'1971.
1.7.2 Enzyme-Linked Immunosorbent assay (ELISA)
A standard ELISA based protocol was first proposed for the measurement of total meningococcal 
serogroup A antibodies(40) and for serogroup C antibodies(106) following the development of 
polysaccharide-protein conjugate vaccines. Use of the ELISA as a standardised method for the
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quantification of total meningococcal polysaccharide antibodies was selected as it was simple, 
sensitive, reproducible and specific for anticapsular antibodies*40,105*. ELISA methods for the 
detection of antibodies against strain specific epitopes and outer membrane proteins of N. 
meningitidis for serotyping and serosubtyping*2* have been developed and are being used for 
measurement of vaccine induced IgG responses. ELISA has been used for the quantification of 
total anti-OMV antibodies following vaccination with an OMV vaccine, with the vaccine strain 
OM V used as the coating antigen*116*. The ELISA is well suited to the screening of many samples 
for a single analyte*167*. The inability to multiplex a standard ELISA means a separate ELISA is 
required for the measurement IgG responses produced for each analyte of interest*167*. This limits 
the use of ELISA in the evaluation of vaccines containing multiple antigens of the meningococcal 
outer membrane. For example, determining the immune response resulting from vaccines such 
as HexaMen and Nonamen would require six and nine separate ELISAs, respectively. Therefore 
use of ELISA for quantification of immune responses to multiple analytes is a tim e consuming 
process; often costly, both in terms of serum volume and intensity of labour*67*, particularly as the 
number of target antigens in vaccines are increasing*167*.
ELISA is used for quantification of antibody responses to vaccination and disease, these results do 
not always correlate well with functional antibody assays*123*. Good correlation with the SBA 
assay is observed particularly when assaying sera from immunised adults*10* or in teenagers and 
young adults following the administration of a single vaccine*158*. The SBA assay and ELISA 
correlate less well in sera from infants or toddlers*171*, or with sera from studies comparing 
polysaccharide vaccine to a conjugate vaccine*176*. Differences in the avidity of the antibodies 
measured are likely to be the cause of differences in correlation between SBA assays and 
ELISA*123*. A modified ELISA was developed to ensure specificity, and favour the detection of high 
avidity antibodies*123* and was found to correlate well with SBA assays.
Other examples of modified ELISA include indirect whole cell ELISA and dot-blot ELISA. The 
indirect whole cell ELISA is similar to the standard ELISA with the addition of an extra antibody 
step. Thereby the number of binding sites available for the enzyme linked antibody is increased
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leading to greater sensitivity of the assay. A dot-blot ELISA, utilising MAbs for the detection of 
serogroup B meningococcal antigens was developed*54* and can be used for the detection of 
antigen specific IgA, IgM and IgG in patient sera*21*. This method/using a nitrocellulose membrane 
in place of a microtitre plate has several advantages over the conventional ELISA. These include, 
easy to use method; minute amount of antigen required; the white background of the cellulose 
membrane aides the detection of positive results; measurement of IgG, IgM and IgA antibodies 
without the need for spectrophotometric readings; and results visible with the naked eye*54,21*.
1.7.2.1 Meningococcal Antigen Typing System
MLST or immunotyping of surface-expressed proteins such as PorA, can be used to show high 
genetic diversity amongst meningococcal populations*185,149*. However, due to the high rates of 
recombination affecting the meningococcal chromosome, these methods do not take into 
account additional surface proteins such as those included in the Bexsero® vaccine*19*, which may 
vary in sequence and level of expression*77*. To evaluate the effectiveness of vaccines such as 
Bexsero® using the accepted correlate of protection against meningococcal disease, would 
require the SBA assay to be performed against many diverse strains for each geographic region*77*. 
As for the standard ELISA, this approach is impractical both in terms of serum volume required, 
particularly in the case of infants, and labour intensity. The meningococcal antigen typing scheme 
(MATS) was developed as a rapid, reliable system to determine the presence, the diversity, and 
expression level of antigens included in the Bexsero® vaccine, and to predict the potential 
coverage of by the vaccine of the circulating isolates*77'294*. MATS is a series of assays that 
combine conventional PorA genotyping with a unique vaccine antigen-specific ELISA to account 
for both the extent of immunologic recognition and viarying expression of fHbp, NadA, and NHBA 
among strains of N. meningitidis, two variables that help to determine whether bacteria are killed 
in the SBA assay*77*. As previously shown, ELISA has good correlation with killing of strains by SBA, 
and is used to measure the quantity and immunologic cross-reactivity of the vaccine antigens*77*. 
In addition to predicting coverage of the Bexsero® vaccine in different geographical regions, MATS
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may also be used for the epidemiological surveillance of meningococci and adapted for the 
assessment of other pathogens*236*.
1.7.3 Multiplex flow cytometric immunoassay
Fluorescence particle based multiplex immunoassays have been developed, using distinctly 
labelled fluorescent microspheres as carriers for different antigens allowing for the detection of 
multiple analytes within a single sample*235,230'167,168'193'67*. This technique is based on the ELISA 
and as such incorporates all the advantage of ELISA with the additional benefits of increased 
sample throughput and reduced serum volume required*167*. Multiplex assays, such as the 
Luminex assay (Luminex, Austin, TX, USA) have the additional benefit of optimal antigen 
presentation through protein coupling protocols, and the use of his-tags etc, for ensuring correct 
exposure of epitopes when utilising microspheres*230*. A major advantage of a multiplex assay 
over the conventional ELISA is adaptability, with the potential for 100 analytes to be measured 
simultaneously. As for the ELISA, these assays are used for the quantification of total serum IgG 
antibodies, not for functional bactericidal antibodies.
Use of the standard ELISA has been limited with the development of multivalent vaccines such as 
HexaMen and Nonamen, due to the need for a separate ELISA to quantify IgG responses to each 
PorA serosubtype. Development of a fluorescence based multiplex assay for the detection of 
antibodies to specific meningococcal PorA antigens would have several advantages over the 
standard ELISA method, overcoming many of the limitations of the standard ELISA in the 
evaluation of multivalent vaccines. W ith the potential for additional PorA serosubtypes to be 
included as required, this assay may also be of use in disease and carriage studies for the 
simultaneous detection of sera responses to multiple PorA serosubtypes. With the development 
of multicomponent vaccines, the flexibility of the assay to incorporate other antigens, such as 
PorB, FetA is also of advantage.
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1.8 Aims o f the Project
The aims and objectives of this thesis were to:
•  Produce a set of highly purified meningococcal protein antigens, including seven 
serosubtypes of PorA, three serotypes of PorB and five variants of FetA;
•  Develop a reproducible and reliable multiplex assay to measure antibody responses to 
specific serosubtypes of PorA;
•  Develop a multiplex assay to measure antibody responses in the pre-clinical and clinical 
trials using a range of sera from individuals vaccinated with one of four meningococcal 
OMV vaccines;
•  Utilise the multiplex assay to evaluate the effect of meningococcal carriage on host 
immunity using sera collected from healthy individuals as part of two Separate carriage 
studies.
Chapter 2. Methods and Materials
2.1 Materials
All chemicals and reagents were obtained from either Sigma-Aldrich Chemicals (Gillingham, 
Dorset, UK) or BDH (AnalaR Grade, Poole, UK), unless otherwise stated. The 
ethylenediaminetetra-acetic acid (EDTA) used was the disodium salt. All water used was purified 
using a Milli-Q purification system (Millipore, Hertfordshire, UK).
2.1.1 Serum samples
Table 2.1 Source of sera used in this study.
Source Study Sera Samples
s e u 2/ v e u 3
(Manchester)
NZ (MNB2)
NW (MNB3) 
Seroepidemiology
9 paired samples 
17 paired samples 
500 samples
RIVM4
Hexamen
Nonamen
32 murine sera 
10 human samples, (1 pre, 2 post, 7 boost) 
32 murine sera
University of Leicester Carriage
8 samples (new carriers)
5 samples (non-carriers)
10 samples (persistent carriers) 
11 samples (cleared carriage)
NIBSC5
Unvaccinated 
serum sample
1 sample (Cat No. 03/118)
Sera used in this study were obtained from several sources as listed in Table 2.1. The HPA 
Seroepidmiology Unit (SEU) serves as a central resource for the collection of anonymised sera 
submitted for microbiological and diagnostic testing. Over 150,000 samples have been collected
2 Seroepidemiology Unit, Health Protection Agency, Manchester, UK.
3 Vaccine Evaluation Unit, HPA, Manchester, UK.
4 National Institute for Public Health and the Environment, The Netherlands.
5 National Institute for Biological Standards and Controls, Hertfordshire, UK. _________ ■______
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through collaboration with participating laboratories throughout England and Wales since 1986 
and collections are continuing to the present day. These samples form a valuable and unique 
public health resource. Part of the HPA SEU, is the Vaccine Evaluation Unit (VEU) specialises in 
the serological determination of immune responses, and has been leading on.the evaluation and 
determination of potential coverage of meningococcal group B vaccines. Meningococcal, 
pneumococcal, Hib, Diphtheria and Tetanus serology assays developed at the VEU are also widely 
used for vaccine trials and clinicians (www.hpa.org.uk). The National Vaccine Evaluation 
Consortium (NVEC) is a consortium that has been working together for over 20 years on vaccine 
trials bringing together the HPA and academia. MNB2 and MNB3 were NVEC studies, performed 
in collaboration with manufacturers of the meningitis B vaccine, to assess how the MeNZB and 
MenBvac vaccines worked in the UK population(92). Vaccines were administered to healthy 
laboratory workers on a three dose schedule, with blood and salivary samples obtained prior to 
vaccination and six weeks after each dose of the vaccine. Samples used in this thesis include pre-- 
and post-vaccination sera collected six weeks after the third dose of the vaccine.
2.1.2 Solutions
Commonly used buffers, culture media and bacterial growth plates and their formulations are 
given in Table 2.2 and Table 2.3. All solutions were made up in water purified using a Milli-Q  
purification system.
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Table 2.2 Composition of commonly used buffers. Solutions were made up in water purified
using the M illi-Q water purification system.
Name Formulation
TE
10 mM Tris 
Im M E D T A  
pH 8.0 adjusted with Hydrochloric acid (HCI)
TIowE
10 m M Tris 
O .lm M E D TA  
pH 8.0 adjusted with HCI
TAE
40 mM Tris 
1 m M EDTA 
0.1 % (v/v) Glacial acetic acid
Tris buffered Saline (TBS)
137 m M Sodium chloride (NaCI) 
20 mM Tris 
pH 7.4 adjusted with HCI
Phosphate buffered Saline (PBS)
137 m M NaCI 
2.7 mM Potassium chloride (KCI)
10 mM Disodium hydrogen phosphate 
1.8 mM Potassium dihydrogen phosphate 
pH 7.4 adjusted with HCI
Dialysis Buffer (1) 20 mM Tris 
0.5 M NaCI 
0.05 % (w/v) ZWITTERGENT® 3-14 (Z3-14) 
pH 7.9 adjusted with Sodium hydroxide 
(NaOH)
Dialysis Buffer (2)
10 mM Tris 
150 m M NaCI 
0.05 % (v/v) Triton X-100  
pH 7.9 adjusted with NaOH
SDS Running Buffer
0.1 M Tris 
0.4 M Glycine 
1 % (w /v) Sodium dodecyl sulphate (SDS)
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Name Formulation
Coomassie Brilliant Blue Stain
0.5 % (w/v) Coomassie Brilliant Blue 
45 % (v/v) Methanol 
10 % (v/v) Glacial acetic acid
Coomassie Brilliant Blue Destain
45 % (v/v) Methanol 
10 % (v/v) Glacial acetic acid
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Table 2.3 Commonly used broths and growth media. Solutions were made up in water purified
using the Milli-Q purification system.
Name Formulation
Luria Broth (LB)/Agar
10 g/LTryptone (Oxoid)
8 g/L NaCI 
5 g/L Yeast extract (Oxoid) 
pH 7.5 adjusted with NaOH 
For agar: 15 g/L Agar flakes
LBKan
Luria broth 
30 |ig/ml Kanamycin (Kan)
M ueller Hinton agar (Oxoid)
300 g/L Dehydrated beef infusion 
17.5 g/L Caesin hydrolysate 
1.5 g/L Starch 
17 g/L Agar
Blood Agar Base No 2 plates (Oxoid)
15 g/L Proteose peptone 
2.5 g/L Liver digest 
5 g/L Yeast extract 
5 g/L NaCI 
12 g/L Agar 
7 % Defibrinated horse blood (Oxoid)
Super Optimal broth (SOC) (Novagen, MERCK, 
Nottingham, UK)
0.5% (w/v) Yeast Extract (Oxoid) 
2% (w/v) Tryptone 
10 mM NaCI 
2.5 mM KCI 
10 mM Magnesium chloride 
10 m M  Magnesium sulphate 
20 mM Glucose
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2.2 Microbiological techniques
Microbial techniques were performed in a Class I safety cabinet unless otherwise stated.
2.2.1 Propagation of N. meningitidis strains
N. meningitidis strains were maintained as frozen stocks at -70 "C on Protect Beads (Technical 
Services consultants, Lancashire, England). To revive frozen stocks, a single bead was extracted 
from the vial, and used to inoculate a blood agar base No.2 plate (Oxoid). Following inoculation, 
plates were incubated at 37 °C in an atmosphere containing 5 % (v/v) carbon dioxide for 
approximately 18 hours (overnight). A loopful of the resulting culture was then used to inoculate 
a second plate and ensured a pure culture was obtained. Routine culture of N. meningitidis 
strains was performed on Mueller Hinton agar plates.
2.2.2 Propagation and Maintenance of E. coli strains
£  coli strains were maintained on Protect Beads, stored frozen at -70 °C. For the production of 
frozen stocks, single colonies were selected and inoculated onto agar plates consisting of LB 
supplemented with 30 pg/ml kanamycin (LBKan). A loopful of the resulting culture was 
resuspended into the Protect Beads cryo-protectant media following the manufacturer's 
instructions, and incubated at room temperature for five minutes. The medium was drained and 
the Protect Beads stored at -70 °C.
£  coli strains were revived, using a single Protect Bead, on LBKan agar plates and streak plates 
were incubated at 37 °C for approximately 15 hours (overnight). LBKan agar plates were used for 
the routine culture of £  coli strains. Liquid cultures were grown in LBKan broth with overnight 
incubation at 37 °C in a shaking incubator.
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2.3 Molecular Biology Techniques
2.3.1 Preparation of Genomic DNA Promega Wizard® Genomic DNA Purification Kit
Genomic DNA (gDNA) was isolated from each bacterial isolate using the commercially available 
Wizard® Genomic DNA purification, kit (Promega, Wisconsin, UK). The method used was as 
according to the manufacturers' instructions. Cells harvested from an overnight culture of 
N.meningitidis by centrifugation of 1 ml culture at >13,000 x g on an Eppendorf 5412 benchtop 
centrifuge were resuspended in 600 pL of nuclei lysis solution and incubated at 80 °C for 5 mins. 
A volume of 3 pL of RNase solution (4 mg/ml) was added to the room tem perature cell lysate, 
mixed by gentle inversion and incubated at 37 °C for 15 - 60 mins. A volume of 200 pL of protein 
precipitation solution was added to the cell lysate, vortexed at high speed and incubated on ice 
for 5 minutes prior to centrifugation at 13,000 x g for 3 mins. Gentle inversion was used to mix 
the supernatant with 600 pL isopropanol in a fresh tube and the mixture was centrifuged at 
13,000 x g for 2 mins on a benchtop centrifuge. The pellet was washed with 600 pL 70 % (v/v) 
ethanol and left to air-dry for 60 mins prior to rehydration with the addition of 100 pL DNA 
resuspension solution and storage at -70 °C.
2.3.2 Preparation of Plasmid DNA
Plasmid DNA was isolated from each bacterial culture using the commercially available GenElute™ 
Plasmid Miniprep Kit (Sigma). The method used was as according to the manufacturers' 
instructions. Cells were harvested from an overnight culture of recombinant E. coli culture by 
centrifugation of 1.5 ml culture at >13,000 x g on a benchtop centrifuge. Cell pellets were 
resuspended in 200 pL resuspension solution, and lysed with the addition of 200 pL lysis solution 
and incubated at room temperature for 5 mins. Cell debris was precipitated with the addition of 
350 pL neutralisation/binding solution, and centrifugation at max speed (13,000 x g) for 10 mins. 
A column was prepared and washed through with 500 pL column preparation solution, prior to 
the addition of the cleared lysate and centrifugation at max speed for 1 min. The flow through 
was discarded and bound DNA was washed using 750 pL diluted wash solution. The column was
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centrifuged at max speed for 30 -  60 secs, and the flow through was discarded. Excess ethanol 
was removed by centrifugation of the dry columns for 1 min at max speed. The column was 
transferred to a fresh tube and DNA was eluted with the addition of 50 pL elution solution and 
centrifugation at max speed f o r i  minute. Plasmid DNA was stored a t -20 °C.
2.3.3 Polymerase Chain Reaction
In accordance with the quantities shown in Table 2.4, the region encoding either the mature PorA, 
PorB, FetA, or fHbp antigen was amplified from the meningococcal DNA preparation using the 
polymerase chain reaction (PCR). Oligonucleotide primers (Invitrogen, Paisley, UK) as shown in 
Table 2.5 were used to amplify the genes. Primers were designed with 5' sequence extensions 
required for ligation into the vector (as underlined), followed by the conserved start sequence of 
the target gene, as identified using DNA sequence alignment. All genes were cloned without the  
signal peptide in order to aid in purification of the expressed protein. Where multiple PCRs were 
set up for the same antigen, a master mix of all the components with the exception of the 
template was prepared and dispensed into individual tubes. A negative control was included 
using sterile water in place of template DNA to detect any contamination of the reagents. The 
PCR reactions were carried out in 0.2 ml thin walled tubes in the DNA Engine thermocycler (MJ 
Research), DNA Engine Dyad thermocycler (Bio-Rad, Hemel Hempstead, UK), or the Veriti 96 well 
thermal cycler (Roche, Hemel Hempstead, UK), programmed as shown in Table 2.6.
At the beginning of each reaction the temperature was held at 94 °C for 5 mins. At the end of the 
reaction, the temperature was held at 72 °C for 10 mins, and finally kept at 4 °C until tubes were  
removed from the block. Several methods were used to optimise PCR conditions. These included 
the use of a gradient PCR machine to assay a range of extension temperature for the reaction, the  
addition of Magnesium Chloride in the reaction mix, and the use of sero- and serosubtype specific 
primers where the target gene did not initially amplify.
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Table 2.4 Reagents used in the standard Ek/LIC insert PCR
Component
(Roche) porA
Antigen
porB fetA fHbp
Forward Primer lp M 1 pM l p M 0.5 pM
Reverse Primer lp M 1 pM lp M 0.5 pM
PCR Reaction Buffer 1.5 mM 1.5 mM 1.5 mM 1.5 mM
Magnesium Chloride - 1.5 mM - -
Deoxynucleotide Triphosphate (dNTP) 100 |iM 100 pM 100 pM 100 pM
AmpliTaq polymerase 50 m ll/pL 50 m ll/pL 50 m ll/pL 50 mU/pL
gDna 2pL 2 pL 2 pL 2 PL
Table 2.5 Sequence of oligonucleotide primers used for PCR amplification of the porA, porB, 
fetA  and fHbp  genes.
Gene Primer Name Orientation Primer Sequence
porA PorALICF
PorALICR2
PorALICF5,2
Forward
Reverse
Forward
G ACG ACG ACAAG AT CG AT GT CAG CCT AT ACGGC 
G AGG AG AAG CCCGGT CT AG AATTT GTGG CG CAAAC 
G ACG ACG ACAAG AT CG AT GTTAG CCT GTACGG C
porB PorBLICF
PorBLICR
PorBLICF2b
Forward
Reverse
Forward
GACGACGACAAGATTGACGTTACCCTGTACGG
GAGGAGAAGCCCGGTCTAGAATTTGTGGCGCAG
GACGACGACAAGATTGACGTTACCTTGTACGG
fetA FetALICF
FetALICR2
Forward
Reverse
G ACG ACG ACAAG AT G G CAG AAAATAAT G CCAAG GTCG 
GAG GAG AAG CCCG GTCT AG AACTT GTAGTT CACG C
fHbp fhbpEKLICfl
fhbpEKLICrl
fhbpEKLICr2
fhbpEKLICr3
Forward
Reverse
Reverse
Reverse
GACGACGACAAGATGTGCAGCAGCGGA 
GAG GAG AAG CCCG GT ATT G CTT G G CG G CAAG 
G AGG AG AAG CCCG GTACT G CTT G G CGG CAAG 
GAGGAGAAGCCCGGTACTGTTTGCCGGCGAT
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Table 2.6 PCR programmes used for amplification of the porA, porB, fetA and fHbp genes.
Stage
Time
(secs) porA /fH b p
Temperature
porB fe ta
Denaturation 60 94 °C 94 °C 94 °C
Annealing 60 65 °C 60 °C 63 °C
Extension 120 72 °C 72 °C 72 °C
For 30 cycles
2.3.4 Agarose gel electrophoresis
Amplification products from the PCR and DNA extraction protocols were analysed using agarose 
gel electrophoresis. 0.8 % (w /v) agarose (Gibco®, Fisher, Leicestershire, UK) was heat dissolved in 
1 x TAE buffer and allowed to cool before SafeView (NBS Biologicals, Cambridgeshire, UK) was 
added to the gel mixture (5 pL/100 ml). The gel was cast and allowed to set at room temperature  
for approximately 1 hour. The gel was submerged in 1 x TAE buffer, DNA samples were mixed 
with gel loading buffer (6 x concentration: 0.25 % (w/v) bromophenol blue, 40 % (w /v) sucrose in 
TE buffer), and the samples were loaded into individual wells using a pipette. A 100 bp /  1 Kb 
DNA ladder (Invitrogen) was run alongside the samples to allow estimation of DNA fragment size.
Following electrophoresis at 80 V for approximately 1 hour, DNA fragments were visualised using 
an ultra-violet (UV) trans-illuminator, photographed using the Kodak Ml camera and fragment size 
was estimated using the Kodak Ml analysis software.
2.3.5 Purification of PCR products
PCR amplified DNA was purified using poly ethylene glycol (PEG) precipitation prior to use in the 
cloning protocol. A volume of 95 pL of the PCR product was mixed with 60 pL of 20 % (v/v) 
PEGgooo /  2.5 M NaCI and incubated at 37 °C for 10 mins. The pellet was harvested by 
centrifugation at full speed for 10 minutes, and washed with 500 pL of 80 % (v/v) ethanol. The 
air-dried pellet was resuspended in 25 pL TIowE buffer and stored at -20 °C.
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2.3.6 Cloning o f porA, porB and fetA genes into pET expression vector (Novagen®)
A)
Kan
T7 terminator
M  A *  '
7  A|  pET-30 Ek/UC
[is-tag 
T7 promoter
— lacl coding sequence
T7 promoter His-Tag LIC site
\  Lac Operator |
7 His-Tag 77 terminator
Figure 2.1 pET-30 Ek/UC vector map. A) shows the complete vector, whilst b) only shows the  
cloning/expression region. His-tags are present on either side of the Ligation Independent 
Cloning (LIC) site to ensure the required gene is expressed with a His-tag. The N-terminal his-tag 
is used in this study and is achieved using the stop codon at the end of the cloned gene sequence. 
Restriction sites have not been shown in these maps.
The pET cloning and expression system was developed to facilitate directional cloning of PCR 
products allowing for the incorporation of a polyhistidine tag at either the N' or C' terminus which 
can be used to aid protein purification. Protein purification is further facilitated by the production 
of inclusion bodies, formed as a consequence of high protein expression in the absence of a signal 
peptide. The use of this cloning system and the resulting inclusion bodies allowed expressed 
proteins to be easily isolated by centrifugation, with the addition of a His-tag used for purification 
purposes and also for bead conjugation thereby ensuring high yield and purity. The presence of a 
gene coding antibiotic resistance aids in the selection process with only cells that have 
incorporated the vector capable of growth on selection media.
Annealing of the vector and the insert was performed utilising T4 DNA polymerase to create 
specific single strand overhangs in the vector and the insert allowing for more efficient annealing
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without the need for restriction digestion or ligation. The insert was controlled by a T7 promoter, 
which was in turn under the control of a lac promoter and operator allowing for inducible 
expression of the target protein as required. The presence of a lad  coding sequence in the vector 
results in the production of lac repressor which binds to the lac operator and, in turn ensures that 
T7 RNA polymerase is not able to bind to the T7 promotor and target protein can not be 
expressed. Expression cells such as BL21 (DE3) have a lac promoter sequence in front of the lac 
operator that native E.coli RNA polymerase is able to bind, in place of a T7 promotor sequence. 
Following induction, the lac repressor is bound by isopropyl p-D-l-thiogalactopyranoside (IPTG), 
native RNA polymerase is able to bind to the lac promoter and T7 RNA polymerase can be 
expressed. E.coli T7 RNA polymerase binds to the T7 promotor on the pET30 vector, and the 
target gene is expressed. IPTG is used as inducer of the lac operon as it is not involved in any 
metabolic pathways, and is not broken down or used by the cell and therefore remains constant 
throughout the induction process. Cloning into NovaBlue was used for screening colonies and for 
the establishment of the plasmid. Novablue cells do not possess a T7 RNA polymerase gene and 
therefore ensure plasmid stability due to a lack of protein expression. Cloning of the vector into 
BL21(DE3) cells is used for expression of the target protein.
For this study, amplified DNA fragments were annealed into the pET-30 Ek/UC vector, 
transformed initially into NovaBlue competent cells, and later into the expression host cells BL21 
(DE3) expression cells using the same method. Cells containing the vector and the desired DNA 
fragment were selected using a kanamycin resistance gene. Purified PCR products were treated  
with T4 DNA polymerase in order to produce the compatible single stranded overhangs required 
for cloning. All components used were supplied as a kit (Novagen). Individual components were 
compiled, as shown in Table 2.7, in a fresh tube stored on ice. The reagents were mixed with a 
pipette tip and incubated at 22 °C for 30 min. The reaction was incubated at 75 °C for 20 mins to  
deactivate the enzyme and stop the reaction. The treated product was then stored at -20 °C.
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Table 2.7 Final concentration of reagents used in T4 DNA polymerase treatment
Component (Novagen) Concentration
Purified PCR product 
T4 DNA polymerase buffer 
2'-Deoxyadenosine-5'-Triphosphate (dATP) 
Dithiothreitol (DTT)
T4 DNA Polymerase
-0 .0 1  pM
2.5 mM  
5 mM  
50 mU/pL
The T4 DNA treated PCR product was annealed to the pET-30 Ek/LIC vector (Novagen) prior to the 
transformation into competent cells. For each insert, 1 pL of Ek/LIC pET-30 Vector was mixed 
with 2 pL of the T4 DNA polymerase treated Ek/LIC insert. The mix was stirred with a pipette tip 
and incubated at 22 °C for 5 mins, before 1 pL of 25 m M EDTA was added. The mixture was again 
stirred using a pipette tip and incubated at 22 °C for 5 mins. The annealed vector/insert was 
stored at -20 °C.
NovaBlue GigaSingles™ competent cells (Novagen) and BL21(DE3) competent cells (Novagen) 
were used as detailed in the Novagen Ek/LIC vector kit protocol. The method was performed 
according to the manufacturers' instructions with a single tube of competent cells used per 
transformation. Competent cells were thawed on ice for 5 mins and then flicked to ensure 
complete and even resuspension of the cells. 1 pL of the annealing mixture was added to the cells 
and stirred using the pipette tip before the mixture was incubated on ice for 5 mins. Each tube 
was then heated for exactly 30 secs at 42 °C (without shaking) and incubated on ice for a further 2 
mins. A volume of 250 pL of room temperature SOC media (Novagen) was added to each tube, 
and incubated with shaking for 60 mins at 37 °C. Transformed cells were plated on to LBKan agar 
plates inverted and incubated at 37 °C overnight. Several volumes (5 pL, 20 pL and 50 pL) of cell 
solution were used to inoculate each plate in order to ensure individual colonies were produced.
In accordance with the quantities shown in Table 2.8, the region encoding the incorporated DNA 
insert was amplified from each transformed colony using PCR. The T7 primer binding site was
61 | P a g e
found on either side of the insertion site, and so can be used to estimate the size of the 
incorporated DNA insert. The sequence of the T7 promoter and term inator primers can be found 
in Table 2.11. Where multiple PCR reactions were set up, a master mix of all the components with 
the exception of the template was prepared and dispensed into individual tubes. A negative 
control was included using sterile water in place of transformed cells to detect any contamination 
of the reagents. The PCR reactions were carried out in 0.2 ml thin walled tubes placed in the DNA 
Engine (MJ Research), DNA Engine Dyad (Bio-Rad), or the Veriti 96 well thermal cycler (Roche), 
programmed as shown in Table 2.9. At the beginning of each reaction the temperature was held 
at 94 °Cfor 5 mins. At the end of the reaction, the temperature was held at 72 °Cfor 10 mins, and 
finally kept at 4 °C until tubes were removed from the block.
The resulting PCR product was examined by gel electrophoresis, UV visualisation and fragment 
analysis to estimate the size of the DNA insert. Colonies containing a single DNA fragment of the 
expected size were taken forward for plasmid DNA extraction and nucleotide sequencing.
Table 2.8 Final Concentration of reagents used in the Colony Screening PCR.
Component (Roche) Concentration
T7 Promoter Primer 
T7 Terminator Primer 
PCR Reaction Buffer 
dNTP
AmpliTaq polymerase
lp M  
1 |iM  
1.5 mM  
200 pM  
50 m ll/pL
Table 2.9 PCR programmes used for amplification of the Incorporated DNA insert
Stage Temperature
Time
(seconds)
Denaturation 94 °C 60
Annealing 43 °C 60
Extension 72 °C 120
For 30 cycles
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2.3.7 Nucleotide sequencing and sequence analysis
ABI prism™ BigDye™ Terminator Cycle Sequencing Ready reaction kit (Roche) was used in the 
preparation of all sequence reactions. Reactions were set up as shown in Table 2.10 below. The 
sequence of the oligonucleotides used in the sequencing reactions are given in Table 2.11. All 
inserts were sequenced using the T7 promoter and term inator regions on the vector in addition to 
primers targeted to internal portions of the gene of interest. PorA was sequenced using the 8U 
and 122L sequencing primers described previously(290). DNA alignments were produced for each 
gene of interest, and conserved regions were used to design primers in order to allow reading of 
the complete gene sequence. The T7 promoter and term inator regions were sequenced using 
primers recommended by Novagen for use with the pET30 Ek/LIC vector kits.
Table 2.10 Reagents used in the standard sequencing reaction.
Reagent Concentration
Term inator Ready Reaction M ix  
PCR product (DNA tem plate) 
Sequencing Buffer 
Sequencing Primer
l x  
~ 20 ng 
l x  
0.5 mM
. Cycle sequencing of the sequencing reactions was performed according to the conditions stated in
Table 2.12 and run on a DNA Engine (MJ Research) following pre-existing laboratory protocols. All 
centrifugation steps for this method were performed using the Sorvall Super T21 centrifuge, with 
the ST-H750 rotor. Products from the sequencing PCR were purified using ethanol precipitation. A 
volume of 10 pL of sterile water and 5 pL 125 m M EDTA were added to each sequencing reaction, 
together with 80 pL 99 % (v/v) ethanol and each sample was incubated at room tem perature for 
approximately 1 hour. DNA was collected by centrifugation at 3000 x g, washed with 200 pL 70 % 
(v/v) ethanol and incubated at room temperature for 5 mins. DNA was harvested by 
centrifugation at 1800 x g for 15 mins and the pellet was dried by spinning the open tubes
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inverted in the centrifuge for 2 mins at 900 x g. Each pellet was resuspended in 10 pL Hi-Dye 
Formamide (Roche) and stored at -20°C prior to loading on the sequencer.
Table 2.11 Sequence of oligonucleotide primers used for sequencing pET-30 vector inserts.
Gene Primer Name Orientation Primer Sequence
pET vector T7 promoter Forward T A AT ACG ACTCACTATAG G G
T7 term inator Reverse GCTAGTTATTGCTCAGCGG
porA 8 U Forward TCCGTACGCTACGATTCTCC
122L Reverse GGCGAGATTCAAGCCGCC
porB PorBfwd Forward GCGAAGCTTCCCTGATTGCCCTGACTTTG
PorBrev Reverse GCGAAGCTTTGTGGCGCAGACCGAC
fetA S I Forward CGGCGCAAGCGTATTCGG
S4 Reverse GCGCTTTGATTTCCTGATGG
fHbp fH bpfl Forward GTCGCCGCCGACATCGGTGCGG
fHbpr2 Reverse CTGCTTGGCGGCGAAATC
fHbpsr3 Reverse GGAACTCTCCACTCTCCAAGG
Table 2.12 Sequencing programme used for cycle sequencing reactions
Temperature Time
cc) (seconds)
96 30
50 15
60 240
For 25 cycles
Separation and detection of the extension products, for all the genes sequenced, was carried out 
on an ABI Prism 3130x1 Genetic Analyzer (Roche). Sequences were analysed using either the  
Vector NTI software analysis programme (Invitrogen), or the Ridom Trace Edit Pro (Ridom GmbH, 
Germany). Variants of PorA, FetA and fHbp  were identified using sequences published on the  
Pubmlst.org website (http://pubm lst.0 rg/A/e/sser/0 / ).
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2.4 Biochemistry Techniques
2.4.1 Expression of target proteins using the His-Bind System (Novagen)
An overnight culture of LBKan and 1 % (w/v) glucose, inoculated with a single bacterial colony was 
used to seed 100 ml of LBKan and 1 % (w/v) glucose in a 500 ml flask. The volume of overnight 
culture used was sufficient to give an optical density as measured at an Optical Density 
wavelength of 600 nm (OD600) value of 0.05, measured using a WPA Biowave Cell Density meter 
(Biochrom WPA, Cambridge, UK). This is a widely used value in protein expression protocols and 
ensured the bacterial cells were in the optimal growth phase prior to induction with IPTG.
The culture was incubated at 37 °C with shaking and sampled hourly until the OD600 value was in 
the range of 0.5 and 0.6. This value is again widely used in protein expression protocols and is 
when the cells have reached the mid log phase of growth and ensured protein production 
following induction.
Bacterial cultures were induced with 1 m M IPTG, and incubated with shaking at 37 °C. Whole cell 
lysate (WCL) samples were taken every hour and the OD600 value was recorded and used to 
prepare a growth curve. Following protein induction, the culture was chilled on ice for 5 mins and 
cells were collected by centrifugation at 4000 x g (Sorvall RT, or RC-5B for larger cultures) for 20 
mins. The culture supernatant was discarded and the wet weight of the pellet was calculated. 
The cell pellet was stored a t -70 °C.
2.4.2 Protein Purification
Protein purification was performed using the Bugbuster® protein extraction reagent (Novagen) 
following the manufacturers protocols. Bugbuster is a propriety mixture of non-ionic detergents, 
used to perforate the cell wall without denaturing soluble protein. The addition of rLysozyme™ 
solution and Lysonase™ bioprocessing reagent (all supplied by Novagen) increased the efficiency 
of protein extraction and facilitated the downstream processing of protein extracts. Lysonase 
bioprocessing reagent was an optimised mixture of rLysozyme and benzonase nuclease.
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rLysozyme was used to lyse gram-negative bacteria whilst benzonase nuclease was an 
endonuclease used to degrade all forms of DNA and RNA, resulting in reduced extract viscosity 
and increased protein yield. All centrifugation steps for this method were performed using the 
Sorvall RT centrifuge. A pre-weighed centrifuge tube was used for the collection of the pellet at 
each stage of purification, in order to allow measurement of the resulting pellet.
The frozen cell pellet was thawed, and resuspended in room temperature BugBuster® reagent 
using 5 ml of Bugbuster® reagent for every gram of w et cell paste. Lysonase was added at 10 \ i l  
per gram of w et cell paste, and the cell suspension was mixed on a shaking platform at a slow 
setting until it was no longer viscous (approximately 20 mins). The suspension was centrifuged for 
20 mins at 16,000 x g and 4 °C and the pellet was resuspended in BugBuster® reagent (5 ml/gram  
pellet w et weight). rLysozyme was added to a final concentration of 1 KU/ml and the mixture was 
incubated at room tem perature for 5 mins. A further 6 volumes of 1:10 diluted BugBuster® 
reagent (in deionised water) was added and inclusion bodies were harvested by centrifugation at
5.000 x g for 15 mins at 4 °C.
The pellet containing the inclusion bodies was washed twice by resuspension in half the original 
volume of 1:10 diluted BugBuster® reagent (10 ml per gram of pellet wet weight), and centrifuged 
at 5,000 x g for 15 mins at 4 °C. Purified inclusion bodies were collected by centrifugation at
16.000 x g for 15 mins at 4 °C, and resolubilised in TE + 8 M Urea to give a final concentration of 
15 mg w et weight per ml of buffer. An equal volume of 20 m M Tris, 1 M NaCI, 2 % (w /v) Z3-14 
was added to the resolubilised solution in order to give the supernatant a final concentration of 
15 mM Tris, 4 M Urea, 0.5 % (w/v) NaCI, 1 % (w /v) Z3-14 prior to dialysis.
Protein was refolded by dialysis against Dialysis Buffer 1. The supernatant was transferred to 
dialysis tubing (Pierce, Fisher), the air bubbles removed and the tubes sealed using clips. Each 
tube was placed in a beaker containing 25 x volume Dialysis Buffer 1 and incubated with gentle 
stirring for 2-3 hours at room temperature. Five changes of buffer were used with the final 
change incubated at 4 °C overnight. Debris was removed by centrifugation at 16,000 x g for 10
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mins at 4 °C and refolded protein was collected. This was a pre-existing method used in the 
laboratory previously for purification of PorA and FetA, and refolding of proteins using this 
protocol have previously been determined. Due to the use of Triton X-100 traditional methods 
for determination of protein refolding could not be used in this study. For the purposes of this 
study, confirmation of refolding and the correct presentation of the variable epitopes of PorA and 
PorB were established with the use of monoclonal antibodies. Anti-FetA antibodies were not 
available, and so could not be used for the structural confirmation.
The following buffers were provided as concentrated solutions in the Novagen His-Bind kit and 
were diluted and supplemented with either Z3-14 or Triton X-100 as described. The volume of 
resin was calculated allowing 1 ml of resin for every 8 mg of protein to be purified.
•  Charge buffer (50 mM Nickel sulphate (NiS04) (Sigma))
•  Bind buffer (20 mM Tris-HCl pH 7 .9 ,0 .5  M NaCI, 5 mM Imidazole, 0.05 % (w/v) Z3-14)
•  Wash buffer (20 mM Tris-HCl pH 7.9, 0.5 M NaCI, 60 mM Imidazole, (9 mM for FetA) 0 .2%  
(v/v) Triton X-100)
•  Elute Buffer (20 mM Tris-HCl pH 7 .9 ,0 .5  M NaCI, 1 M Imidazole, 0.2 % (v/v) Triton X-100) 
For small scale purification, columns were packed with 2 ml his-bind resin (Novagen) using a wide 
mouthed pipette and allowed to settle under gravity flow, to give a 1 ml settled bed volume. 
Once the level of storage buffer dropped to the top of the column bed, the column was washed 
and charged with 3 column volumes of water, 5 column volumes of l  x charge buffer and 3 
column volumes of 1 x bind buffer. For large scale purification, 20 ml of resin was used, allowing 
for a 10 ml settled bed volume, and each step was performed using centrifugation at 500 x g 
(Sorvall RT centrifuge) for 1 minute.
Imidazole was added to the refolded protein extract at a final concentration of 5 mM before the  
extract was loaded onto the column. The extract flow through was collected and reapplied to  
the column to ensure sufficient binding of the protein to the charged resin. The column was 
washed with 10 column volumes 1 x binding buffer and 6 column volumes 1 x wash buffer prior to
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elution of the purified protein using 6 column volumes of 1 x elution buffer. Imidazole was 
removed from the purified protein using dialysis against Dialysis Buffer 2. Imidazole acts by 
competing with Nickel sulphate to bind the His-tag on the target protein. Low concentrations of 
Imidazole are used in the wash buffer to limit non-specific binding, whilst a much higher 
concentration in the elution buffer ensures elution of the protein from the Nickel charged protein 
purification column.
Protein was concentrated using Ultra-15 centrifugal filters (Amicon, Millipore, Billerica, MA, USA) 
with a 10 kDa molecular weight cut off and centrifugation at 4000 x g for 20 mins (Sorvall RT).
2.4.3 Protein Concentration
SDS polyacrylamide gel electrophoresis (PAGE) was used to separate proteins according to size. 
Gel casting equipment (Bio-Rad) was assembled and the resolving gel was prepared as shown in 
Table 2.13. The gel was poured between the assembled plates, and overlaid with water saturated 
butanol to ensure a flat even surface at the top of the gel, and to exclude air which would have 
prevented polymerisation. The gel was allowed to set for an hour at room tem perature, prior to 
removal of the butanol with several washes of water. The sandwich was blotted dry with blotting 
paper and the resolving gel was overlaid with the stacking gel, assembled as described in
Table 2.14. A comb was inserted into the top of the stacking gel and the gel was allowed to set at 
room temperature.
Table 2.13 Reagents used in the preparation o f the resolving gel.
Reagent Concentration
Bis-Acrylamide (Bio-Rad)
Tris-HCl pH 8.8 
SDS
Ammonium persulphate (APS) (Amresco) 
Tetramethylethylenediamine (TEMED) (Bio-Rad)
1 2 % (v/v) 
390 mM  
0.1 % (w/v) 
0.1 % (w/v) 
0 .04%  (v/v)
Total Volume 35 ml
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Table 2.14 Reagents used in the preparation of the stacking gel.
Reagent Concentration
Bis-Acrylamide 
Tris-HCl pH 8.8 
SDS 
APS 
TEMED
9.75%  (v/v) 
325 mM  
0.26 % (w/v) 
0.25 % (w/v) 
0.1 % (v/v)
The gel was submerged in 1 x SDS running buffer and protein samples were mixed with an equal 
volume of 1 x SDS loading buffer, made up as shown in Table 2.15. The mixture was incubated at 
97 °C for 5 mins and loaded into individual wells using a pipette. A prestained SDS-PAGE broad 
range standard (Bio-Rad) was used to allow estimation of protein band size, following 
electrophoresis at 30 mA (or 8 mA if run overnight) until the dye front reached the bottom of the 
gel. In order to visualise the protein bands, the gel was submerged in Coomassie brilliant blue 
solution and incubated at room temperature overnight, with gentle shaking. Excess stain was 
removed with several washes in Coomassie brilliant blue destain until bands were clearly visible. 
The gel was then photographed and band size was estimated using the Kodak Ml camera, and 
Kodak Ml analysis software.
Table 2.15 Chemical composition of the SDS loading buffer.
Reagent Concentration
Sucrose 
SDS 
Tris-HCl pH 6.8 
B-Mercaptoethanol 
Bromophenol Blue
10 % (w/v)
2 % (w/v)
62.5 mM  
5 %  (v/v) 
Enough to add colour
Protein concentration was determined using the BCA assay (Perbio, Fisher). A standard curve was 
produced using nine concentrations of bovine serum albumin (BSA) ranging from 0 - 2  mg/ml in 
water. The working reagent was prepared by combining 50 parts Reagent A with 1 part Reagent B.
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Samples were diluted in dialysis buffer to give a dilution range from 1:10 to 1:100 in order to 
ensure the concentration could be calculated from the standard curve. A volume of 200 pL of the 
working reagent was added to 10 pL of each standard and sample (undiluted and diluted) in a 96- 
well plate, and mixed for 30 secs on a microtitre plate shaker. The plate was covered with a plate 
lid and incubated at 37 °C for 30 mins. The absorbance was read at a wavelength of 570 nm using 
a microtitre plate reader (Labsystems Multiskan MS), and used to produce a standard curve. A 
line of best fit was used to estimate concentration of the purified protein.
2.4.4 Monoclonal Antibody Concentration
Monoclonal antibody concentration was determined using the Easy-Titer Mouse-IgG kit (Thermo, 
Fisher). A standard curve was produced using six concentrations of Mouse IgG whole molecule 
control standard (Thermo, Fisher) ranging from 500 -  15.6 ng/ml in dilution buffer. Anti-IgG 
sensitised beads were mixed thoroughly and vortexed vigorously for 60 seconds prior to use in 
the assay. MAbs were diluted in dilution buffer to give a dilution range from 1:100 to 1:5000 in 
order to ensure the concentration could be calculated from the standard curve. A volume of 20 
pL of the sensitised beads was added to 20 pL of each standard and sample (undiluted and 
diluted) in a 96 well plate and mixed for 5 mins on a microtitre plate shaker on moderate to high 
speed. A volume of 100 pL blocking buffer was added to each well and mixed for 5 mins on a 
microtitre plate shaker on moderate speed to prevent spills. The absorbance was read at a 
wavelength of 340 nm using a microtitre plate reader (Labsystems Multiskan MS), and used to 
produce a standard curve. A line of best fit was used to estimate MAb concentration.
2.5 Liquichip Assay
A Liquichip assay is a microsphere assay based on Luminex xMAP technology and involves the use 
of internally labelled fluorescent microspheres as a solid phase platform for the interaction of 
immobilised, microsphere bound capture molecules with analytes in solution. The reaction was 
quantified using a secondary reporter molecule specific for the analyte. Each microsphere is 
labelled with a combination of red and infrared dyes, resulting in a unique fluorescent signature,
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with the potential for up to 100 different microspheres to be used within a single assay. Coupling 
different capture molecules to different microspheres enables the individual detection of multiple 
antigens simultaneously.
2.5.1 Bead Preparation
Bio-Plex™ carboxy microsphere sets (Bio-Rad) were prepared as described previously*170’. Bio- 
Plex™ carboxy microsphere sets were washed 3 times and resuspended to 2 x 108 
microspheres/ml in 0.05 M 2-(N-morpholino)ethanesulfonic acid buffer (MES) (pH 6.5, Fisher 
Scientific) with centrifugation at 14,000 x g for 2 mins in a benchtop centrifuge. Microsphere sets 
were activated with the addition of 0.1 mg N-hydroxysuccinimide (NHS) (Acros chemicals, Fisher) 
and 1 mg l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCI (EDC) (Fisher) per 1 x 108 
microspheres and incubated at 22 °C for 10 mins with shaking.
Microspheres were collected by centrifugation at 14,000 x g for 2 mins, and resuspended in 0.1 M 
4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) (pH 8.0) (Sigma) to give a final 
concentration of 1 x 108 microspheres/ml. 1 mg of EDC and 0.1 mg NHS were added per 1 x 108 
microspheres prior to the conjugation with N-(5-amino-l-carboxypentyl)iminodiacetic acid (NTA) 
ligand (Sigma, Fluka chemicals). The microsphere mix was incubated with 4 x 1010 molecules of 
NTA ligand for every microsphere and incubated at 22 °C for 18 hours.
Microspheres were harvested by centrifugation at 14,000 x g for 2 mins and resuspended in 1 ml 
50 mM Tris buffer, pH 8.0 + 0.005 % tween 20 in order to remove residual free carboxy groups. 
The pellet was washed twice with 600 pL PBS + 0.005 % tween 20 using centrifugation at 14,000 x 
g for 5 mins. Microspheres were resuspended in 1 ml of 500 pM nickel chloride (Fisher) and 
incubated at 22 °C for 2 hours, prior to 3 washes and final pellet resuspension to 5 x 107 
microspheres/ml in PBS + 0.005 % (v/v) tween 20. Nickel coated microsphere sets were stored at 
4 °C protected from light.
Nickel coated microspheres were diluted to 1 x 107 microspheres/ml in PBS/BSA/Triton X 100 
buffer (PBS + 0.1 % (w /v) BSA + 0.05 % (v/v) Triton X-100) in preparation for protein coating and
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vortexed to ensure an even suspension, prior to incubation with an equal volume of 100 pg/ml 
purified protein solution. The mixture was protected from light and incubated at 4 °C for 3 days.
Microspheres were transferred to a microcentrifuge tube and harvested by centrifugation at
10,000 x g for 2 mins using a benchtop centrifuge. The pellet was washed twice with 1.5 ml 
PBS/BSA/Triton X-100 buffer and resuspended at approximately 2 x 107 microspheres/ml in 
PBS/BSA/Triton X-100 + 0.05 % (w /v) sodium azide buffer.
Whilst conformation of the PorA protein following microsphere labelling was not checked, 
antibodies specific to either VR1 or VR2 regions were used to determine the correct presentation 
of the antibody binding sites for this protein using the Liquichip assay (chapter 4).
A Guava EasyCyte flow cytometer (Millipore) was used to count the protein labelled microsphere. 
A sample sheet was set up, using the following parameters: 2500 microsphere counts; 300 sec 
timeout; 0 replicates; medium flow rate, and microsphere solutions were used to prepare a 1:125 
diluted sample in PBS/BSA/Triton X-100 buffer. The samples were read according to the machine 
settings described in Table 2.16 and the number of microspheres per millilitre was calculated.
Table 2.16 Setting used to set up the Guava EasyCyte flow Cytometer
Variable Setting
Red 850
Yellow 850
Green 0
FSCGain 32
SSC 346
MinMax 150%
Flow Rate Medium
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2.5.2 PorA Assay
A LiquiChip filter microplate (Qiagen, Crawley, UK) was used for the assay, and the solution was 
removed following each step using a vacuum pump.
Microsphere sets were made up to contain 2500 of each PorA labelled microspheres, in a total 
volume of 25 pL, for every assay point to be measured. In a separate microplate, six 3 - fold serial 
dilutions of the standard, the samples and a buffer-only control were prepared, with 25 pL of sera 
used for each assay point. Each well of the 96-well filter microplate was pre-wet with 50 pL 
PBS/BSA/Triton X-100 buffer, which was removed using the vacuum pump and discarded. This 
step ensured proper filtration of the samples. A volume of 25 pL of the serum sample and the 
standard was added to the plate followed by 25 pL of the microsphere mixture, then vortexed to 
ensure an even suspension of microspheres. The microplate was agitated with a Whirlimixer 
(Fisher) used with a plate attachment, ensuring the contents of the wells were not spilt. The plate 
was covered in foil and incubated on a platform shaker at room temperature for 25 mins. The 
supernatant was removed using the vacuum pump and the microplate was washed twice with 50 
pL PBS/BSA/Triton X-100 buffer, to remove any unbound antibodies.
A total of 200 ng anti-IgG recombinant phycoerythrin (rPE) conjugate (directed against human or 
mouse IgG as required) in a volume of 50 pL was added to each well and the plate was agitated 
and incubated as before. The supernatant was removed and the microplate was washed twice 
with 50 pL PBS/BSA/Triton X-100 buffer to remove any unbound antibodies. The 
microsphere/serum mixture was resuspended in 150 pL PBS/BSA/Triton X-100 buffer and agitated 
using a whirlimixer with a plate attachment prior to loading on the Liquichip 100 workstation 
(Luminex, Qiagen).
A sample volume of 70 pL, a minimum of 100 microspheres and a tim eout of 45 secs were used 
for the measurement of each sample. These values were used as stated in the Liquichip manual. 
Microsphere regions were matched with the corresponding protein, and standards were assigned 
an arbitrary concentration of 0 -1 0  ng/ml in order to aid calculation of sample concentrations and
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to allow comparison of samples over several assays. Due to the unknown concentration of 
antibodies present in the human standard used, the most concentrated standard (1:100 dilution) 
was assigned an arbitrary concentration of 10 ng/ml, and the most dilute standard (1:24300 
dilution) assigned an arbitrary concentration of 0.04 ng/ml. In total six dilution in a three dilution 
series were used. These values were then used to plot a standard curve for the determination of 
sample concentrations.
Prior to use, the Liquichip workstation was calibrated using both control and calibration beads as 
provided by Qiagen. Using the Luminex IS 2.1 software (Qiagen), a standard curve was plotted 
using the 4 Parameter Logistic (4PL) nonlinear regression model and used to calculate the 
arbitrary concentrations for each of sample. This model is commonly used for curve-fitting 
analysis in bioassays or immunoassays such as ELISAs.
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Chapter 3. Cloning. Expression and Purification of the PorA. PorB and FetA gene 
variants.
3.1 Introduction
The aim of this project was to develop a multiplex assay for the detection and quantification of 
outer membrane proteins. In order to do this, variants of PorA, PorB and FetA had to be cloned, 
expressed and purified. These proteins, particularly PorA and PorB, are important as vaccine 
components*79* as they have been shown to be the targets of bactericidal antibodies*347*. These 
proteins are also used for serotyping (PorB) and serosubtyping (PorA) meningococci*101*.
Stocks of purified antigens needed to be produced in order to develop a multiplex assay for the  
detection of PorA, PorB and FetA variants. For this: seven PorA serosubtypes; a PorA mutant 
(P I.__,_), cloned and expressed as a PorA protein in which both VR1 and VR2 regions were 
deleted; four PorB serotypes; and five FetA variants were cloned and used for the expression of 
protein. Polyhistidine-tags (His-tag) are able to bind metal ions such as nickel with good efficiency 
under specific buffer conditions. The proteins were expressed with a His-tag at their 1ST terminus 
to facilitate affinity purification of protein using a His-Bind resin column charged with a nickel 
sulphate solution, with proteins bound to the nickel within the column prior to elution with an 
elution agent such as Imidazole. Additionally, affinity between the His-tag and the nickel ions can 
be used and as a method for coupling the protein to a nickel coated microsphere for use in the  
assay described in Chapter 4.
For each of these antigens, variants were chosen for their association with hypervirulent lineages, 
ability to cause disease and their continued presence among circulating strains in England and 
Wales(126). In addition, PorA serosubtypes were chosen to include variants used in vaccines. A 
PorA P l._ ,_  mutant was also cloned, and protein from this mutant was purified to determine the  
responses, if any, to the backbone of the PorA protein. The pET cloning and expression system is 
widely used for the protein expression was chosen for several reasons. This system allowed for 
the directional cloning of PCR products without restriction digestion; the incorporation of a
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polyhistidine tag (Figure 3.1); and has been shown to be reliable for high efficiency expression and 
purification of meningococcal proteins*1295, N. gonorrhoeae proteins NspA*3585, and PorB*57'1785.
T7 promoter His-Tag LICsite His-Tag
^ Lac Operator J |
==HZZ>~1====M  - | .......  - ■
Figure 3.1 Cloning/Expression region of the pET30/EkLIC vector.
In this system, the expression of the cloned gene is under the control of a 17 promoter, which is in 
turn under the control of a lac promoter and operator allowing for inducible expression of the 
target protein as required. The selective and active T7 promotor ensure that almost all of the 
cell's resources are directed to expression of the target gene resulting in the protein of interest 
making up more than 50 % of the total cell proteins*1295. A kanamycin resistance gene, also 
contained within the vector, provides for the selection of transformed colonies and adds stability 
to the vector. The formation of inclusion bodies, a consequence of high protein expression in the 
absence of a signal peptide, facilitates purification, resulting in less contamination with unwanted 
E. coli proteins. The protein antigens were purified using immobilised metal affinity 
chromatography (IMAC). The target protein, expressed with an incorporated His-tag, binds to the  
nickel cations, which in turn bind to the His-Bind resin column. Elution of protein from the His- 
Bind column was achieved by the use of imidazole containing buffer.
The porin PorA is 44 -  47 KDa outer membrane protein. It has a 16-stranded (3-barrel structure 
with eight cell surface exposed loops, and two distinct VRs, VR1 and VR2 corresponding to loops 1 
and 4, respectively*198,1885. VR1 and VR2 are the longest surface exposed loops and induce 
bactericidal antibodies*3245. A third VR is located on loop 5 however this is less variable and 
therefore not thought to be as immunologically important. High sequence homology is observed 
throughout the rest of the protein.
PorB makes,up the majority of channels in the Neisserial outer membrane*3565. It is between 37 -  
42 KDa and has a similar transmembrane structure to PorA. The surface exposed loops showing
T7 terminator
/>
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the greatest variability are also the longest (loops 1, 5 /6 , and 7 )(318'313). These loops contribute to 
the discontinuous serotype epitopes that are recognised by MAbs used for serotyping*855. 
However, antibody-based typing is decreasingly used for meningococcal typing having largely 
been superseded by nucleotide sequence based typing*2'3,2965. PorB is an important component of 
OM V vaccines, including Bexsero and antibody responses against epitopes of PorB have 
previously been reported in up to 74 % of individuals following vaccination*735. However, no 
response against PorB antigens was observed following immunisation with four doses of the 
Norwegian OMV vaccine*2145. More recently, the use of PorB as vaccine adjuvant to boost the  
immune response with fewer doses of the vaccine has been described*2345.
The iron repressible FetA OMP is a member of the TonB dependant class of outer membrane 
proteins*605. FetA, like PorA and PorB is also highly variable, and consists of a transmembrane P 
barrel structure with 13 surface exposed loops, of which loop 7 is the longest and most 
immunodominant variable region*3225. There are nine main families of FetA, consisting of over 400 
variants, and more being identified regularly (http://pubmlst.org/A/e/sser/o/FetA/). As for PorA 
and PorB, the high degree of variability observed with this protein is a sign that the FetA antigen is 
a target for a potentially protective immune response in humans and suggests it may be an 
important component of strain specific OMV vaccines*296,795. However the diversity of FetA types 
presents several challenges in the design of a vaccine, with difficulties associated with achieving 
coverage over a wide range of strains*297,3305. Conversely, meningococci collections have been 
found to be dominated by a relatively small number of discrete combinations of PorA, FetA 
variants and clonal complexes. These antigenic types are found to persist of periods of time  
sufficient for the administration of vaccination programs and proliferate globally, suggesting the
promise of FetA as a vaccines candidate*3405.
The complement system is an important component of innate immune defences against the  
meningococcus, and deficiencies in the components of the alternative complement pathway lead 
to an increased risk of meningococcal disease*1745. The alternative pathways includes a 
mechanism which amplifies the deposition of C3b on the microbial surfaces using a positive
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feedback loop, in addition to maximising the killing activity elicited by select anti-meningococcal 
Abs(15). Factor H limits the unwanted activation of alternative pathway through irreversible 
disassociation of the alternative pathway C3 convertase, limiting C3 activation*1745. Meningococci 
fHbp is critical for meningococcal survival in the human host as it is thought to interact specifically 
with human factor H resulting in down-regulation of the alternative complement pathway 
through the down-regulation of deposition and inactivation of C3b on the meningococcal surface 
leading to serum resistance of the bacteria and protection form immune attack <272'125'146)> The 
fHbp protein has proved to be a virulence factor for N. meningitidis and a target for functional 
bactericidal antibodies*2005. Diverse activities have been reported for anti-fHbp antibodies, from  
inhibition of factor H binding, to increased meningococcal killing in strains with low level 
expression of fHbp. This protein is an important component of a meningitis vaccine that has 
undergone clinically trials and has been licensed for use as part of a multicomponent vaccine. 
However, some meningococcal isolates, collected from patients of invasive disease have been 
found to lack expression of fHbp, suggesting some meningococcal strains possess novel means of 
inhibiting complement activation in the absence of the fHbp*1805. As with the other proteins 
mentioned, multiple variants of this antigen have been described 
(http://pubm lst.org/Neisseria/fHBP/)*195'2115.
3.2 Aims of this Chapter
The aims of this chapter were to:
•  To develop cloning strategies to express these antigens as polyhistidine tagged proteins in 
E. coli;
•  To purify the predominant variants of these antigens from hypervirulent isolates and 
commonly circulating meningococci as a basis for the development of a multiplex 
antibody binding assay.
3.3 Results
3.3.1 Amplification and Cloning of porA,porB  and fe tA  genes
Sixteen N meningitidis isolates (Table 3.1) were cultured and gDNA was extracted prior to PCR 
amplification targeting either the porA, porB, fetA  or fHbp  gene as shown in Table 3.1. 
Meningococcal isolates encoding the required serotype, serosubtype or FetA type were identified 
in the NIBSC database. Isolates encoding two of more of these genes were picked where possible 
in the first instance and used for the extraction of gDNA. Isolates used for the amplification of 
fHbp  were provided by the UK-MHPHLS for the purpose of this study.
A single PCR product corresponding to the predicted size of amplified bacterial DNA was observed 
for all genes amplified (Figure 3.2, Figure 3.3 and Figure 3.4). Figure 3.2 shows amplification of 
the porB gene encoding the 2a serotype with a PCR product of ~ 1 Kb. Figure 3.3 shows 
amplification of the fetA  gene encoding the F3-6 variant with a PCR product of ~ 2.1 Kb, and the  
porA gene encoding the P I. 19-1,15-11 serosubtype with a PCR product of 1.3 Kb. Figure 3.4  
shows amplification of the fHbp  gene encoding the v2.4 variant with a PCR product of ~ 800 bp. 
For most variants, 100 % of the colonies picked were successfully transformed. Successful 
transformation was found to be dependent on the quality of DNA resulting from amplification. 
For example transformation of the porA gene encoding the P l.5,2  variant of PorA and the gene 
encoding the 2b serotype of PorB was less successful due to failure of the PCR to amplify DNA 
encoding a single gene of interest. For isolates in which multiple PCR products were observed, a 
number of methods were utilised to optimise PCR amplification. These included increased 
stringency, decreased template DNA concentration, nested PCR or excision of the required band 
and subsequent gel purification. For PCR reactions where no band was produced, an alternate 
Neisseria (meningococcal) isolate was used in the first instance, followed by lower stringency 
conditions, including higher concentrations of magnesium chloride and a lower annealing 
temperature. For both of these variants, primers specific to the sequence of the isolate were  
ordered and used for PCR amplification. Eight serosubtypes of PorA were amplified in this way
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along with three serotypes of PorB, five variants of FetA and four variants of fHbp. It was not 
possible to amplify a single PCR product for the 2b serotype of porB and fHbp  variant 1.11. 
Possible explanations for difficulties in the amplification of these genes may include differences in 
secondary structure of DNA. The primer sequence used for the amplification of porB was based 
on the FAM18 sequence, believed to be the PorB 2a protein and may result in insufficient primer 
binding for successful amplification of the porB 2b gene. Poor quality of gDNA used for 
amplification or size of the insert may also explain difficulties in amplification of the required 
target however problems with amplification of these variants has not previously been reported, 
and the use of alternative gDNA and strain specific primers did not aid in cloning attempts.
10180 bp
Figure 3.2 Agarose gel electrophoresis o f PCR products following amplification of the porB  gene 
using the PCR conditions as described in Section 2.3.3. Lane 1 shows the 1 Kb ladder 
(Invitrogen), Lanes 2 -  4 show PCR products resulting from amplification of porB from Nm 2918 
(PorB 2a), with increasing concentrations of DNA used as a template, and Lane 5 contains a 
negative control.
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Figure 3.3 Agarose gel electrophoresis of PCR products following amplification of the fetA  and 
porA  genes, using the PCR conditions as described in Section 2.3.3. Lane 1 contains a negative 
control, Lanes 2 - 4  show PCR products resulting from amplification of fetA  from Nm 2828 (F3-6) 
and Lanes 5 - 7  show PCR products resulting from amplification of porA  from Nm 3069 (P I.19- 
1,15-11). Lane 8 contains a 1 Kb Ladder (Invitrogen) used to estimate the size of the PCR 
products.
10180 bp
Figure 3.4 Agarose gel electrophoresis of PCR products following amplification of the fHbp  gene 
using the conditions described in section 2.3.3. Lane 1 and 12 shows the 1 Kb ladder 
(Invitrogen), Lanes 2 - 1 1  show PCR products resulting from amplification of fHbp  from Nm 3059 
(v2.4) with extension temperatures increasing from 60 °C to 70 °C. All temperatures were found 
to produce a single PCR product of approximately 800 bp.
81 | P a g e

83 
| 
P 
a 
g 
e
3.3.2 Screening of transformed colonies
3.3.2.1 Colony PCR
Twelve single colonies were picked from each transformation and screened using colony PCR, 
with primers directed towards the T7 promoter and the T7 term inator sites, found on either side 
of the inserted gene sequence within the cloning region of the vector. Incorporation of the 
correct DNA fragment and vector was confirmed by a shift in the size of the PCR product from  
vector alone (360 bp) to the expected size of the vector with the complete DNA fragment, 
approximately 1.4 Kb for variants of the porA and porB genes, approximately 2.5 Kb for variants of 
th efe tA  gene (Figure 3.5) and approximately 1.1 Kb for variants of th efH b p  gene. PCR products 
of the expected size were produced for all genes and variants. For the porA gene, 100 % of the  
transformed colonies picked were found to have successfully incorporated the gene insert. For 
porB and fetA  approximately 60 % of picked colonies were found to have been successfully 
transformed. This may be due to the size of the FetA insert, which is considerably larger than the 
other target genes. Incomplete corporation of the porB gene may be a result of issues with 
amplification of the gene, with multiple bands observed in the gel following amplification of the  
target gene (Figure 3.2), it is possible that a smaller fragment had been inserted into the vector in 
preference to the larger porB fragment.
10180 bp
Figure 3.5 Agarose gel showing a shift in fragm ent size from  vector alone (lanes 1 and 2) to  
colonies transformed w ith the fetA  gene (lanes 3 -  6). Lane 7 contains the 1 Kb molecular weight 
ladder.
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3.3.2.2 Sequencing
Plasmid DNA was sequenced using both forward and reverse primers and used to deduce the 
amino acid sequence. DNA and amino acid sequences were compared by alignment with known 
reference sequences for each antigen, and the variant was identified by comparison to the 
sequence of variants documented at the nesseria.org website (w w w .Neisseria.org). Four 
transformants were sequenced for each antigen variant to ensure that the gene insert was 
present in its complete form with no shifts in the reading frame or base changes as a result of the 
transformation process. Over 90 % of the porA transformants, 90 % of the porB transformants, 70 
% of the fetA  transformants and 100 % of th efH bp  transformants sequenced were found to have 
successfully incorporated the correct DNA sequence. The majority of FetA transformants that 
were not sequenced successfully were as a result of an incomplete read as opposed to an 
incorrect read. Transformants with an incorrect sequence due to base insertions or deletions or 
lack of an N-terminal His-tag were discarded. The incorporation of the N-terminal His-tag into the 
correct reading frame, to allow for the expression of the full target protein was confirmed using 
the deduced amino acid sequence. Alignments for the deduced amino acid sequence for each 
antigen are given in the Appendix.
3.3.3 Protein Expression
A single clone was chosen for the expression of protein for each variant of PorA, PorB and FetA. 
An initial 100 ml culture was inoculated for the expression o f PorA, PorB and FetA proteins in the  
first instance. Bacterial growth was estimated by measurement of OD600 using a cell density 
m eter over a five hour period following induction with IPTG. The growth curve was plotted 
(Figure 3.) and highlighted the effect of induction of transcription on cell growth. The maximum  
cell density for cultures induced with a final concentration of 1 m M IPTG, was achieved two hours 
following protein induction.
Samples of cells were collected hourly and analysed using SDS-PAGE to check protein expression, 
as shown in Figure 3. Expression of the target protein was seen as early as 1 hour following IPTG
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induction, and was absent within the control samples. A lower level of contaminating proteins 
was observed in the IPTG induced culture than in the control culture due to the induced 
expression of the target protein. Similar results were observed for each protein purified in this 
way. The level of protein expression appears to be constant at all tim e points through the  
induction period, however the loading volume was standardised according to the OD600 
measurement. Further large scale bacterial cultures (500 ml) were used for purification of the 
remaining antigenic variants and were induced with IPTG for the optimal induction time of 2-3 
hours.
4.5
ID
1.5
Number of hours following Induction with ImM IPTG
$■"  Induced —O — Control
Figure 3.6 Growth curve showing the effect of Induction w ith Im M  IPTG on a culture of PorA 
variant P l.7 ,16  (Nm 2851). A single culture was grown to an OD600 of 0.6 and was then split into 
2 cultures, one of which was induced with IPTG and the other used as a control.
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Figure 3.7 An SDS gel showing the effect of Induction w ith 1 m M  IPTG on a culture of PorB 
variant 15 (Nm 2851). Lanes 1 - 4  show the WCL of the control culture taken at 2 -  5 hour time  
points, whilst lanes 5 - 9  show the WCL of the induced cultures taken at 1 -  5 hour time points 
following the addition of IPTG.
3.3.4 Protein Purification
The w et weight of the pellet was measured at several stages during the protein purification 
process. . This was achieved by using a pre-weighed centrifuge tube to weigh the pellet after 
removal of the supernatant following centrifugation. As some of the supernatant is likely to still 
be contained with the centrifuge tube, this is termed the wet weight of the pellet. The cell pellet 
wet weight was measured following harvest of whole cells following IPTG induction, and will 
include the weight of the f.coli cell wall and outer membrane components. The w et weight of the  
inclusion bodies was measured following purification of the inclusion bodies from cell lysates 
using the Bugbuster Protein Extraction Reagent. The percentage of inclusion body w et weight 
purified from ,the cell pellet w et weight ranged from 13.3 % for the P I.7,16 serosubtype of PorA 
to 39.3 % for the PorB serotype 2a (Table 3.2).The amount of total protein purified from 500 ml of 
cell culture ranged from 36.73 mg for the F3-9 variant of FetA to 213.75 mg of the P._,_ variant of 
PorA following the solubilisation of the inclusion bodies. With a similar level of purified protein 
observed for the variants of each antigen. The percentage of total protein purified from the wet 
weight of the inclusion body ranged from 7.2 % for the PorB 2a serotype to 30.5 % for the P l.7,16
87 [ P a g e
serosubtype of PorA. Again the weight of the inclusion body was measured as a w et weight, and 
may have accounted for these variations.
Following the final column purification step, the yield of pure protein ranges from 4.5 mg of FetA 
to 110 mg of the P l._ ,_  PorA variant. There was a significant difference in the percentage of final 
purified target protein in relation to the total inclusion body proteins, and ranged from 9 % for the 
F3-6 variant of FetA to 88.5 % for the P I.5-1,2-2 serosubtype of PorA. PorA proteins were seen to 
be purified in higher concentrations and as a percentage than the PorB proteins. The lowest 
amount of protein was purified for the FetA antigens. This may be due to several reasons. The 
large molecular weight of the FetA proteins in relation to the PorA and PorB may have resulted in 
a decrease in protein production. There are several stages between purification of total proteins 
from the inclusion bodies, and the final protein, including a dialysis step and column purification. 
Some of the FetA protein may not have been bound to the His-Bind column sufficiently prior to 
washing and have washed through the column prior to elution. The FetA proteins, in particular, 
were found to have issues with precipitation occurring during dialysis. Whilst the concentration 
of FetA proteins found in the resolubilised precipitate was low, this may account for the reduced 
yield in protein observed with this antigen.
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3.3.4.1 SDS Gel Electrophoresis/Purity of Protein
Samples collected from the each stage of the purification process were analysed using SDS-PAGE 
to assess purity of the protein and the efficiency of the purification process, in order to optimise 
the purification method (Figure 3.).
As previously observed, IPTG induces expression of the target protein with increased expression 
levels observed at successive sampling points (lanes 1-3, Figure 3.). In addition to the target 
protein, low levels of many other bacterial proteins were also observed, however most of these 
contaminants were removed following inclusion body purification. The localisation of the target 
protein within the inclusion bodies was confirmed in lane 4 and 5 (Figure 3.) where no protein 
bands are observed in the supernatant following removal of the inclusion bodies. Protein was 
visible (lane 6, Figure 3.) following resolubilisation of the inclusion bodies, whilst many of the 
other bacterial proteins were not. This confirmed the high expression of the recombinant protein 
in the absence of the signal peptide and the removal of contaminating bacterial proteins from the 
proteins extract.
Once the protein extract was loaded on the His Bind resin column very little protein was lost, 
although a small amount was visible in the wash fraction (lane 10, Figure 3.). This may have been 
a result of overloading of the column, or due to the increased concentration of imidazole present 
in the wash buffer, and elution of any loosely bound proteins. Elution with 1 M imidazole 
produced a single band of the expected size for each of the purified proteins. High level of 
protein purity was observed as there were no contaminating bands observed on the SDS PAGE gel 
following analysis. A similar result was obtained for the purification of all PorA, PorB and FetA 
variant proteins using this method. A difference in the size of the protein band was observed 
before and after the final dialysis step. This may have been due to insufficient boiling of the 
protein extract prior to loading on the gel or as a result of differences in the composition of 
Elution buffer and Dialysis buffer 2.
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Figure 3.8 An SDS PAGE gel image showing the purification of P l.5 -1 ,2 -2  (Nm 2794) at various 
stages of the purification process. Lane 1, 2 and 3 show the WCL at 0, 1 and 2 hours following 
the addition of IPTG, respectively. Lane 4 shows the resulting supernatant following removal of 
the inclusion bodies with the supernatant from a subsequent wash step shown in lane 5. Lane 6 
shows the purified protein extract prior to dialysis in Dialysis Buffer 1. Lane 7 shows the extract 
following dialysis in Dialysis Buffer 1. Lanes 8 to 12 shows flow through from various stages of the  
His Bind column purification. Lane 8 shows the flow through following application of the protein 
extract to the column. Lane 9 shows the flow through following application of the binding buffer 
to the column. Lane 10 shows the flow though after the column is washed. Lane 11 shows the 
eluted purified protein prior to dialysis in Dialysis Buffer 2 and lane 12 shows the final purified 
protein extract following dialysis in Dialysis buffer 2. Lane 13 is the SDS-PAGE Standards, Broad 
range marker (Bio-Rad).
3.4 Discussion
The objective of the part of the project described in this chapter was to clone, express and purify 
His-tagged proteins from variant strains of the major meningococcal outer membrane proteins, 
PorA, PorB and FetA. These purified antigens are to be used to produce a panel of protein coated 
microspheres to be used in the development of multiplex antibody binding assays.
This objective was achieved with the successful cloning, expression and purification of all target 
antigens including eight serosubtype strains of porA, three serotype strains of porB and five
variant strains of fetA . Although the fHbp antigen was not originally considered a target antigen 
for the purpose of this study, four variant strains of fHbp  were also cloned. These strains were 
not available until later in the project and were not used to express protein due to time  
constraints. Two antigenic variant strains could not be cloned. The strain of variant encoding for 
the PorB serotype 2b protein could not be cloned following PCR optimisation. This may have 
been due to differences in the secondary structure of DNA, however even with the use of DNA 
from alternative isolates and the use of strain specific primers for the PorB type 2b protein, 
cloning was unsuccessful. Alternative isolates were not available for the fHbp variant 1.11 so this 
variant strain was discarded.
A method that has largely been adopted for the purification of recombinant proteins includes the  
expression of protein as inclusion bodies, resolubilisation and refolding using detergents(264). A 
number of Neisserial OMPs have been purified using this method including PorA, PorB and 
FetA(206'143'161). The most widely used method for purification of recombinant proteins utilises the 
His-tag and allows for purification of the tagged protein using IMAC(179) with an increasing 
concentration of imidazole to allow for any loosely bound proteins to be washed away before 
elution of the purified protein. The use of commercially available cloning and purification kits 
ensures optimal and consistent overexpression and purification of recombinant proteins. Cloning 
and transformation of antigenic variant strains was performed using the pET expression system. 
Use of the pET vector system for the overexpression of His-tagged OMPs such as PorA has 
previously been described(129) with protein purity and yields comparable to those described in this 
thesis. FetA proteins were found to have a specific issue with this method with precipitation 
observed for several of these proteins during the removal of urea through dialysis. Protein 
precipitation during dialysis has previously reported(129) however, despite the low amount of 
protein purified for these antigens, precipitation was found to be due to urea coming out of 
solution as opposed to protein precipitation. Analysis of both the supernatant and the  
resolubilised precipitate, using a BCA protein determination assay, confirmed that whilst protein 
was found in the supernatant, no protein was present in the precipitate. No precipitation was
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observed following dialysis for any of the PorA or the PorB proteins and all purified proteins were 
found to be of the expected size, and purity. The lowest concentration of protein was purified for 
the FetA proteins in comparison to the PorA and PorB proteins and is likely to be a result of 
differences in the size of the proteins. FetA is a larger protein than both PorA and PorB and would 
have been more difficult to express.
The use of the Triton X-100 detergent in the final elution buffer to stabilise the recombinant 
membrane proteins(181) hampered refolding studies and although dialysis was performed 
following elution, complete removal of Triton from the purified protein extract was not possible. 
These minimal amounts of Triton X-100 were found to interfere with many of the assays used to 
confirm correct refolding of the target proteins. Whilst methods such as Circular Dichroism 
Spectrophotometry under near and far UV(181) were attempted (with Dr. Angela Martino), these 
could not be used to confirm the protein had been refolded correctly. However, the proteins 
have been used for separate studies in the laboratory and refolding of the protein for the correct 
exposure of immunogenic epitopes has been confirmed. Immunisation studies (performed by Dr. 
Hannah Chan as part of a different project) in mice have shown that purified PorA and FetA 
proteins are in the correct conformation as to elicit the production of bactericidal antibodies (data 
not available), and are thereby sufficiently refolded for use in the development of the multiplex 
assay. Further proof of the confirmation of the PorA binding epitopes, using monoclonal 
antibodies are shown in Chapter 4. Purified recombinant PorB proteins have been shown to bind 
to MAbs, confirming the correct refolding of these antigens using slot blot assays. The FetA 
proteins have also been used to elucidate the structure and function of FetA(265,266). In addition to  
the studies investigating the structure and function of OMPs, the antigens purified in this chapter 
potentially have a variety of uses. These include use of the antigens as standards reagents for use 
in immunogenicity assays including the SBA assay and ELISA; meningococcal typing schemes; and 
in immunisation experiments for the production of specific monoclonal or polyclonal antibodies. 
These antigens can also be used in the development of new vaccines as vaccine candidates, or for 
the detection of specific immune responses following vaccination.
For the purposes of this thesis, these antigens were found to be pure and of sufficient 
concentration to be carried forward for conjugation to microspheres in order to produce a panel 
of antigen labelled microspheres for use in the development of a multiplex Liquichip assay to 
measure serological responses to specific meningococcal antigens.
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Chapter 4. Developm ent and  Validation o f  a  m ultip lex assay fo r the detection o f  
serological responses to PorA
4.1 Introduction
The current method used for the quantification of PorA serum antibodies relies on their reactivity 
with the epitopes of the protein in ELISA or dot-blot based methods(13'260'344). The ELISA is a 
specific, and reproducible assay and provides a good assessment of immune responses but is only 
an indirect measure of protective immunity with no information about antibody functional 
activity(281). The ELISA, whilst suitable for the measurement of multiple samples for a single 
antigen, cannot be used for the quantification of multiple antigens within a single serum sample. 
The need for multiple ELISAs in addition to the multiple serum dilutions required for each antigen 
, mean that the ELISA becomes time consuming and requires relatively large volumes of both the  
target antigen for plate coating and sera(332,167).
Multiplex flow cytometric immunoassays have been developed which allow for the measurement 
of multiple antigens within a single serum sample(41'332). This method has all the advantages of the 
ELISA for the measurement of serological responses with additional benefits of reducing the 
volume of sera and the amount of time required for the analysis of multiple antigens and 
increasing sample throughput(41,332'167). A method that allows for the addition of new variants as 
required in a simple and effective manner would also be beneficial. Use of a multiplex form at 
assay of this type could be used for measuring antibody responses in the evaluation of new 
vaccines, such as OMV, combination, and protein based vaccines. Serological responses to 
meningococcal and pneumococcal capsular polysaccharides have been successfully analysed using 
this technology(167'168'166'275).
A multiplex system, such as the LiquiChip assay can be used to simultaneously quantify multiple 
antigens within a single assay(103). This method uses microspheres in place of the solid support 
used for ELISA. Each microsphere set is labelled with a combination of red/infrared dyes, 
resulting in a unique fluorescent signature. Capture molecules can be coupled to different
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microsphere sets and mixed together enabling the individual detection of multiple antigens 
simultaneously1411. A secondary green reporter molecule, phycoerythrin, is conjugated to an 
antibody specific for the antibody of interest and is used to quantify the reaction. The process is 
summarised in Figure 4.1. Data is collected using a LiquiChip workstation, a flow cytometer 
designed for this purpose, which quantifies the fluorescent signals from each microsphere. The 
red/infrared fluorescence is used to differentiate between microsphere sets, whilst the green 
fluorescence is used to quantify antibody binding.
Due to the nature of the microsphere and the wide scope of the Luminex technology, there is the 
potential for a range of capture molecules to be used for labelling of the microspheres including 
cytokines, proteins, polysaccharides, lipopolysaccharides, antibodies and nucleic acids. There are 
several methods by which the protein may be attached to the microspheres. Direct conjugation 
may be performed using carboxylated or activated microspheres, through the amine groups of 
lysine residue, or the thiol groups of cysteine residues within the protein. Direct conjugation was 
not used as this method may reduce immunogenicity of the primary antigen and limit signal 
amplification. Indirect methods involving coupling of a capture molecule, such as nickel- 
nitriloacetic acid (Ni-NTA) or Penta-His antibodies, to bind 1ST terminal tagged proteins. These 
methods allow for correct exposure of the epitope for antibody binding, resulting in increased 
sensitivity and signal amplification. Avidin coating can also be used to bind biotinylated proteins 
using indirect conjugation. Use of Ni-NTA as a capture molecule for the affinity purification of 6x 
his-tagged proteins*561 has become a universal method for the purification of recombinant 
proteins, with binding between the nickel ion and the 6x his-tag shown to have high affinity and 
selectivity*271'3601. The Ni-NTA/His-tag is not dependent on three-dimensional confirmation and 
can be used under native and denaturing conditions. This is a valuable and flexible metal 
chelation system and has been exploited for a number of purposes with Ni-NTA /His-tag binding 
used for a range of methods including: protein- labelling schemes*3601; immobilisation of 6x his- 
tagged proteins on agarose beads*2711; microtitre plates*2711 and microsphere beads*1701 such as 
those used in this study. Ni-NTA microspheres have been developed by LiquiChip for the universal
directed immobilisation of 6x His-tagged proteins using the Luminex assay, and for the purpose of 
this study, Ni-NTA labelled microspheres were conjugated to the His-tag of the purified PorA 
proteins.
4.2 Aims of this chapter
The aims of this chapter were:
•  To develop a multiplex assay, based on Luminex technology using microspheres labelled 
with purified his-tagged PorA proteins to be used for the detection of IgG responses to 
specific serosubtypes of PorA simultaneously;
•  To optimise this assay for the measurement of antibody responses using mouse MAbs 
and human sera;
•  To demonstrate the validity of this assay, including specificity, reproducibility, and 
sensitivity of the assay.
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Microsphere
Nickel coated 
microsphere
Figure 4.1 Summary of the LiquiChip assay. Microspheres are selected from a range of 100 
uniquely labelled microspheres and coated with NTA moieties, which in turn are bound to nickel 
ions. The nickel of these metal chelator complexes bind to the His-tag, expressed as part of the 
PorA proteins resulting in a protein coated platform. Protein labelled microspheres are used to 
bind antibodies in serum. Phycoerythrin labelled secondary antibodies, specific to serum 
antibodies, is added and the microspheres are analysed using the LiquiChip workstation. A red 
classification laser detects the microsphere set used, whilst a green reporter laser quantifies the 
reaction.
4.3 Source of sera used
Sera used in this chapter were obtained from several sources as listed in Table 4.1. Serum from  
the VEU was collected as part of an NVEC study, from healthy laboratory workers vaccinated with 
three doses of either the P l.7,16 OMV vaccine (NW) or the P I.7-2,4 OM V vaccine (NZ). Serum
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from this collection was selected for use in this study based on the assumption of high titres of 
anti-PorA antibodies, present in serum following vaccination with one of two PorA vaccines. 
Serum 03/118 was an unvaccinated serum sample from an individual healthy laboratory worker, 
known to contain high titres of anti-PorA antibodies directed against multiple PorA serosubtypes. 
Selection of these sera were also based on locality, with both these sets of sera maintained in the 
NIBSC collection and have previously been used in the laboratory.
Table 4.1 Source of sera used in this chapter.
Source Serum Sera Samples
VEU (Manchester)
P1.7,16 0 M V  vaccine (NW) 17 samples
P1.7-2,4 0 M V  vaccine (NZ) 9 samples
03/118 1 sample
NIBSC Mouse Antibodies 
(detailed in Table 4.2)
9 monoclonal
Table 4.2 Monoclonal antibodies used in this chapter.
Serosubtype Monoclonal
P1.19 WRAIR7A2-11
P1.5 NVI MN22A19.9
P1.7 NVI MN14C11.6
P I .15 NVI MN3C5C
P1.10 NVI MN20F4.17
P1.4 NVI MN20B9.34
P I .16 NVI MN5C11G
P1.2 NVI MN16C13F4
Universal 05 /194
The Universal is an anti-meningococcal PorA monoclonal mouse antibody. The epitope for this 
antibody is undefined but has been found to cross-react in whole cell ELISA and co- 
agglutination.assays.
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4.4 Results
4.4.1 Optimisation of the PorA LiquiChip assay
In order to determine the minimum number of bead required for the detection of anti-PorA 
antibodies in each serum sample, the Liquichip assay was performed using 5000, 2500 or 1250 
microspheres for each PorA panel serosubtype, per assay point. Pooled human serum, previously 
collected from healthy laboratory workers following immunisation with three doses of the 
Norwegian (P l.7 ,16) OMV vaccine was used to produce standard curves, plotted using the mean 
fluorescence intensity (MFI) recorded for each microsphere subset (Figure 4.2). Similar MFI 
values were obtained at lower sera concentrations, regardless of the total number of 
microspheres used. As the concentration of sera increased, MFI values for both the 5000 and the 
1250 microspheres per data point appeared, to plateau, or in some cases, such as the P l.5-2 ,10  
PorA serosubtypes, actually decreased. This was not observed when 2500 microspheres were 
used. The highest MFI, for the panel of PorA labelled microspheres, were recorded using 2500  
microspheres per assay point. This number of microspheres therefore provided the widest 
dynamic range of concentrations at which the assay could be performed. Additionally, the 
minimum microsphere count of 100, per data point was not achieved for all assay points when 
1250 microspheres were used (data not shown).
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Figure 4.2 Standard curves for pooled serum from healthy laboratory workers vaccinated w ith  
the P l.7 ,16  O M V vaccine. The LiquiChip assay was performed on pooled human sera previously 
collected from healthy laboratory workers following immunisation with three doses of the P l.7 ,16  
OM V vaccine. Two replicates of pooled sera sample were tested using 1250, 2500 or 5000  
microspheres as two independent assays. MFI values were recorded and standard curves were 
plotted for the panel of PorA coated microspheres.
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4.4.2 Assay Specificity
4.4.2.1 Specificity using mouse MAbs
Specificity of the multiplex assay was assessed using MAbs corresponding to VRs of the purified 
PorA serosubtypes proteins. These are the mouse monoclonal antibodies used for the PorA 
serosubtyping scheme. MAbs were found to react only with the microspheres coated with the 
corresponding PorA serosubtypes and closely related variants (Table 4.3). No reaction was 
observed between the MAbs and microspheres coated with PorA proteins from different 
serosubtype families.
The P I .19 MAb was found to cross-react with both P I.19 and the P l.19-1  serosubtypes. The P1.5 
MAb was found to cross-react with both P I.5 and the P l.5-1  serosubtypes, however this antibody 
did not exhibit any response to the P I.5-2 serosubtype. The P I.7 MAb was found to cross-react 
with both P I.7 and the P l.7-2  serosubtypes. The P I.2 MAb was found to cross-react with both 
P I.2 and the P l.2-2  serosubtypes. Whilst the P I .15 MAb showed only a limited response with the 
P I.15-11 serosubtype. MAbs corresponding to P I.10, P1.16 and P1.4 were only found to react 
with the expected serosubtypes of PorA.
The Universal antibody, so named because of its ability to recognise multiple PorA epitopes, was 
found to respond to four of the eight the PorA labelled microspheres, including the Pl.5,2; P1.5- 
1,2-2; P l.7 -2 ,4 and the P l.7,16 labelled microspheres. Again, no cross reactivity was exhibited 
between the P1.5 and the P l.5-2  serosubtypes. The Universal antibody was found to cross react 
with the P l._ ,_  labelled microsphere, whilst no IgG response was observed between this protein 
and any of the other MAbs.
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4.4.2.2 Inhibition of MAbs w ith purified proteins
A pool of MAbs was produced by mixing equal volumes of each MAb shown in Table 4.3, with the 
exception of the Universal antibody. This MAb mixture was pre-incubated together with a 
purified PorA protein, resulting in the specific inhibition of binding between the corresponding 
PorA labelled microsphere set and the MAb mixture (Figure 4.3).
Whilst pre-incubation with the P I .19,15 protein was shown to inhibit binding to both the P I .19,15 
and P l.19 -1 ,15-11 microsphere sets, pre-incubation with the P I.19-1,15-11 protein however 
showed limited inhibition with the P I .19,15 microsphere set and complete inhibition with the 
P I.19-1,15-11 PorA labelled microsphere set. Pre-incubation with the P I.5-2,10 protein resulted 
in limited inhibition of the IgG response to the P l.5 -2 ,10 labelled microspheres, but did not 
exhibit any effect on either the P l.5 ,2  or the P I.5-1,2-2 labelled microspheres. Inhibition was not 
observed between the P1.7 and the P l.7-2  minor variants with the IgG response thought to be 
due to binding of antibodies corresponding to the VR2 P1.16 and P1.4 regions of PorA protein.
There are several possible explanations for the incomplete binding exhibited between several of 
the PorA antigens and the corresponding MAbs. These include a high concentration of MAbs in 
relation to the antigen; antibody affinity; and competition between binding sites bn the free 
protein and the microsphere bound protein. MAbs are produced in mice in response to a human 
antigen, and this may affect the mechanism of action between the antibody and the inhibiting 
protein leading to incomplete inhibition.
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Figure 4.3 Inhibition of MAbs with purified proteins. A m ixture  o f MAbs was pre-incubated, fo r  1 
hour at room  tem pera ture , w ith  purified  100 pg/m l PorA proteins corresponding to  the 
m icrosphere sets used. Control sample o f un inh ib ited  MAbs were also tested using the  LiquiChip 
assay, and the  e ffect o f inh ib ition  is expressed as a percentage o f the  contro l sample. Results are 
expressed as the  average o f tw o  replicate samples run on tw o  independent assays.
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4.4.2.3 Inhibition of human serum responses with purified proteins
Serum collected from a healthy laboratory worker (NIBSC 03/118) was incubated with purified 
PorA proteins, prior to running on the LiquiChip assay.
Inhibition with every protein resulted in a reduction in binding response to the corresponding 
microsphere set (Figure 4.4). IgG responses to the P l._ ,_  labelled microsphere were largely 
unaffected following incubation with all of the PorA proteins. The effect on other microsphere 
sets however varied. Inhibition with both P I .19,15 and P l.19 -1 ,1 5 -1 1 'proteins resulted in a 
decrease in antibody binding for all microspheres to a similar extent, with the exception of the 
P I l a b e l l e d  microspheres. Some inhibition was observed in response to all microsphere sets 
following incubation with either the P l.5 ,2  or the P l.5-1 ,2-2  protein, however, the most 
significant decrease in IgG response in both cases was observed for binding to the microsphere 
sets labelled with the homologous proteins. The P l.5-2 ,10  protein exhibited a blocking response 
on the P l.5-1 ,2-2  and the P l.5,2  microsphere sets, which is thought mainly to be attributed to the 
VR1 P I.5. More specific inhibition was observed following incubation with the P l.7,16 and the 
P l.7 -2 ,4 proteins with inhibition due to the VR1P1.7, as demonstrated using MAbs.
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P l.19 -1 ,15-11 P I .19,15
Figure 4.4 Inhibition of human serum with purified proteins (error bars represent 95 % 
confidence intervals). A human serum sample (03/118) was pre-incubated, fo r 1 hour at room 
tem pera ture , w ith  purified  PorA proteins corresponding to  m icrosphere sets used. An un inh ib ited  
sample o f the 03/118 human serum was used as a contro l and also tested using the  LiquiChip 
assay. The e ffect o f inh ib ition  is expressed as a percentage o f the  contro l sample. These results 
are expressed as the average o f tw o  replicate samples run on th ree  independent assays.
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4.4.3 Assay reproducibility
Sera from healthy laboratory workers immunised with three doses of either the P l.7,16 OMV or 
the P l.7 -2 ,4 OMV vaccine (from the SEU, Manchester, Table 4.1) were pooled and used to 
produce a standard curve for the calculation of antibody concentrations in human sera using the 
liquichip assay. Six dilutions of the sera were used for the production of the standard curve and 
ranged from a 1:100 dilution of the pooled sera, to a 1:24300 dilution using a 1:3 dilution series. 
As the actual concentration of anti-PorA antibodies in the standard serum was not known, an 
arbitrary concentration was assigned for each of the serosubtype specific anti PorA antibodies 
with the highest concentration of standard used (1:100 dilution) assigned an arbitrary 
concentration of 10 ng/ml. The lowest concentration of standard (1:24300) was assigned an 
arbitrary concentration of 0.04 ng/ml. A standard curve was produced by plotting the MFI for 
each dilution of standard against the concentration of that standard. A line of best fit was applied 
to these values and allowed for an arbitrary sample concentration to be determined for all sera 
samples based on the MFI values measured using the Liquichip assay. A different standard curve 
was produced for each serosubtype specific anti-PorA antibody measured using this assay. Use of 
an arbitrary concentration allowed for the comparison of serosubtype specific anti-PorA titres in 
samples over several assays, however, the concentration of antibodies directed against different 
PorA serosubtypes cannot be compared.
Assay reproducibility was determined using replicate sera samples from a pool of healthy 
laboratory workers following immunisation with three doses of the human P l.7,16 OM V and a 
pool of healthy laboratory workers following immunisation with three doses of the human P1.7-
2,4 OMV vaccine (from the SEU, Manchester, Table 4.1). The coefficient of variation (CV) for each 
of the panel of PorA labelled microspheres was determined for each set of repeat samples.
4.4.3.1 Intra-Assay variability
Intra- assay variability was determined using seven replicates, at three dilutions, of sera samples 
from a pool of healthy laboratory workers immunised with the P l.7 ,16  OMV vaccine. The assay
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was found to have little intra-assay variability with the CV ranging from 3.82 % for the P I. 19,15 
microsphere set to 15.97 % for the P l.5-1 ,2-2  microsphere set within the 1:300 dilution (Table 
4.4). From 6.74 % for the P l.7 -2 ,4 microsphere set to 12.39 % for the P l.5-2 ,10  microsphere set 
for the 1:900 dilution and from 3.54 % for the P I.19-1,15-11 microsphere set to 8.46 % for the 
P I.7-2,4 microsphere set within the 1:2700 dilution o f human serum. Although these values 
appear to be significantly different, they are only based on a small number of replicates at low 
concentrations/and increasing the number of replicates used for the validation is likely to bring 
these values down. Possible reasons for variations between the CV values include inaccurate 
pipetting, splashing of reagents against the walls of the well, and temperature variations across 
the plate. However whilst a CV value of >25 is considered unacceptable, a CV value of <20 is 
considered to be a sign of good assay reproducibility, and all these values fall below this target
(167)
Table 4.4 Intra-Assay Variability of replicate serum samples (n = 7) from a pool of healthy 
laboratory workers following immunisation with three doses of the Pl.7,16 OMV vaccine. *CV
was not determined as the IgG titre of anti-P l.7 ,16 antibodies was too high to be determined 
accurately at this concentration.
PorA
serosubtype 1:300
CV(%)
1:900 1:2700
Pl.19,15 3.82 9.46 6.53
Pl.19-1,15-11 8.97 7.70 3.54
P1.5,2 14.26 7.55 7.74
Pl.5-1,2-2 15.97 7.94 4.34
Pl.5-2,10 6.39 12.39 6.52
Pl.7,16 N /D * 9.82 4.95
Pl.7-2,4 12.58 6.74 8.46
8.23 7.86 7.69
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4.4.3.2 Inter-assay variability
Inter-assay variability was determined using three individual LiquiChip assays of human sera from  
healthy laboratory workers immunised with either the P l.7,16 or the P I.7-2,4 OMV vaccine. This 
assay was found to have low inter-assay variability. The CV of antibody concentration (Table 4.5) 
ranged from 1.40 % for the P l.19 -1 ,15-11 microsphere set to 12.92 % for the P l.5-,2-2  
microsphere set, for sera from healthy laboratory workers immunised with the P l.7,16 OMV  
vaccine. The CV of antibody concentration of sera from laboratory workers immunised with the 
P l.7 -2 ,4 OMV (Table 4.6) ranged from 4.79 % for the P l.7 -2 ,4 microsphere set to 21.86 % for the  
P l.19 -1 ,15-11.
I l l  | P a g e
Ta
ble
 
4.5
 
In
te
r-a
ss
ay
 
va
ria
bi
lit
y 
sh
ow
n 
us
ing
 
the
 
ar
bi
tra
ry
 
co
nc
en
tra
tio
n 
an
d 
CV 
of 
th
re
e 
in
de
pe
nd
en
t 
as
sa
ys
 u
sin
g 
se
ra 
fro
m 
he
alt
hy
 
lab
or
at
or
y 
wo
rk
er
s 
im
m
un
ise
d 
w
ith
 
th
re
e 
do
se
s 
of 
the
 
Pl
.7
,1
6 
OM
V 
va
cc
in
e.
 
Ar
bi
tra
ry
 
an
tib
od
y 
co
nc
en
tra
tio
ns
 
we
re
 
de
te
rm
in
ed
 
us
ing
 
a 
st
an
da
rd
 
co
ns
is
tin
g 
of 
po
ol
ed
 
se
ra 
fro
m 
he
al
th
y 
la
bo
ra
to
ry
 
w
or
ke
rs
 
im
m
un
is
ed
 
wi
th
 
the
 
Pl
.7
,1
6 
an
d 
Pl
.7
-2
.4
 
OM
V 
va
cc
in
e.
 
Co
nc
en
tra
tio
ns
 
ca
lc
ul
at
ed
 
us
ing
 
2 
re
pl
ic
at
e 
of 
6 
di
lu
tio
ns
 
of 
se
ra
.
oo
ID
oo
CNLDcncn
CO
00
id minoo
rH
in  
m  
oo. CM
cnip
id
in>3-
00in oo
a.
in oo
in
ooinco
cnat
in
oo 00
in
CN
Q.
(N m
>»
CO
T3
CUw
'E
3
E
E
cu
!_
o
5
£•o4-1
tot_oJQm
>»JC
4 -4
(0QJJZ
Eo
<4-
ro1-<u
V)
bo
a
s_
o  
5 
■ >> 
o4->TO1_
o
X !
CO
E
o
*4—
CO1_cuto
~oQ)
O
o
a .
oo
c
to>.
roT3 i—oto c 4->to ro _3to +->
ro to "D4->E ro IDcu oo <+-
■ c Oc ‘to CUQ> 3 4—<Q. TJ rouOJT3 0)C Q.C
E ai_Vcu
t_a CN
4-> 00£ a c4-> TJ "to<4-o cut_ 3
>u
cu
5
~ocu4—1
*o to _roE c 3ro o u4-> roc ro uo i— to+->'5 C ' ■ cCO
*4 au o4->c c rocuu ou 4—1cc >- cuo T3 u(J O c
ro
w
JD
'+->C
ou
4-> ro cuIE >- ct_ro rot_ o0) roJZ Id >44 t_ >00E <
‘in cu O3 . c
C u cn""
5 uro
■
o•Cto
>
>
rHCL
>*4-> T3C— O ro
IE IDro CN rH
ro ir>* r f> rH
> rHQ. Q.ro CUto CU jzto JZ 4->ro■ 4-> X>4- 4-4cu O
54-> toE aj T3
ID «no CUto
TJ ’c
_QJ cu 3a;k. Ero
1- JZ+■> E
ID CN
00
00
00
cn
oooo cnr^ .in
cn
mm
in
rv
in
ooooinoo
CL
IDrq
oo
CN01 CN
& 4
CN
00ro oo
in
CN
in
rorq
in
ro^o
oo
m ID
0000rHicn cn
m
rq
id
CN
ID
O
00ro
oo
a.
ro
>>
CM
11
2 
| 
P 
a 
g 
e
4.4.4 Monoplex vs. M ultiplex
The ability to determine IgG concentrations of multiple anti-PorA antibodies within a single 
reaction would be of benefit in terms of tim e and volume of sera required. In order to determine 
whether use of a multiplex assay affected the detection of individual anti-PorA antibodies within a 
single reaction, serum samples were measured both in a monoplex and a multiplex assay. Pooled 
serum from individuals vaccinated with the P l.7,16 OM V vaccine was tested, in three dilutions in 
duplicate, using individual microsphere sets in a monoplex assay and a mixture of microsphere 
sets as a multiplex assay conducted on three different days. Arbitrary IgG concentrations were 
calculated using a standard curve for both the monoplex and the multiplex assay, and the CV was 
calculated for each set of microspheres (Table 4.7). No difference was found in IgG response to  
the PorA labelled microsphere, assayed using a monoplex or multiplex assay. The CV ranged from  
0.01 % for the P l.5,2  microsphere set to 6.13 % for the P I .19-1,15-11 microsphere set.
Table 4.7 Comparison of monoplex and multiplex formats. Four concentrations of pooled serum 
samples from healthy laboratory workers immunised with three doses of the P l.7,16 OMV  
vaccine were tested in duplicate using the LiquiChip assay in both monoplex and multiplex 
formats, run on two different assays. Relative antibody concentrations were determined using a 
standard consisting of pooled sera from healthy laboratory workers immunised with the P l.7,16  
and P l.7 -2 ,4 OM V vaccine.
Arbitrary IgG 
Concentration (ng/m l) 
M ultiplex Monoplex
CV
(%)
(M ulti vs. Mono)Serosubtype
P l.19 ,15 20.82 20.91 0.32
P l.19 -1 ,15-11 19.57 21.34 6.13
P l.5 ,2 17.98 17.98 0.01
P l.5-1 ,2-2 20.47 21.97 5.03
P l.5-2 ,10 18.53 18.62 0.35
P l.7 ,16 25.94 24.42 4.25
P l.7 -2 ,4 21.55 20.33 4.13
21.83 20.52 4.37
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4.4.5 Assay Sensitivity and Limit of Detection.
The MFI value was recorded for the blank wells over the course of 70 assays, and the average was 
calculated for each microsphere set (Table 4.8). The average MFI value for the negative control 
sample ranged from 4.5 for the P l.5-1 ,2-2  microsphere set to 6.3 for the P l.5,2  microsphere set. 
Serial dilutions of each MAb were used to perform the Liquichip assay, and standards curves were 
produced, with known concentration of MAbs, as determined using the Easy-titer mouse IgG 
Assay kit. The lowest concentration of MAb at which background (no sera) MFI values (n = 70) 
were observed was calculated using the standard curve, and the limit of detection was 
determined as the mean MFI plus two standard deviations (SD). The limit of detection was then 
obtained from the standard curve. The limit of detection ranged from 41.75 pg/ml for the P1.5 
MAb to 176.88 pg/ml for the P1.19 MAb (Table 4.8).
Table 4.8 Sensitivity of the LiquiChip assay. Sensitivity was estimated by determination of the 
highest concentration of MAb at which the MFI+ 2 SD was less than or equal to background MFI 
values. A mouse IgG quantification kit was used to estimate the IgG concentration of each MAb 
preparation. The multiplex assay was performed for a dilution series of each MAb and the  
antibody concentration at which background MFI values were observed was calculated.
PorA serosubtype Background MFI Concentration of M Ab(pg/m l)
P l.19 -1 ,15-11 5.4 176.88
Pl.5-1,2-2 4.5 41.75
Pl.19,15 5.4 78.25
P l.7 -2 ,4 4.8 113.98
Pl.5-2 ,10 5.8 55.96
5 . 42.34
Pl.7,16 5.8 79.37
P l.5,2 6.3 68.80
4.5 Discussion
A multiplex LiquiChip assay was developed and used for the quantification of serum IgG responses 
to multiple serosubtypes of PorA in a single sample. 2500 microspheres was determined to be 
the optimum for each antigen to be tested. This is in agreement with other microsphere based 
multiplex assays(242). This provided the greatest dynamic range of the assay, defined as the range 
over which there is a linear relationship between antibody concentration and MFI. Differences in 
the IgG response determined using different numbers of microspheres may be due to saturation 
of the microspheres with antibody. With a constant amount of serum antibody, microsphere 
saturation with antibodies will decrease as the number of microsphere increase and may result in 
microspheres that have not been bound to antibodies. As MFI was calculated as an average of 
100 microspheres, this will be affected by the presence of microspheres not bound to anti-PorA 
antibodies and the MFI will be reduced. Conversely, as the number of microspheres is reduced, 
saturation of the microspheres with anti-PorA IgG will be increased. Once all the anti-PorA 
binding sites on the microspheres have been saturated, the maximum MFI has been reached and 
will not be affected by the presence of unbound antibodies in the serum samples. Therefore, use 
of this number of microsphere allows for the assay to be performed at an increased range of 
concentrations reducing the need for sera to be retested at different concentrations. This wide 
dynamic range should lead to a reduction in the number of sample dilutions required, whilst the 
accuracy of the assay is increased and lower levels of antibody can be detected'1671.
The use of a multiplex assay was not found to compromise the results of this assay, and no 
evidence of interference between microsphere sets was detected. Similar concentrations were 
measured for anti-PorA IgG concentrations using the monoplex and multiplex assay confirming 
suitability of the Liquichip assay to detect IgG responses to multiple PorA serosubtypes 
simultaneously. Assay reproducibility was demonstrated with low CV values calculated for both 
inter- and intra-assay variability similar to those reported for assays using other 
antigens'167'168'67'329'2751.
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The limit of detection, the lowest level of antibody response that can be detected, as opposed to 
a true negative value was determined using MFI values from the negative control sample plus two 
SD and the corresponding MAb concentration at which this MFI was recorded. The assay was 
found to be highly sensitive with the lowest detectable concentration ranging from 42.75 -176 .88  
pg/ml. In comparison, the lowest concentration of anti-PorA IgG detected using ELISA has been 
reported as <2 ng/m l'128'3431 and an ELISA for the detection of IgG directed to the P64K protein of 
N. meningitidis reported a limit of quantification validated to 1.25 ng/m l'1751. Whilst no direct 
comparison between ELISA and the multiplex assay were performed in this study, previously 
studies have shown the multiplex assay to be more sensitive than ELISA(242/325), although good 
correlation between IgG concentrations measured using the ELISA and multiplex assay has been 
observed'1671. Multiplex assays based on the detection of anti-capsular antibodies have been 
shown to be less specific than the anti-PorA assay with a range of 370 to 650 pg/ml observed for 
anticapsular antibodies quantified using a tetraplex assay'1671. The chemical composition of 
antibodies may be a cause of the differing sensitivity, with marked differences produced in 
immune responses to polysaccharide vaccines and protein vaccines as stated in Chapter 1.
MAbs directed to a single VR of the PorA protein were used to demonstrate the assay was specific 
for the detection of anti-PorA IgG responses with cross-reactivity only observed between anti- 
PorA antibodies and microspheres labelled with variants of the same PorA family, correlating with 
published results on the specificity of these MAbs'2,348,239,3441. Assay specificity was further 
demonstrated using inhibition of MAb binding with purified proteins, and inhibition was only 
observed in the binding of MAbs specific to the PorA serosubtype of the inhibiting protein. For 
the majority of the PorA labelled microsphere sets, complete inhibition of MAb binding with the 
corresponding PorA protein was observed, whilst limited inhibition was observed in others. There 
are several possible explanations for this limited inhibition including: (i) a high concentration of 
MAbs and insufficient protein to ensure complete binding of antibodies; (ii) antibody affinity 
influencing the effect of inhibiting protein; and (iii) competition between binding sites on the free 
protein and the microsphere conjugated protein. As PorA has two VRs, inhibition of binding to
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one of the VRs does not inhibit antibody binding to the second VR'1981 resulting in partial inhibition 
of the IgG response.
Whilst the specificity of the assay was clearly demonstrated with the use of mouse MAbs, 
produced in response to a specific PorA serosubtype, a different response was measured using 
the more complex human sera. Carriage of meningococci in humans and the resulting immune 
response has been well documented'114,3561. The presence of pre-existing antibodies 
corresponding to multiple PorA serosubtypes in human serum would therefore be expected, with 
immune responses directed to one or both of the two VRs produced in response to either 
vaccination or carriage'3241. Whilst pre-incubation of human serum with PorA resulted in 
decreased antibody binding to the corresponding protein labelled microspheres, a decrease in 
binding response was also observed with unrelated PorA serosubtypes. It is possible pre-existing 
antibodies in serum may be cross-reacting with the purified protein used for inhibition. 
Alternatively the presence of antibodies in serum may be cross-reacting to the protein labelled 
microsphere. The Pl.19,15, P I.19-1,15-11 and the P I.5-2,10 proteins had the greatest inhibitory 
effect on all the microspheres sets tested. All of these had a shared amino acid sequence in loop 
6 (Figure 1.4) that differed from the deduced amino acid sequence of the other PorA proteins 
used in this assay and may be a potential site for cross reactivity. The P1.5 MAb was not found to 
bind to the P l.5 -2  epitope of purified PorA protein however some cross-reaction between the 
serosubtype P l.5 -2 ,10 purified PorA protein and the serum antibodies was detected against the 
P1.5 and the P l.5 -1  epitope. This suggests the possibility of serum antibodies binding to parts of 
the protein outside of the epitope recognised by the MAb. A possible explanation for the limited 
inhibition of P l.7,16 and the P l.7-2  MAb, is that P l.7-2  PorA serosubtype has been shown to have 
a hidden epitope that may not be available for antibody binding using whole cell ELISA'3451. This is 
due to a deletion in the P I.7 epitope causing movement of the epitope towards the outer 
membrane where it is masked by the other loops. The presence of this hidden epitope may also 
explain the inhibition observed between the P1.7 MAb and P l.7 -2 ,4 labelled microspheres'3451. 
Another possible explanation for the limited inhibition in binding observed between the P1.7 MAb
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and the P I.7-2,4 labelled microspheres may be explained by competition between the P I.7 and 
the P l.7-2  epitopes. The P I.7 MAbs are more weakly bound to the P l.7 -2  epitope than they are 
to the P1.7 epitope, and so are more likely to be outcompeted following inhibition with the P1.7- 
2,4 protein. Although it is more likely that the IgG response measured for this protein is due to 
binding of MAbs corresponding to the VR2 region of the protein. Similarly the P I .15 antibody has 
a higher affinity for the P I .15 epitope than the P l.15-11. In order to determine antibody affinity 
to specific epitopes, a competition assay would need to be performed with titration of a 
competitor. MAbs are mouse antibodies produced in response to a human antigen, and 
monoclonal antibodies may produce a differing response to human sera antibodies. Reactivity of 
these antibodies are also determined using ELISA, and the MAbs may respond differently in a 
Liquichip assay.
It is important to note that the standard used for the calculation of all human sera IgG responses 
in this assay, was composed of sera collected from individuals vaccinated with three doses of 
either the P l.7,16 or the P l.7-2 , 4 OMV vaccine. Difficulties arise with the use of pooled human 
sera from vaccinated laboratory workers as a standard, due to unknown concentrations of 
antibodies to different PorA serosubtypes. Each serosubtype specific IgG response produced by 
the standard was assigned the same arbitrary concentration, resulting in a serosubtype specific 
anti-PorA antibody with a low MFI value, assigned the same relative concentration as one with a 
high MFI value. As serum antibody levels were quantified relative to the respective PorA specific 
antibody concentration in a standard serum, whilst the concentration of antibodies directed to 
the same PorA serosubtype can be compared over several assays, direct comparison cannot be 
made for IgG responses and antibody concentrations between different serosubtypes. 
Additionally, whilst assay sensitivity can be measured using mouse MAbs, it is not possible to 
measure assay sensitivity using human sera. However, this can be improved with the use of a 
suitable reference serum consisting of known concentrations of human meningococcal 
antibodies. Production of a human standard with known concentrations of serosubtype specific 
anti-PorA would aid in comparisons of anti-PorA titres across differing serosubtype within the
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same assay, and comparison of this assay with similar assays. Unfortunately, no reference 
standard is available for this purpose and would be very difficult to produce due to the complex 
nature of human adult sera. Infant sera, with no previous exposure to meningococcal isolates are 
unlikely to have cross reacting antibodies, and post-vaccination sera would be ideal for use as a 
human standard. However due to the limited volumes of infant sera available, this is not a 
feasible option.
The Liquichip assay described in this chapter was optimised using mouse MAbs and human sera 
and was found to be specific, sensitive and reproducible. There are several advantages to the use 
of a multiplex assay such as the one described in this chapter, including a greater dynamic range 
over which the assay can be performed, and increased sensitivity in comparison to the traditional 
ELISA. The multiplex nature of this assay allows for the detection of antibodies directed to eight 
serosubtypes of PorA simultaneously, thereby saving both tim e and volume of sera required for 
the assessment of immune responses. This would be of benefit for the evaluation of immune 
response resulting from immunisation with multicomponent vaccines and the use of multiplex 
assays to enhance preclinical evaluation of immune responses has previously been described for 
meningococcal capsular polysaccharides, diphtheria, tetanus toxin, Hib capsular polysaccharide 
and Bordetella pertussis  antigens I230-167'168'242-285). Another advantage of the liquichip assay is the 
potential ability to extend the assay to quantify additional serosubtypes of PorA or alternative 
antigens, such as the PorB, FetA and fHbp proteins described in the previous chapter.
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Chapter 5. Analysis o f  human and  mouse sera using the PorA Liquichip assay following
vaccination w ith  outer m em brane vesicle vaccines.
5.1 Introduction
Availability of capsule based vaccines have contributed to the prevention of meningococcal 
disease caused by four of the five major-disease causing serogroups of N. m e n in g itid is^ . 
However, disease caused by serogroup B meningococci continues to be a problem, due to poor 
immunogenicity of the serogroup B capsule and immunological similarity to host sialic acids'354,931. 
OMV vaccines have been shown to confer immunity and can be used to control the incidence of 
serogroup B disease, however these tend to be limited to specific epidemic strains, such as the 
Norwegian based P l.7,16 OM V vaccine (MenBvac), and the New Zealand based P l.7 -2 ,4 OMV  
vaccine (MeNZB)'27,191,274,2161. Vaccines such as these afford little cross protection against 
antigenically diverse meningococcal strains'295,3491. This lack of cross protection is due to the  
variability of the major immunodominant proteins such as PorA and Opc present in OMV  
vaccines'2531. In order to overcome the limited coverage of OMV vaccines based on a single 
serosubtype of PorA, vaccines based on two or more OMVs, each containing multiple PorA 
proteins have been engineered'421. Further development of vesicle vaccines include incorporation 
of purified subcapsular antigens or multivalent formulations such as the Hexamen (6-valent) or 
Nonamen (9-valent) OM V vaccines'42,108,316,2591.
The evaluation and comparison of immune responses to meningococcal vaccines have classically 
been performed using two basic groups of laboratory assays: antibody binding assays and 
functional assays. Antibody binding assays provide a good indication of immune responses to 
vaccination, but only an indirect measure of protective immunity. Antibody binding assays such 
as the ELISA detect both functional and non-functional antibodies, with antibodies of lower 
avidity giving poor correlation with functional assays. Modified ELISAs have been developed for 
the detection of high avidity antibodies. Functional assays such as the SBA assay predominantly 
measure high-avidity antibodies shown to be superior to low avidity antibodies for bactericidal
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activity'2381. The ability of SBAs to confer protection against meningococcal disease is widely 
accepted, and the presence of SBAs is generally considered the best indicator of protective 
immunity'1131. For purposes for licensure of meningococcal vaccines, regulatory agencies 
generally accept induction of these antibodies as evidence of vaccine effectiveness'32,2071. The SBA 
assay has been evaluated as the correlate of protection for OMV vaccines, and is primarily used 
for the determination of immunogenicity of OM V vaccines'189,216,921, with a relationship between 
SBA and anti-PorA antibodies noted'27,253,3491.
5.2 Aims of this chapter
The aims of this chapter were:
•  To assess the ability of the multiplex PorA assay to measure increases in binding antibody 
titres to specific PorA serosubtypes induced by vaccine candidates in preclinical 
immunogenicity trials;
•  To assess the ability of the multiplex PorA assay to measure increases in antibody binding 
titres to specific PorA serosubtypes induced by vaccine candidates in clinical 
immunogenicity trials.
5.3 Source of Sera used
Sera collected as part of four separate vaccine trials were analysed in this chapter (Table 5.1). 
Sera samples obtained from the RIVM, The Netherlands, were collected as part of the Hexamen or 
the Nonamen vaccine trial. These studies were performed to determine reactogenicity and 
immunogenicity of the two OMV vaccines. Following vaccination with the Hexamen vaccine, 
ELISA and bactericidal assays were used to demonstrate serosubtype specific responses in mice, 
with antibody responses observed against all serosubtypes of PorA included in the vaccine. The 
magnitude of antibody responses was not found to be equal across all PorA serosubtypes. The 
highest titre was raised against the P l.5-1 ,2-2  serosubtype of PorA, followed by the P l.7,16  
serotype. The lowest immune responses were found to be induced against the P I .19,15-1 and
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Pl.7-2 ,4  serosubtypes. Similar results were observed for the production of bactericidal antibodies 
with 12-fold higher titres observed against the P l.5-1,2-2, P l .5 -2 ,10 and P l.7,16 serosubtypes of 
PorA than the P l.7-2 ,4, P I.19,15-1 and P l.12-1,13 serosubtypes of por/\(319'323'50'182); immune 
responses to the nine PorA serosubtypes in the Nonamen vaccine were also found to vary in mice, 
with the highest SBA responses determined against the P I,7,16, P l.5-1 ,2-2, P l.5 -2 ,10 and the 
Pl.22 ,14  serosubtypes of PorA. The lowest SBA response was again determined against the 
P I.19,15-1 serosubtype of PorA(64,63,316).
Murine sera was collected following immunisation with two injections of 1 /10  human dose of 
either Hexamen or Nonamen vaccine. Human sera were collected following immunisation of 
healthy Netherlands toddlers of 2 - 3 years of age, and children of 7 -  8 years of age with three 
injections of the Hexamen vaccine'64,63'3161.
Sera from the SEU were collected following vaccination of healthy laboratory workers with OMV 
vaccines based on single strains of serogroup B meningococci as part of two NVEC studies'921. 
Laboratory workers were immunised with three doses of either the P l.7,16 or the P l.7 -2 ,4  OMV  
vaccines, and pre- and post-vaccination sera were collected. Unfortunately, SBA data were not 
available for any of the sera samples described in this chapter, and could not be used for 
correlation with data collected using the Liquichip assay.
Table 5.1 Source of sera used in this chapter.
Source Serum Sera Samples
RIVM (The Netherlands)
Hexamen OMV vaccine
32 samples (Murine)
11 samples (Human)
Nonamen OM V vaccine 32 samples (Murine)
SEU (Manchester)
NW Pl.7 ,16  OMV vaccine 
(MenBvac)
17 samples (Human)
NZ P l.7-2 ,4  OM V vaccine 
(MeNZB)
9 samples (Human)
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5.4 Results
5.4.1 Analysis of murine sera following vaccination with either Hexamen (6 - valent) or 
Nonamen (9 - valent) OMV vaccine
Serum samples from mice immunised with either the Hexamen or the Nonamen vaccine were 
obtained from the RIVM and analysed using the PorA Liquichip assay developed in chapter four. 
Similar IgG responses were detected following immunisation with both the Hexamen and the 
Nonamen vaccines, with no significant difference in the geometric mean titre (GMT) for 
antibodies directed to any of the PorA serosubtypes tested. The lowest GMT was determined 
using the P l.7,16 labelled microspheres and the greatest responses directed towards the P I.5- 
2,10 and the P l.7-2 ,4  serosubtypes (Figure 5.1). IgG responses could not be detected for the 
unvaccinated control group to any of the PorA labelled serosubtypes, with the exception of P l.7 -
2,4 for which a low GMT was detected.
□  Nonamen
□  Hexamen
□  Unvaccinated
Figure 5.1 Geometric mean IgG titres of murine sera vaccinated with Nonamen or Hexamen 
OMV vaccine and an unvaccinated control group (error bars represent 95 % confidence 
intervals). Samples were obtained from Balb/c mice immunised with 1 /10  human dose o f vaccine 
(1.5 pg/PorA) on days 0 and 28 with blood taken on day 42. Data were based on n = 32 with the 
exception of the P l.5 -2 ,10 serosubtype, where n = 30 and n = 31 for Nonamen and Hexamen, 
respectively, and for the P l.7-2 ,4  serosubtype, where n = 31 for the Nonamen vaccinated group. 
All samples were run in duplicate within a single experiment. Titres were determined using a 
standard composed of a mixture of mouse monoclonal antibodies.
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5.4.2 Analysis of human toddler and child sera following vaccination with Hexamen OMV 
vaccine
Serum samples from healthy toddlers ( 2 - 3  years old) and children (7 -  8 years old) immunised 
with the Hexamen OM V vaccine were obtained from the RIVM and analysed using the PorA 
Liquichip assay (Figure 5.2). Samples consisted of one pre-vaccination sample, two post-primary 
samples (following immunisation with the second dose of the vaccine) and seven post-boost 
samples (following immunisation with the third dose of vaccine). None of these samples were 
from the same individual. An adult serum sample was used as a positive assay control, as this 
sample was known to have high levels of anti-PorA antibodies. Sample selection was based purely 
on availability of samples, as all samples and the positive assay control were kindly donated by 
the RIVM for use in this study. Similar antibody titres were observed against all serosubtypes 
used in this assay, with low IgG titres observed for the pre-vaccination and post-primary samples 
in comparison to the post-boost samples. In particular, for GMTs determined against the Pl.5,2, 
Pl.5-1 ,2-2  and P l.5 -2 ,10 and P l.7 ,16  serosubtypes, the effect of the  first dose of vaccine was 
minimal, with similar titres determined for both post-primary sera and pre-vaccination serum. 
Clear differences between the two post-primary samples were evident. Lower IgG concentrations 
were determined against all PorA labelled microspheres for post-primary 1 serum than for the 
pre-vaccination serum with the exception of the VR1 and VR2 deleted PorA mutant, Pl._,_. In 
contrast, sera from post-primary individual 2 demonstrated a higher antibody response to all PorA 
serosubtypes with the exception of the P l.5,2  and the P l.5 -2 ,10 serosubtypes, where a lower 
response was observed in relation to pre-vaccination serum (Table 5.2). In particular, IgG 
concentrations determined against the Pl.19,15; P I.19-1,15-11; P l.7 -2 ,4  serosubtypes and the  
PorA P l._ ,_  mutant were shown to exhibit a greater than two-fold higher response in relation to 
pre-vaccination serum.
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1000 -
□  pre-vaccination  
O  post-primary 1
□  post-primary 2
□  post-boost 
□ A d u lt
Microsphere serosubtype
Figure 5.2 Geometric mean IgG titres of sera from  healthy toddlers ( 2 - 3  years old) and children 
( 7 - 8  years old) vaccinated w ith the Hexamen O M V vaccine. An adult serum sample was 
included as a positive assay control (error bars represent 95 % confidence intervals). The vaccine 
was administered at 0, 2, and 8 months. Pre-vaccination serum was taken prior to the first dose, 
whilst post-primary and post boost sera was taken four - six weeks following the second and third 
dose of vaccine, respectively. The pre-vaccination and adult serum response are representative 
of single individuals, post-primary sera responses of tw o individuals (shown separately) and the 
post boost sera responses are the GMT of seven individuals with the exception of P l.5-1,2-2, 
P I a n d  P l.5,2  serosubtypes where n = 6 and P l.5-2 ,10  serosubtype where n = 5. All samples 
were run in duplicate within a single experiment and titres were determined using a standard 
curve composed of pooled sera from healthy laboratory workers following immunisation with the 
Pl.7,16 or the P l.7-2 ,4  OMV vaccine.
The largest IgG titres, determined against all serosubtypes were observed for the post-boost 
samples, with a greater than two-fold higher response observed in GMTs for all serosubtypes in 
relation to the pre-vaccination sample. The IgG titres for the adult sample were found to be 
higher than those observed for the pre-vaccination sample for all PorA serosubtypes, with a 
greater than two-fold higher response in titre determined against the Pl.5-1,2-2; P I .19,15; P I .19-
1,15-11; P l.7-2 ,4  serosubtypes and the P l._ ,_  PorA mutant.
The Liquichip assay is used to determine the presence of antigen binding antibodies, it is not a 
measure of functional bactericidal activity. The detection of antigen binding antibodies does not
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confirm a protective immune response, and demonstration of bactericidal antibody responses 
would need to be confirmed with use of the SBA assay. This data would be of particular 
importance in the evaluation of vaccines, as the SBA assay is considered to be the gold standard 
for determining meningococcal vaccine efficacy, and is used to confer protection against 
meningococcal disease. Data from SBA assays has been found to show good correlation with 
antigen binding antibody assays, such as the ELISA). In particular, good correlation was observed 
using sera from immunised teenagers and adults following immunisation with a single vaccine (10>. 
SBA data was not available for the sera used in this experiment.
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5.4.3 Analysis of human sera following vaccination w ith O M V vaccines
The effect of vaccination on PorA specific IgG concentrations was evaluated using sera from  
healthy human adults developed against either the P l.7 ,16  or the P l.7 -2 ,4  OMV vaccine. Pre- 
and post-vaccination sera were analysed using the PorA Liquichip assay and IgG titres were 
determined against the PorA labelled microsphere panel. A standard curve was used to quantify 
the antibody response in human sera with an arbitrary concentration assigned for each PorA 
specific IgG response determined against each of the PorA serosubtypes included in the assay as 
described earlier in this thesis.
5.4.3.1 Analysis of human adult sera following vaccination w ith the P l.7 ,16  O M V  vaccine
1000 1
100 -
B pre-vaccination 
0 post-boost
X  .A
o V
Microsphere serosubtype
Pl.5-1,2-2 P!._,_ Pl.19,15 Pl.19-1,15-11 PI.5,2 Pl.5-2,10 Pl.7,16 Pl.7-2,4
0.74 1:28 0.84 0.74 0.84 0.96 0.82 0.66
Figure 5.3 Geometric mean IgG titres of sera from healthy laboratory workers vaccinated w ith  
the P l.7 ,16  O M V vaccine (error bars represent 95 % confidence intervals). Pre-vaccination sera 
were collected prior to administration of the first dose, post-vaccination (boost) sera were taken 
six weeks following the third dose of vaccine. Responses are shown as the GMT of 17 individuals 
with the exception of P l.5-2,10, where n=16 for the pre-vaccination Sample. Samples were run in 
duplicate at two dilutions in order to ensure antibody concentrations were within the linear range 
of the assay. Differences in GMTs between pre- and post-vaccination sera are shown. Titres were 
determined using a standard curve composed of pooled sera from healthy laboratory workers 
following immunisation with either the P l.7,16 or the P l.7-2 ,4  OMV vaccine.
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Sera from seventeen healthy adults were collected both prior to vaccination and six weeks after 
administration of the third dose of the P l.7,16 OM V vaccine. Paired samples were analysed and 
GMTs were calculated for both pre- and post-vaccination sera. Similar GMTs were observed for 
all samples tested (Figure 5.3), with slightly reduced titres in response to the P l._ ,_  labelled 
microspheres. Although high titres were observed, no significant difference was observed 
between the pre- and post-vaccination sera samples and may be due to pre-existing antibodies 
present in the samples. Unfortunately, SBA data were not available for these serum samples, and 
could not be used for correlation with data produced using the Liquichip assay.
NW10= 10000C 10000
Microsphere serosubtypeMicrosphere serosubtype
Figure 5.4 Arbitrary antibody titres from tw o  individuals showing a specific increase in the titre  
of P l.7 ,16  antibodies. Pre-vaccination sera were taken prior to administration of the first dose 
and post-vaccination (boost) sera were taken six weeks following the third dose of the P l.7,16  
OMV vaccine. Each sample was run in duplicate at two dilutions in order to ensure antibody 
concentrations were within the linear range of the assay. Titres were determined using a 
standard curve composed of pooled sera from healthy laboratory workers following immunisation 
with either the Pl.7,16 or the P l.7-2 ,4  OM V vaccine.
The presence of both high responders, exhibiting increased titres to all serosubtypes, and low 
responders, exhibiting unchanged or decreased IgG titre to all serosubtypes were evident when 
sera were analysed individually. Pre- and post-vaccination titres were determined against all PorA 
labelled microsphere sets for individuals. Only two individuals, NW3 and NW10, exhibited a 
specific increase in IgG titre determined using the P l.7,16 PorA labelled microspheres (Figure 5.4). 
A decrease in IgG titre was observed against all other PorA serosubtypes following vaccination of
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individual NW3 with the P l.7 ,16  OMV vaccine, with the exception of the P l.7,16 serosubtype, for 
which a 2.9-fojd increase was found. IgG titres in sera from individual NW10, were found to be 
largely unaffected following vaccination with the exception of the P l.7,16 serosubtype against 
which a 23-fold increase was measured. An increase was also observed against the unrelated 
Pl.5-2 ,10  serosubtype of PorA with a 3.3-fold increase in IgG titre.
Several individual were found to be positive responders with an increase in IgG titre observed 
against all PorA serosubtypes included in the Liquichip assay (Figure 5.5). Whilst the magnitude of 
response varied between individuals, the largest increase in titre for all individuals, with the 
exception of NW17, was determined using the PorA P l._ ,_  mutant. Difference in titres 
determined against the P l._ ,_  labelled microspheres may be misleading, due to the low 
concentration of antibodies able to bind to this protein in the human standard. Use of arbitrary 
concentrations result in low levels of antibodies assigned the same concentration as antibodies 
present in much higher concentrations. A small difference in MFI value could therefore result in a 
large difference in arbitrary concentration for this microsphere set. The increase in IgG titre for 
Individual NW13 ranged from 1.38 to a maximum of 4.0 fold determined against the P l.5-2 ,10  
and P l._ ,_  PorA mutant labelled microspheres, respectively. Individual NW21 exhibited a slight 
decrease in IgG titre determined against the P I.5,2 and the related variant P l.5-1 ,2-2  labelled 
microspheres. An increase was observed against all other serosubtypes and ranged from 1.48 to 
12.03 fold determined against the P l.5-2 ,10 and the PorA mutant, respectively. Individual NW2 
was found to be a particularly high responder with significant increases in IgG titre determined 
against the P l.5-1,2-2; P l.5 ,2  and P l.7-2 ,4  serosubtypes of PorA with 139, 88.67 and 97.94 fold 
increases observed, respectively. IgG titres determined against P I .19,15 and the related P I .19-
1,15-11 labelled microsphere were not affected by vaccination for this individual. Individuals 
NW7 and NW17 were determined to have elevated IgG titres following vaccination against all 
serosubtypes of PorA analysed in this assay. The smallest increase in IgG titre  for NW7 was 
determined against the P l.7,16 labelled microspheres whilst the largest increase was again 
determined against the P l._ ,_  PorA mutant labelled microsphere set. Serum from individual
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NW17 was shown to have elevated IgG titres against all the PorA serosubtypes, with the smallest 
4.13 fold increase determined against the P l.5-2 ,10  labelled microspheres. Unlike the other high 
responders, the largest increase in IgG titre for Individual NW17 was determined against the P l.7 -
2,4 labelled microspheres with a 29.42 fold increase. The highest IgG titres were observed in 
serum collected from individual NW14, with increases ranging from 4.27 to 417 fold determined 
against the P l.7,16 and PorA P l._ ,_  mutant labelled microspheres, respectively. These sera have 
been collected from adult laboratory workers and as such are likely to have had previous natural 
exposure to meningococcal isolates, confirmed by the presence of serosubtype specific anti-PorA 
antibodies observed in pre-vaccination sera. The vaccine may be acting to boost a pre-existing 
immune response, and use of this vaccine has previously been reported to induce significant 
increases in IgG responses to homologous and heterologous PorA antigens(342). SBA assay data for 
these sera would be of value in determining whether the production of bactericidal antibodies 
had been induced by this vaccine.
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Figure 5.5 Arbitrary antibody titres from individuals found to have increased IgG titres to all 
PorA serosubtypes following immunisation w ith the P l.7 ,16  O M V vaccine. Pre-vaccination sera 
were taken p rio r to  adm in istra tion  o f the  firs t dose, post-vaccination (boost) sera were taken six 
weeks fo llow ing  the  th ird  dose o f vaccine. Each sample was run in duplicate at tw o  d ilu tions in 
o rder to  ensure antibody concentrations were w ith in  the  linear range o f the  assay. Individuals are 
grouped in to  d iffe ring  m agnitudes o f IgG titres , shown as A, B and C. T itres w ere determ ined 
using a standard curve composed o f pooled sera from  healthy labora tory w orkers fo llow ing  
im m unisation w ith  the  P l.7 ,16 or the  P l.7 -2 ,4  OMV vaccine.
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The majority of individuals vaccinated with the P l.7,16 OMV vaccine were found to be non­
responders when sera were analysed using the Liquichip assay. Post-vaccination sera from eight 
individuals were found to have unchanged or decreased IgG titres determined against all PorA 
labelled microspheres in relation to pre-vaccination sera (Figure 5.6). IgG titres in sera collected 
from individuals NW6, NW8 and NW11 were hot found to be affected following vaccination with a 
Pl.7,16 OMV vaccine, with a less than twofold difference determined against any of the PorA 
labelled microspheres. Decreases in IgG titre were determined to all PorA labelled microsphere 
for individuals NW4, NW12, NW16, NW18 and NW20 following vaccination with three doses of 
the P l.7,16 OM V vaccine. As previously stated, the likelihood of pre-existing antibodies directed 
against PorA serosubtypes representative of those prevalent in the UK is increased with the use of 
adult human sera due to prior natural exposure. High pre-vaccination titres of anti-PorA antibody 
in the pre-vaccination may therefore result in the vaccine appearing to have little or no effect.
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Figure 5.6 Arbitrary antibody titres from individuals determ ined to be non-responders using the 
Liquichip assay, w ith decreased IgG titres observed following immunisation w ith  the P l.7 ,16  
O M V vaccine. Pre-vaccination sera were collected p rio r to  adm in istra tion  o f the  firs t dose, post­
vaccination (boost) sera w ere taken six weeks a fte r the  th ird  dose o f the  P l.7 ,16  OMV vaccine. 
Each sample was run in duplicate at tw o  d ilu tions in o rder to  ensure an tibody concentra tions 
were w ith in  the  linear range o f the assay. Individuals are grouped in to  d iffe ring  m agnitudes o f 
IgG titres , shown as A and B. The pre-vaccination IgG titre  o f NW18, was no t de te rm ined  against 
the  P l.5 -2 ,10  labelled m icrospheres. Titres were determ ined using a standard curve composed o f 
pooled sera from  healthy laboratory w orkers fo llow ing  im m unisation w ith  the P l.7 ,16  o r the  P l.7 -
2,4 OMV vaccine.
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5.4.3.2 Analysis of sera from healthy human adults following vaccination w ith the P l.7 -2 ,4  
O M V vaccine
1000 1
100 -
10 - B pre-vaccination 
0  post-vaccination
Microsphere serosubtype
Pl.5-1,2-2 Pl.19,15 Pl.19-1,15-11 Pl.5,2 Pl.5-2,10 Pl.7,16 Pl.7-2,4
1.57 , 4.74 10.97 5.56 1.46 0.99 1.87 11.44
Figure 5.7 Geometric mean IgG titres of sera from healthy adults vaccinated w ith the P l.7 -2 ,4  
O M V vaccine (error bars represent 95 % confidence intervals). Numbers in bold represent a 
greater than two fold increase in titre following vaccination. Pre-vaccination sera were taken 
prior to the first dose, and post-vaccination sera were collected six weeks after third dose of the  
Pl.7-2 ,4  OMV vaccine was administered. Each sample was run in duplicate at tw o dilutions in 
order to ensure antibody concentrations were within the linear range of the assay. Responses are 
shown as the GMT of 9 individuals for both pre- and post-vaccination sera. Fold increases in GMT 
observed following vaccination are shown in relation to pre-immunisation samples. Titres were 
determined using a standard curve composed of pooled sera from healthy laboratory workers 
following immunisation with either the P l.7,16 or the P l.7-2 ,4  OMV vaccine.
Sera was collected from nine healthy laboratory workers both prior to vaccination and six weeks 
after administration of the third dose of the P l.7-2 ,4  OM V vaccine. Paired samples were analysed 
using the Liquichip assay and GMTs were calculated for both pre- and post-vaccination sera. In 
contrast to results obtained with sera following vaccination with the P l.7 ,16  OM V vaccine, 
increased GMTs were determined against all PorA serosubtypes following vaccination with the 
Pl.7-2 ,4  OMV vaccine, with the exception of the P l.5 -2 ,10  labelled microsphere set (Figure 5.7).
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The greatest increases in antibody titre were determined against the PorA P l._ ,_  mutant; 
Pl.19,15; P l.19-1,15-11 and P l.7-2 ,4  labelled microsphere sets, all of which revealed a greater 
than two fold increase in the GMT of post-vaccination sera in comparison to pre-vaccination sera. 
A more limited increase was observed against the P l.7,16 labelled microspheres and the 
unrelated Pl.5,2; Pl.5-1,2-2; and P l.5-2,10 serosubtypes. The P l._ ,_  is a PorA mutant expressed 
as a PorA protein without the VR1 and VR2 antigenic binding epitopes. Bactericidal antibodies 
directed against the VR3 region of PorA have been produced, and any antibody titres determined 
against the P l._ ,_  -PorA protein are likely to be directed against this region.
JlHMI
/  £  A^ 'V*-v5'  ❖  cP' A ' .A>’ <r .v  s? « P'
/^licrosphere serosubtype
= 1000 n
? <P-
3 100 ■
I
NZ2
I pre
3 100 ■
E post <§ M  , h
NZ4
B pre 
D post
•P- o f £  A>° A^ #.v < p  •£’ «v «>' O kV
* * *
Iviicrosphere serosubtype 
NZ10
II B pre D post
JV y $> .A
<p <.v” .A
? <P oT
<p'Microsphere serosubtype
Figure 5.8 Arbitrary antibody titres from three individuals showing increased IgG titres  
determ ined against all PorA labelled microspheres following vaccination w ith the P l.7 -2 ,4  O M V  
vaccine. Pre-vaccination sera were taken prior to administration of the first dose, post­
vaccination (boost) sera were collected six weeks after the third dose of the P l.7 -2 ,4  vaccine. 
Each sample was run in duplicate at two dilutions in order to ensure antibody concentrations 
were within the linear range of the assay. Titres were determined using a standard curve 
composed of pooled sera from healthy laboratory workers following immunisation, with either the  
Pl.7,16 or the P l.7-2 ,4  OMV vaccine.
The effect of vaccination was again found to be dependent on the individual, with both high and 
low responders to the vaccine observed when sera was analysed individually. Individuals NZ2, 
NZ4 and NZ10 were found to have increased IgG concentrations determined against all panel
136 | P a g e
PorA labelled microspheres following vaccination with the P l.7-2 ,4  OM V vaccine (Figure 5.8). IgG 
titres determined against the P I .19,15 labelled microspheres for all these individuals were found 
to be below the limit of detection in pre-vaccination sera. Pre-vaccination sera from individual 
NZ2 was also found to have IgG titres below the limit of detection using microspheres labelled 
with serosubtype P l.19 -1 ,15-11 and P l.7-2 ,4  purified PorA proteins.
^icrosphere serosubtypeMlcrosphere serosubtype
Wrosphere serosubtype
Figure 5.9 Arbitrary antibody titres from three individuals showing increased IgG titres  
determined against P l.7 -2 ,4  labelled microspheres following immunisation w ith the P l.7 -2 ,4  
O M V vaccine. Pre-vaccination sera were taken prior to administration of the first dose, post­
vaccination (boost) sera were taken six weeks following the third dose of the P l.7 -2 ,4  vaccine. 
Each sample was run in duplicate at two dilutions in order to ensure antibody concentrations 
were within the linear range of the assay. Titres were determined using a standard curve 
composed of pooled sera from healthy laboratory workers following immunisation with either the 
Pl.7,16 or the P l.7-2 ,4  OMV vaccine.
As observed with the P l.7,16 OM V vaccine, sera samples were collected from laboratory workers, 
and as such are likely to have had previous natural exposure to meningococci isolates expressing 
homologous or heterologous PorA serosubtypes to those used in the Liquichip assay. The effect 
of vaccination on pre-existing anti-PorA antibodies must be considered. Use of this vaccine has 
previously been reported to induce significant increases in IgG responses to homologous and 
heterologous PorA antigens(342) and may explain the cross-reactive effect of the vaccine observed.
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Sera from three individuals were found to have increased IgG titres determined against PorA 
labelled microspheres homologous to the vaccine strain, in addition to other serosubtypes (Figure 
5.9). However, unlike individuals NZ2, NZ4 and NZ10, they were not found to have increased 
titres against to all the PorA panel serosubtypes. Individual NZ7 was found to have increased IgG 
titres determined against four of the eight PorA labelled microspheres, including P1.5,2; P l.5-1 ,2- 
2; Pl.7,16; P l.7-2 ,4  and the PorA P l._ ,_  mutant. The largest increase in IgG titre however was 
seen against microspheres labelled with purified P l.7-2 ,4  protein with a 3.15 fold increase in IgG 
titre. Decreases in IgG titre were determined against the P I .19,15; P l.19 -1 ,15-11 and P l.5-2,10  
labelled microspheres. Increased titres were determined against five of the eight PorA labelled 
microsphere sets for individual NZ8 with the largest increase (10.26 fold) in IgG titre determined 
against the PorA P l._ ,_  mutant labelled microspheres. Increases of 5.59 and 5.24 fold were 
observed in IgG titre determined against the P I .19-1,15-11 and the vaccine strain homologous 
Pl.7-2 ,4  labelled microspheres. Individual NZ9 was found to have an increased IgG titre specific 
to the vaccine serosubtype with a 2.39 fold increase in IgG titre determined against the P l.7-2 ,4  
labelled microspheres. A decreased IgG titre was determined against the P l.7 ,16  serosubtype 
labelled microspheres. No differences were observed using any of the remaining panel PorA 
serosubtypes for this individual.
As for the previous samples, much of the immune response observed following vaccination with 
the P l.7-2 ,4  OMV vaccine can be explained by the presence of cross-reacting, pre-existing 
antibodies. High IgG concentrations determined in pre-vaccination sera complicate assessment of 
the immune response induced by administration of vaccine. As with the P l.7 ,16  OM V vaccine, 
the P l.7-2 ,4  vaccine has been shown to elicit significant increases in IgG binding to homologous 
and heterologous OMV antigens(342).
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Figure 5 .10  Arbitrary antibody titres from  individuals found to  be non-responders using the 
Liquichip assay w ith decreased IgG titres observed following immunisation w ith the P l.7 -2 ,4  
O M V vaccine. Pre-vaccination sera were taken prior to administration of the first dose, post­
vaccination (boost) sera were taken 4 weeks following the third dose of the P l.7 -2 ,4  OMV  
vaccine. Each sample was run in duplicate at two dilutions in order to ensure antibody 
concentrations were within the linear range of the assay. Individuals are grouped into differing 
magnitudes of IgG titres, shown as A and B. The post-vaccination IgG titre of NZ1, was not 
determined against the P I.19,15 labelled microspheres. Titres were determined using a standard 
curve composed of pooled sera from healthy laboratory workers following immunisation with the 
Pl.7,16 or the P l.7-2 ,4  OMV vaccine.
Individuals NZ1, NZ3 and NZ11 were not determined to be responders to the P l.7 -2 ,4  OMV  
vaccine when sera was analysed using the Liquichip assay. Post-vaccination sera from these 
individuals were found to have unchanged or decreased IgG titres determined against all PorA 
labelled microspheres (Figure 5.10). For these individuals, the IgG titres determined against the  
Pl.7-2 ,4  labelled microspheres, homologous to the vaccine strain, were found to be unaffected 
with less than a 50 % decrease in IgG titre observed. The post-vaccination IgG titre determined 
using P l.19,15 labelled microspheres was found to be lower than the limit of detection for 
Individual NZ1. Decreased IgG titres were determined using microspheres labelled with P1.19-
1,15-11; Pl.5,2; P l.5-2 ,10  and P l.7-2 ,4  PorA purified proteins while IgG titres determined against
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the remaining panel of PorA serosubtypes were unaffected following vaccination. Individual NZ3 
was found to have decreased IgG titres determined using five of the eight PorA labelled 
microsphere panel with the largest decrease determined using the P l.5-2 ,10 serosubtype. 
Decreases were also observed using microspheres labelled with Pl.5-1,2-2; P I.19-1,15-11; P I.5,2 
and the P l._ ,_  PorA mutant purified proteins. Decreases were determined using five of the eight 
serosubtype labelled microspheres in sera from individual NZ11, with the largest decrease 
determined using the P l.5,2  labelled microspheres. Natural exposure to meningococcal isolates 
may result in the high titres of anti-PorA antibodies observed in pre-vaccination serum. The 
immune response produced following administration of the vaccine, would therefore be masked, 
and result in the vaccine appearing to have little or no effect on the individual.
5.5 Discussion
Binding antibody assays are traditionally used for the detection of functional and non-functional 
antibodies. The PorA multiplex assay is one such assay, and was successfully used for the 
detection of increases in serum IgG titres against specific PorA serosubtypes following vaccination 
with one of four different OMV vaccines in preclinical and clinical trial sera.
Differences in the effects of vaccination were more easily defined with the use of mouse sera and 
healthy toddler and child sera. Both these sets of sera were used to demonstrate low levels of 
antibodies in pre-vaccination and unvaccinated control sera alongside a specific vaccine induced 
increase in antibody titres in post-vaccination sera. The serosubtypes or related variants included 
in the current assay are also present in the Hexamen and Nonamen vaccines and as such, an 
increased titre against all serosubtypes was predicted(31G). Similar increases in GMTs were 
detected using each of the PorA labelled microspheres in murine and human toddler/child sera 
following vaccination with up to three doses of either the HexaMen (6-valent) or the NonaMen (9- 
valent) OMV vaccine in comparison to the unvaccinated control group. The antibody response 
detected following the booster dose of the vaccine was shown to have the largest GMTs.
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The absence of pre-existing antibodies in murine serum, was confirmed by the lack of antibodies 
detected using the Liquichip assay in sera from unvaccinated mice. Mice do not carry 
meningococci and as such, murine sera would not be expected to contain pre-existing anti- 
meningococcal antibodies. Conversely, murine sera collected post-vaccination would only be 
expected to contain antibodies that recognise the epitopes of PorA serosubtypes expressed in the 
vaccine and was confirmed with an antibody titre measured against all PorA serosubtypes 
included in the assay following vaccination.
A similar response would be expected in the detection of vaccine induced responses in sera from  
human child sera. As a result of the low carriage rates observed in toddlers and young children, 
previous carriage of meningococcal strains is unlikely(43). With serum IgG antibody levels 
remaining low until adolescence(114) the only anti-meningococcal antibodies present in toddler 
sera would be specific to the vaccine serosubtypes. Sera from unvaccinated children are 
therefore unlikely to contain serum antibodies to any PorA serosubtypes and the absence of pre­
existing antibodies or the presence at very low levels would have been expected. This was 
confirmed by a significantly higher GMT detected in child/toddler serum following immunisation 
with the Hexamen vaccine than detected in the pre-vaccination serum sample. The high 
variability of individual responses was demonstrated in the post-primary vaccination samples, 
with high titers of specific anti-PorA antibodies detected in one sample, no response was 
observed in the IgG titre of the second sample. However, without the availability of pre­
vaccination serum sample from the same individuals, the effect of vaccination on serum 
antibodies cannot be determined. It is possible that the increased level of specific PorA 
antibodies maybe due to the effect of vaccination boosting an existing immune response whilst 
antibodies to the remaining serosubtypes are not elevated until the third dose of the vaccine. 
This suggests that fold-differences in titre following vaccination may be just as important as 
absolute IgG titres in the evaluation of post vaccination responses, particularly in individuals likely 
to have pre-existing immunity.
Responses to vaccination were found to vary between individual human adults following 
vaccination with either the P l.7 ,16  or the P l.7 -2 ,4  OMV vaccine. Increased IgG titres against 
specific PorA serosubtypes were measured in human adult sera following vaccination with three 
doses either of the P l.7,16 or the P l.7 -2 ,4  OMV vaccine. Several individuals exhibited large-fold 
increases in antibody titre against heterologous serosubtypes as well as to the corresponding 
PorA serosubtype protein. Conversely, other individuals did not respond well against any of the 
PorA serosubtypes. It is therefore likely that a good response may be dependent on the individual 
rather than on the vaccine in question, highlighting the need for paired sample analysis and 
comparison of IgG titres both prior to and post vaccination. Due to peak carriage rates in young 
adults, the likelihood of carriage or previous carriage of meningococci with a homologous or 
heterologous serosubtype of PorA to those expressed in the vaccine is increased in adult 
humans(43). With the presence of pre-existing, cross reacting antibodies, all of which have an 
influence on the immune response initiated in response to either a new infection or vaccination, it 
is difficult to distinguish between a pre-existing antibody response and a vaccine-induced 
response. As such the immune response elicited following vaccination of human adults may 
result in what appears to be non-specific responses.
Carriage itself can act as a priming event(59) with subsequent vaccination acting as a booster to 
elicit a specific immune response. In particular, previous carriage of meningococci with the 
homologous PorA serosubtype as the vaccine strain would lead to a high anti-PorA IgG titre  
measured against that serosubtype. Carriage of meningococci with a heterologous PorA 
serosubtype would initially result in a less marked immune response, increasing over tim e(267). 
The effect of immunological priming is highlighted using sera from adults vaccinated with either 
the P l.7,16 or the P l.7-4 ,2  OMV vaccine. As the vaccines were administered to adult laboratory 
workers, previous carriage of meningococcal isolates and immunologic priming was probable and 
likely to have an effect on post-vaccination IgG titres. HexaMen has previously been shown to 
induce a cross-reactive antibody response against isolates with one VR identical to the vaccine 
serosubtype and to minor VR variants of serosubtypes included in the HexaMen vaccine(330). The
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amount of time elapsed between meningococcal carriage and vaccination would also be expected 
to be a major factor in the antibody response observed following administration of the vaccine. 
High levels of protective antibody have been seen following carriage of meningococcal strains for 
several months after the carriage strain has been lost(249).
The immunodominant VR of each serosubtype is of importance for vaccine design with individual 
serosubtype combinations having differing immunodominant VRs. Although the P l.7 -2  and P1.7 
epitopes are related, the P1.4 epitope is thought to be the major target for immune response for 
the P l.7-2 ,4  OMV vaccine(190) with the majority of antibodies targeted against the VR2 region of 
this protein. Similarly, the VR2 of P l.5-2 ,10 and possibly the P I .19,15 were found to be 
immunodominant in the Hexamen vaccine. There is some debate as to whether the VR1 or the 
VR2 of the P l.7,16 is the immunodominant epitope. Whilst some studies have found VR1 to be 
the immunodominant \/R(324'91), others have determined VR2 to be the immunodominant 
epitope(341'349). Whilst the variable nature of the VR regions is due to immune selection by 
functional antibodies in human, the production of anti-PorA antibodies not specific to either VR1 
or VR2 has been reported previously*324* and would suggest an immunogenicity of the rest of the 
PorA structure in adults. Additionally, as previously observed, high antibody titres against the 
P l._ ,_  PorA protein may to appear elevated due to the low level of anti-P l._,_  antibodies in the 
standard used to quantify the response.
This assay has been successfully used in this study to analyse sera from humans, and mice 
vaccinated with the multivalent Hexamen and Nonamen OM V vaccines as well as the strain- 
specific Norwegian P l.7,16 and New Zealand P l.7-2 ,4  O M V vaccines. Whilst increased antibody 
titres were detected in sera following vaccination with each of the OMV vaccines, the detection of 
specific anti-PorA antibodies was found to be dependent on the source of serum. The small 
number of samples analysed in this chapter, limit the conclusions that can be drawn on vaccine 
efficacy, and would need to be repeated on a larger scale with paired pre- and post-vaccination 
sera samples. This assay can be further expanded for the detailed assessment of immune 
responses to both combination vaccines and antigenic variants.
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Chapter 6. D eterm ination o f na tu ra l im m unity in serum samples using both longitudinal 
and cross-sectional studies
6.1 Introduction
The only known reservoir of N. meningitidis is the human nasopharynx and colonisation by the 
non-invasive meningococci, resulting in asymptomatic carriage as opposed to disease, is essential 
for meningococcal survival and the first step of pathogenesis*46,356*. Carriage is itself an 
immunising event*114* leading to the development of bactericidal antibodies, directed to the 
colonising strain of meningococci*109*. A peak in SBA and anti-OMV IgG titres has previously been 
found to coincide with the peak in meningococcal carriage with evidence of the induction of SBAs 
as a result of carriage. The level of bactericidal antibodies may remain elevated for several 
months following an episode of carriage*298*. Whilst infection with N. meningitidis rarely leads to 
invasive meningococcal disease, asymptomatic carriage of meningococcal strains is a common 
occurrence with approximately 5 - 10 % of healthy individuals carrying N. meningitidis at any 
time*303*. Increased rates of carriage, approximately 25 %*302* were found in adolescents and 
young adults. In particular, increased rates of meningococcal carriage have been found in military 
recruits and college students as a consequence of closed, crowded living conditions and mixing 
with new communities*287,36*. Mobilisation of current strains is the principal method of 
transmission of pathogenic and commensal strains of meningococci, and infection is usually from  
within the healthy population rather than from individuals with the disease*36*. As such, an 
understanding of transmission of meningococcal isolates is an important part of public health 
management.
Carriage studies provide useful information about the epidemiology and pathogenesis of 
meningococcal disease. Risk factors for carriage in young adults, such as smoking, kissing and 
attending night clubs have been identified through carriage studies*43,46,141*, in additional to 
providing knowledge that can be used for widespread outbreak management*356*.
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This chapter uses the Liquichip assay to analyse sera samples collected as part of two separate 
studies. Serum samples were collected from healthy students from the University of Nottingham 
as part of a carriage study carried out jointly by the University of Leicester and the University of 
Nottingham, to analyse phase variable genes of meningococcal isolates using genetic and 
serological methods. Throat swabs, blood and saliva samples were taken from 190 first year 
students, recruited from five halls of residence. Repeat samples were taken from the same 
individuals at t  = 4, t  = 12 and t = 24 weeks. Isolates were identified as meningococci by the 
presence of crgA, ctrA, and porA genes. DNA analysis was used for serogrouping, porA typing, 
fetA  typing, MLST and repeat tract analysis*25*. A selection of these samples were used in this 
study, and individuals were grouped into categories consisting of: eight non-carriers, of whom  
four individuals provided several samples over the period of 4 - 24 weeks, where no serosubtype 
was identified; five new acquirers, where serosubtype was detected following a non-carrier 
sample (Table 6.2); ten persistent carriers, where the same serosubtype was detected over 
multiple time points (Table 6.4); and eleven eliminators, where a loss of serosubtype was 
observed following carriage (Table 6.6). Using the Liquichip assay, arbitrary antibody 
concentrations were calculated and differences in titres over a 24 week period were analysed to 
ascertain whether antibody concentration had a direct effect on carriage of the colonising 
meningococci and the effect of strain acquisition.
Sera from five hundred healthy individuals ranging from 15 -  19 years of age were obtained from  
the HPA SEU7 collection*215'300*. Samples were randomly chosen with approximately 100 
representative samples taken from those collected in 1990, 1994, 1998, 2002 and 2006. This 
collection is comprised of residual samples submitted by participating laboratories, based around 
England and Wales, following routine diagnostic testing representing the entire age range of the 
population. Whilst the reason the blood sample was taken is not recorded, samples from  
immunocompromised individuals are excluded. Prior to 1996, samples submitted for testing for 
antibodies to HIV or Hepatitis B infection were also excluded, however these are now included in
7 http://www.hpa.org.uk/Topics/lnfectiousDiseases/lnfectionsAZ/SeroepidemiologyProgram m e/ ______
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order to provide a complete sample. Each sample is assigned a unique identity number and the 
age (or date of birth) and sex of the donor, year of collection, and participating laboratory are 
recorded, whilst all laboratory numbers are removed ensuring samples are anonymous. Sera 
samples from this collection were intended to examine potential changes in exposure to different 
meningococci over time, and have been tested for a variety of diseases including Measles, Mumps 
and Rubella, Diphtheria and Tetanus*215*.
6.2 Aims of this chapter
The aims of this chapter were:
•  To examine the effect of meningococcal carriage on host immunity by measurement of 
IgG concentrations in sera collected from university students with known carriage states 
over a 24 week period as part of a longitudinal study.
•  To examine the IgG titre of antibodies specific to serosubtypes of PorA in sera 
representative of young adults throughout England and Wales over a 16 year period 
(1 9 9 0 -2 0 0 6 ).
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6.3 Results
6.3.1 Association of increases in IgG concentrations in direct comparison to carriage status
6.3.1.1 Non-carriers
Non-carrier serum was found to exhibit low level IgG responses to all of the PorA serosubtypes in 
this assay (Figure 6.1). Whilst direct comparison cannot be made between IgG titres directed 
against each of the PorA serosubtypes, the GMT of IgG against all of the PorA subtypes were 
significantly higher than for the PorA mutant P l._,_, in which the two major antigenic variable 
regions (VR1 and VR2) had been deleted (p < 0.05).
160 -
140 - ' _
cu
Microsphere serosubtype
Figure 6.1 Geometric mean IgG titres of sera from healthy university students from  the  
University of Nottingham (error bars represent 95 % confidence intervals). Responses are 
shown as the GMT of twelve samples collected from eight individuals (multiple samples were 
used for four individuals). Serum was assayed using tw o replicate samples at two dilutions in 
order to ensure the antibody concentration was within the linear range of the assay. Titres were 
determined using a standard curve composed of pooled sera from healthy laboratory workers 
immunised with three doses of the P l.7,16 or the P l.7 -2 ,4  OMV vaccine as described previously.
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Multiple sera samples from four individuals were collected at multiple time points. The initial 
sample was collected at t  = 0 weeks, and additional samples were collected at t = 4, t  = 12 and t = 
24 weeks. Samples for every tim e point were not available for each of these four individuals. 
Little difference was observed in IgG responses in sera from the same individual sampled at 
multiple time points, with a less than 1.3 fold increase observed for all serosubtypes (Table 6.1). 
As a result of the low IgG titres of anti-PorA measured in these sera, differences in the calculated 
IgG titre determined against each of the PorA labelled microsphere sets in these samples are likely 
to be a result of noise, or fluctuations in the system, with a difference or one or tw o MFI, giving a 
large difference in assigned arbitrary concentration.
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6.3.1.2 New Carriers
To investigate whether the recent acquisition of the meningococcus stimulates host immunity 
resulting in an increase in circulating IgG, sera from five individuals (Table 6.2), who had acquired 
meningococcal carriage over the course of the study, were analysed using the Liquichip assay. 
Samples from the same individual were analysed, with samples collected at various intervals to 
monitor the induction of PorA variant specific antibodies following acquisition of carriage. Of the 
five individuals known to have acquired carriage of meningococci, each was found to have been 
colonised with isolates expressing different serosubtypes of PorA (Table 6.2). These were: 
P I.21,16; P l.21-7,16; P I.5-1,2-2; P I.5,2; and P I.5-1,10-1. Whilst all of these serosubtypes are not 
included in the Liquichip assay, closely related minor variants were present and were used to 
analyse sera responses.
Table 6.2 Individuals found to have acquired carriage of meningococci during this study. The
corresponding microsphere PorA type is given, with the homologous serosubtype (or minor 
variant of) shown in bold.
Individual
Serosubtype of Acquired Isolate 
VR1 VR2
Microsphere PorA type 
VR1 VR2
N1 21 16 7 16
N2 21-7 16 7 16
N3 5 2 5 2
N4 5-1 10-1 5-2 10
N5 5-1 2-2 5-1 2-2
Acquisition of carriage was associated with an increase in IgG response to the specific PorA 
serosubtype of the carried isolate. Figure 6.2 shows IgG responses to each of the PorA 
serosubtypes included in the assay. The effect of acquisition on heterologous serosubtypes was 
found to vary among individuals. Individuals N1 and N2 were found to exhibit increased IgG 
concentrations in response to one or more of the heterologous serosubtypes of PorA. Responses 
to the remaining serosubtypes were largely unaffected for individuals N3 and N4, whilst increases
in IgG concentration were observed in response to all serosubtypes for individual N5 as shown in 
Figure 6.2. As observed with the non-carrier individuals, the lowest IgG concentration was 
determined against the mutant P l._ ,_  PorA serosubtype for all individuals.
Individual N l, identified as a new carrier of a meningococcal isolate with the P I.21,16 
serosubtype of PorA, was shown to exhibit a 2.1 fold increase (Table 6.3) in IgG concentration 
directed towards the corresponding P I.7,16 labelled microspheres. A 13.5 fold increase was also 
observed in antibody concentration directed against the P I.5-2,10 serosubtype, a 3.7 fold 
increase against the P l.19 -1 ,15-11 serosubtype and a 1.8 fold increase against the P l.5-1 ,2-2  
serosubtype of PorA. Similarly, a 19.3 fold increase in IgG concentration directed towards the 
Pl.7,16 serosubtype labelled microspheres was observed for N2, following acquisition of a 
carriage isolate with the P l.21-7,16 serosubtype PorA. Increased IgG concentrations, determined 
against the P l.19 -1 ,15-11 and P I.5-2,10 PorA labelled microspheres, were observed with 
responses to all remaining serosubtypes unaffected. These data appear to suggest cross­
reactivity between PorA epitopes, in particular between antibodies directed against the P I.21,16 
serosubtype of PorA, and both the P I.5-2, 10 and P I .19-1,15-11 protein labelled microsphere. 
Interestingly, cross-reactivity is not observed with the related P I .19,15 protein labelled 
microspheres. These proteins share the same variant of VR3 and it is possible that serum 
antibodies raised in response to meningococcal isolates with the P.21,16 serosubtype of PorA are 
binding to this epitope on the purified PorA proteins.
Individuals N3 and N4 exhibited large increases in sera IgG responses, specific to the serosubtype 
of the carriage isolate acquired. Following colonisation of individual N3 with a carriage isolate 
expressing the P l.5,2  serosubtype o f PorA, increased IgG concentrations were observed against 
both the P l.5,2  and P l.5-1 ,2-2  serosubtype labelled microspheres, with a 7.7 fold and a 3.9 fold 
increase observed, respectively, up to 12 weeks following colonisation. This increase was 
amplified in the final sera sample, taken up to 24 weeks post-colonisation with a 65.6 fold and 
34.5 fold increases, respectively. Subsequent colonisation with a P I.5-1,10-1 carrier isolate was 
identified at the University of Nottingham. Whilst an increase in IgG concentration directed
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against the P l.5-1 ,2-2  labelled microspheres was observed, no increase was observed using the 
P I.5-2,10 labelled microspheres (Table 6.3). W ith increases in serosubtype specific antibody titre 
have been reported as early as two weeks following the onset of carriage, it is likely that 
colonisation with the P l.5-1,2-2 carrier isolate was very recent.
Acquisition of a meningococci isolate expressing the P l.5 -1 ,10-1 PorA by Individual N4, resulted in 
a 10.8 fold increase in IgG concentration determined using the corresponding P l.5-2 ,10  
serosubtype labelled microspheres. A more limited, 2.4 fold increase in IgG concentration was 
determined using the P l.5-1 ,2-2  labelled microspheres, along with a 2.6 fold increase against the 
related P l.5,2  labelled microspheres (Table 6.3). This suggests the immunodominance of the VR2 
region of the PorA protein as a target for antibody binding.
Individual N5, a new carrier of a carriage isolate expressing the P l.5-1 ,2-2  serosubtype of PorA, 
exhibited an increase in IgG concentration in response to all serosubtypes of PorA included in this 
assay. The largest increase was directed against the P l.19,15 and P l.19 -1 ,15-11 labelled 
microspheres with 22.3 and 22.9 fold increases observed, respectively. Similar increases in IgG 
concentrations were observed for related serosubtypes. An increase of 11.8 and 13.1 was 
determined using the P l.5-1 ,2-2  and P l.5,2  labelled microspheres, respectively. A 3.0 and 3.6 
fold increase observed using microspheres labelled with the P l.7,16 and P l.7-2 ,4  serosubtypes of 
PorA, respectively (Table 6.3 and Figure 6.2). An increase in IgG concentration directed to all 
serosubtypes of PorA may have been a result of previous carriage and clearance of meningococcal 
isolates with a serosubtype homologous to the protein labelled microspheres, and boosting of an 
existing immune response following an episode of carriage.
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Figure 6.2 IgG titres of sera from individuals known to have acquired meningococcal carriage.
Individuals were found to  be non-carrier o f meningococci at in itia l sampling, how ever w ere found 
to  have acquired meningococcal carriage at a la ter tim e  point. Individuals N2 and N3 w ere found 
to  have acquired carriage o f the  meningococci a t 12 weeks. The rem aining individuals w ere found 
to  have acquired carriage o f meningococci at 24 weeks. W hilst the  hom ologous serosubtype was 
not tested fo r in every case, closely related variants are present, and IgG responses are expected 
to  be d irected to  these variants. All samples were tested in duplicate at tw o  d ilu tions o f serum. 
Titres were determ ined using a standard curve composed o f pooled sera from  labora to ry  w orkers 
fo llow ing  im m unisation w ith  the P l.7 ,16  o r the  P l.7 -2 ,4  OMV vaccine.
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6.3.1.3 Persistent carriers
To evaluate the effect of persistent carriage of the meningococcus on the serosubtype-specific 
antibody concentrations, sera from ten individuals (Table 6.4) identified as persistent carriers of 
meningococcal isolates over at least two sampling periods over the course of this study, were 
analysed on the Liquichip using the panel of PorA-coated microspheres. Samples from the same 
individual were analysed, with samples collected at various intervals to monitor differences in IgG 
concentration of PorA variant specific antibodies during persistent carriage. Ten individuals were 
known to have persistent carriage of meningococcal isolates with one of five serosubtypes of 
PorA. These were P l.21,16; P l.5 -1 ,10-1; P l.5,2; P l.5-1 ,2-2  and P l.19 -1 ,15-11. Whilst these 
serosubtypes are not all included in the Liquichip assay, closely related variants were present and 
were used to analyse sera responses (Table 6.4).
Table 6.4 Individuals found to be persistent carriers of a meningococcal isolate w ith a single 
serosubtype of PorA. The corresponding microsphere PorA serosubtype is given, with the  
homologous serosubtype (or minor variants of) shown in bold.
Individual
Serosubtype of Carriage Isolate 
VR1 VR2
Microsphere PorA type  
VR1 VR2
P I 21 16 7 3.6
P2 21 16 7 16
P3 21 16 7 16
P4 21 16 7 16
P5 5-1 10-1 5-1 10
P6 5-1 10-1 5-1 10
P7 5 2 5 2
P8 5 2 5 2
P9 5-1 2-2 5-1 2-2
P10 19-1 15-11 19-1 15-11
IgG responses to the panel of PorA coated microsphere, over a 12 -  24 week period are shown in 
Figure 6.3, Figure 6.4 and Figure 6.5. A decrease in IgG concentration was determined using
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microspheres labelled with the PorA serosubtype homologous to the carriage isolate for many 
serotypes with the exception of P l.5 -1 ,10-1. Individuals P5 and P6 exhibited 1.43 and 1.13 fold 
increases in IgG concentrations directed to the P l.5-2 ,10  PorA labelled microspheres, respectively 
(Table 6.5). The effect of persistent carriage on the IgG concentration to the remaining non- 
homologous panel PorA-serosubtypes was found to vary by individual. IgG titres determined 
using microspheres labelled with non-homologous PorA serosubtypes were largely unaffected for 
Individuals P3, P4, P5, P6 and P8 (Figure 6.4 and Figure 6.5), and more pronounced for others such 
as Individual P I (Figure 6.3). Changes in IgG concentration were not found to be serosubtype- 
specific following periods of persistent carriage for any of the Individuals tested in this study. 
Duplicate samples for sera collected from individuals were assayed using the liquichip assay. As 
no statistical analysis was performed on these data, these comments are merely observations of 
trends.
10000 -
i r  i o o o  -
100 -
PI
B .t=  0 weeks 
D t=  24 weeks
Microsphere serosubtype
Figure 6.3 IgG titres of sera from individual P I, known to be a persistent carrier of a 
meningococcal isolate w ith the P l.21 ,16  serosubtype of PorA. Sera responses to specific 
serosubtypes were determined following analysis with the Liquichip assay. Sera were tested in 
duplicate at two dilutions, to ensure the antibody concentration was within the linear range of 
the assay. Titres were determined using a standard curve composed of pooled sera from  
laboratory workers following immunisation with the P l.7,16 or the P l.7-2 ,4  O M V vaccine.
A known carrier of the P l.21 ,16  serosubtype, individual P I was found to have increased 
concentrations of IgG directed against the P I .19-1,15-11 and the P l.5-2 ,10  PorA labelled 
microspheres (Figure 6.3), with an increase of 2.82 and 7.37 observed, respectively (Table 6.5).
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Responses to the remaining panel of PorA labelled microspheres, including the Pl.7,16  
serosubtype, were unaffected with a concentration difference ranging from a minimum of 0.89 to 
a maximum of 1.14 across the panel of PorA labelled microspheres. As for new carriers, cross 
reactivity, due the shared VR3 region between the antibodies directed against the Pl.21,16  
serosubtype of PorA, and both the P I.5 -2 ,10 , and P I.19-1,15-11 protein labelled microspheres is 
suggested.
During persistent carriage of a meningococcal isolate with the P l.21,16 serosubtype of PorA, 
individual P2 was found to have decreased IgG concentrations in response to every serosubtype 
of PorA used in this assay over a 24 week period (Figure 6.4). The magnitude of decrease varied 
with a minimum 0.85 fold difference observed using the P l.5-1 ,2-2  labelled microspheres, similar 
differences were observed against the P I. 19,15; Pl.5,2; and the P l.7,16 serosubtypes. The 
maximum decrease in IgG concentration was observed against the P l._ ,_  labelled microspheres 
with a 0.15 fold difference over the 24 week study period. The effect of persistent carriage of a 
Pl.21,16 serosubtype meningococcal isolate by individual P3, was found to be serosubtypie 
specific, with increases in IgG concentration determined in response to the P l.5 ,2  and the P l.5 -  
2,10 serosubtype labelled microspheres, with 1.44 and 1.23 fold differences, respectively (Figure
6.4). Decreases in IgG concentration were observed in response to all other serosubtypes on the  
PorA panel. The maximum decrease was determined against the P l.19 -1 ,15-11 and P l.19,15  
labelled microspheres with a 0.61 fold and a 0.74 fold difference observed, respectively over a 24 
week period. GMTs determined using the panel of PorA labelled microspheres were largely 
unaffected for individual P4, also a carrier of a P l.21,16 serosubtype carrier isolate (Figure 6.4). 
Increased IgG concentrations were found in response to P l._ ,_  and P l.7 ,16  labelled microspheres 
with a 1.91 and 1.38 fold difference, respectively, whilst differences in the IgG concentration in 
response to the remaining panel of PorA labelled serosubtypes ranged from a minimum 0.82 to a 
maximum 1.14 fold difference. Differences in IgG concentration in response to the P l._ ,_  labelled 
microspheres may have been exaggerated, due to the low IgG concentrations in response to the  
Pl._ ,_  PorA mutant. Decreases in sera responses were, again, observed in response to all
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serosubtypes o f PorA used in th is  assay fo r individual P10 during persistent carriage o f a 
meningococcal isolate w ith  a P I .19-1,15-11 over a 24 week period (Figure 6.4). The smallest 
d ifference in IgG concentra tion was found to  be d irected tow ards the  hom ologous P I.19-1,15-11 
PorA labelled m icrospheres w ith  m in im um  0.89 d ifference. The maxim um  decrease was 
determ ined in response to  the  P l.7 -2 ,4  serosubtype labelled m icrospheres w ith  a concentra tion 
d ifference o f 0.24 observed over a 24 week period.
5 1 0 0 0  -
■  t  = 0  weeks
t=  24  weeks
P l.5 -1 .2 -2 P I .1 9 ,1 5  P I . 1 9 -1 ,1 5 -1 1  P l.5 ,2
Microsphere serosubtype
P l.5 -2 ,1 0 P l.7 ,1 6 P l.7 -2 ,4
10000
o c1000 - JO o t  = 0 weeks
t = 24  weeks» ;  ioo -
P l.5 -1 ,2 -2 P I . 1 9 ,15  P l.1 9 -1 ,1 5 -1 1  P l.5 ,2
Microsphere serosubtype
P l.5 -2 ,1 0  P l.7 ,1 6
1000
ro i  100 t = 4  weeks
t=  12 weeks
P I .1 9 ,15  P I . 1 9 -1 ,1 5 -1 1  P l.5 ,2
Microsphere serosubtype
P l.5 -2 ,1 0  P l.7 ,1 6 P l.7 -2 ,4
t  = 0  weeks
SL t; 100 -
t  = 2 4  weeks
P I .1 9 ,15  P l .1 9 -1 ,1 5 -1 1  P l.5 ,2  P l.5 -2 ,1 0
Microsphere serosubtype
P l.7 ,1 6 P l.7 -2 ,4
Figure 6.4 IgG titres of sera from individuals known to be persistent carriers of a meningococcal 
isolate. Sera responses to  specific serosubtypes were determ ined fo llow ing  analysis w ith  the 
Liquichip assay. Sera were tested in duplicate at tw o  d ilu tions. T itres were de te rm ined  using a 
standard curve composed o f pooled human sera from  healthy labora tory w orkers vaccinated w ith  
e ithe r the  P l.7 ,16  or the  P l.7 -2 ,4  OMV vaccine. Individuals P2 -  P4 w ere found to  be carriers o f a 
meningococcal isolate w ith  the  P l.21,16 serosubtype o f PorA. Individual P10 was found to  be a 
carrier o f a meningococcal isolate w ith  the  P I .19-1,15-11 serosubtype.
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Microsphere serosubtype
Pl.7-2,4
Figure 6.5 IgG titres of sera from individuals known to be persistent carriers of a meningococcal 
isolate. Sera responses to  specific serosubtypes were determ ined fo llow ing  analysis w ith  the 
Liquichip assay, using a standard curve composed o f pooled human sera from  individuals 
vaccinated w ith  e ithe r the  P l.7 ,16  or the  P l.7 -2 ,4  OMV vaccine. Two samples w ere analysed fo r 
all individuals w ith  the  exception o f individuals P6 and P9 w here samples from  th ree  tim e  points 
were available. Sera w ere tested in duplicate at tw o  d ilu tions, to  ensure the  an tibody 
concentra tion was w ith in  the  linear range o f the  assay. Individuals P5 and P6 w ere known to  be 
persistent carriers o f a meningococcal isolate w ith  the  P l.5 -1 ,10-1 serosubtype, Individuals P7 
and P8 carriers w ith  the  P l.5 ,2  serosubtype and Individual P9 a ca rrie r o f an isolate w ith  the  P l.5 -
1,2-2 serosubtype.
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Persistent carriage was again found to have a limited effect on the antibody responses of 
individuals P5 and P6, both found to be carriers of a meningococcal isolate with the P l.5 -1 ,10-1 
serosubtype. For Individual P5, differences in IgG concentrations ranged from a minimum of 0.74 
determined against the P l._ ,_  labelled microspheres, to a maximum 1.43 increase determined 
using P l.5-2 ,10  PorA labelled microspheres (Table 6.5). Similarly, for individual P6, differences in 
IgG concentrations ranged from a minimum 0.41 fold difference determined using the P l.19 -1 ,15- 
11 labelled microspheres, to a maximum 1.23 fold increase determined against the P l.5-1 ,2-2  
PorA labelled microspheres over a 12 week period. No difference in IgG concentration in 
response to any of the panel PorA labelled microspheres was observed in sera collected at t = 4 
and t  = 12 week timed intervals (Figure 6.5). Non-serosubtype specific decreases in IgG 
concentrations were observed in response to all of the PorA labelled microspheres for individuals 
P7 and P8, following persistent carriage of a meningococcal isolate with a P l.5 ,2  serosubtype over 
a 12 week period (Figure 6.5). Responses directed to six of the eight panel PorA serosubtypes 
were found to have decreased to less than half of the initial IgG concentration (0.38 -  0.48 fold) 
for individual P7. Differences determined against the remaining P l.7,16 and P l.7-2 ,4  serosubtype 
labelled microspheres were less marked, with a 0.70 and 0.72 fold difference, respectively (Table
6.5). Whilst decreased IgG concentrations were also observed for individual P8, these were not as 
marked as for individual P7, and ranged from a difference in IgG concentration from 0.62 -  1.05 
determined against the P l._ ,_  PorA mutant and P l.7,16 PorA labelled serosubtypes, respectively. 
Decreases in serological responses to the panel of PorA labelled microspheres were observed, to 
an similar extent, following persistent carriage of a meningococcal isolate with a P l.5-1 ,2-2  
serosubtype for over a 12 week period by individual P9 (Figure 6.5). Surprisingly, the difference in 
IgG concentration determined using P l.7,16 PorA labelled microspheres was found to change 
from a minimum 0.90 fold at t  = 12 weeks, to a maximum 2.04 fold increase at t  = 24 weeks (Table
6.5). This difference was not observed in IgG titre determined using any of the other PorA 
labelled microspheres.
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Carriage of meningococcal isolates may be prolonged (over a few months), intermittent (last days 
to several weeks) or transient*35,2865. As such a carriage study performed over a period of 24 
weeks can be useful for demonstrating all aspects of carriage, from acquisition of carriage, 
through persistent carriage, to clearance of the meningococcal isolate. In particular, a study of 
this length can be a useful tool in the observation of trends in meningococcal spread and carriage 
within a confined population such as students returning to university following a long period of 
absence, or students from diverse locations attending university for the first time. This is 
particularly true where subjects are unlikely to return over a prolonged sampling period. Carriage 
studies performed over a short period can only be used for the assessment of carriage prevalence 
within a given population.
Prolonged episodes of meningococcal carriage show the benefit of carriage studies performed 
over a much longer time period, often years. There are several advantages to a prolonged study, 
including monitoring the effects of persistent carriage, the rise and decline of bactericidal and 
binding antibodies raised in response to carriage of a meningococcal isolate. Studies such as 
these can be useful in predicting trends in the carriage of meningococcal isolates over a much 
larger population and geographical area. Prolonged studies are also for the evaluation of 
vaccines, and their effect on herd immunity.
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6.3.1.4 Clearance of carriage
To investigate whether increases in circulating IgG resulted in clearance of the meningococcus, 
sera from eleven individuals (Table 6.6), found to have cleared carriage of the meningococcal 
isolate over the course of the study, were analysed on the Liquichip using the panel of PorA- 
coated microspheres. Samples from the same individual were analysed, with samples collected at 
various intervals to monitor the induction of PorA variant specific antibodies preceding clearance 
of carriage. Twelve individuals were known to have cleared carriage of the meningococcus with 
one of six serosubtypes of PorA. These were Pl.21,16; P I.21-7,16; P l.5 -1 ,10-1; P l.5 -1 ,10-26; 
Pl.5,2  and P l.5-1,2-2. Whilst these serosubtypes are not all included in the Liquichip assay, 
closely related variants were present and were used to analyse serological responses.
Table 6.6 Individuals found to have cleared meningococcal carriage, over the course of this 
study. The corresponding microsphere PorA type is given, with the homologous serosubtype (or 
minor variants of) shown in bold.
Individual
Serosubtype of Cleared Isolate 
VR1 VR2
Microsphere PorA type 
VR1 VR2
Cl 21 16 7 16
C2 21 16 7 , 16
C3 21 16 7 16
C4 21 16 7 16
C5 21-7 16 7 16
C6 ■5- 1 10-1 5-1 10
C7 5-1 10-1 5-1 10
C8 5-1 10-26 5-1 10
C9 5 2 5 2
CIO 5 2 5 2
C ll 5-! 2-2 5-1 2-2
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Figure 6.6 Antibody concentration for individuals known to  have cleared carriage of 
meningococcal isolates. Sera responses to specific serosubtypes was determined, following 
analysis with the Liquichip assay. IgG titres were determined using a standard curve composed of 
pooled human sera from healthy laboratory workers vaccinated with either the P l.7,16 or the 
Pl.7-2 ,4  OMV vaccine. Three samples were analysed for C7, a carrier of a meningococcal isolate 
with the P l-5-1 ,10-1 serosubtype, to determine increases in serosubtype specific IgG responses 
both prior to and post clearance of the meningococcal isolate. Two samples were analysed for 
CIO, found to be a carrier of a meningococcal isolate with the P l.5,2  serosubtype, to determine 
increases in serosubtype specific IgG responses following clearance.
Two to three samples taken over a period of 12 - 24 weeks were analysed for each individual. 
Greater than 2 fold increases were found in the level of PorA specific antibodies either when the  
carriage isolate was last detected in the sample, or at the following time point where the carriage 
isolate could no longer be detected for six of the eleven individuals analysed (Table 6.6). The 
greatest increase in IgG titre was observed immediately preceding clearance. In particular, 
individuals C7 and CIO were found to have a 44.09 and 94.81 fold increase, respectively in IgG 
titre specific to the serosubtype of the carried isolate (Figure 6.6). Although an increase in IgG 
titre was not determined for Individuals C3 and C5, high concentrations of serosubtype specific 
antibodies homologous to the serosubtype of the carriage isolate were found (Figure 6.8). No 
increase was found preceding clearance of the P l.5-1 ,2-2  carriage isolate in C l l ,  however, serum
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was only available from one individual found to have cleared carriage of a meningococcal isolate 
with the P l.5-1,2-2 serosubtype, so it was not possible to determine whether this was an 
individual response, or a serosubtype specific response (Figure 6.9).
The largest increase in IgG concentration was observed in response to the P1.5>2 labelled 
microspheres, homologous to the serosubtype of the meningococcal isolate following clearance. 
CIO exhibited a 94.81 fold increase, with a similar 74.77 increase in PorA antibodies in response to 
P l.5 ,2  and related P l.5-1 ,2-2  labelled microspheres, respectively. Similarly a 44.09 fold increase 
was also observed for Individual C7 in response to the P l.5-2 ,10  labelled microspheres prior to 
clearance of a meningococcal isolate with the P I.5-1,10-1 serosubtype. Analysis of the C7 post­
clearance sample revealed a reduced 9.92 increase in response to the same microsphere set 
(Figure 6.6).
Clearance of carriage was preceded by a greater than two fold increase, in serosubtype specific 
antibodies for individuals C l, C2, C6 and C9 (Figure 6.7). Sera responses for individuals C l and C2, 
known to have cleared carriage of a meningococcal isolate with a P l.21,16 serosubtype, were 
found to be largely serosubtype specific, with responses to the remaining panel of PorA labelled 
microsphere largely unaffected. A 1.78 fold increase was determined using P l.7 -2 ,4  labelled 
microspheres for C l, however this may have been due to the low IgG concentrations determined 
for this sample. Clearance of meningococcal isolates on individuals C6 and C9 was found to have 
a non-serosubtype specific effect (Figure 6.7). Increases in IgG concentration were determined 
against all PorA serosubtype labelled microspheres for C6, known to have cleared carriage of a 
meningococcal isolate with a P l.5 -1 ,10-1 serosubtype. A minimum 1.49 fold increase was 
observed against P l.5,2 and P l.7,16 labelled microspheres and a maximum 2.31 fold increase 
observed in response to P I .19,15 labelled microspheres. Decreased IgG concentrations were 
observed for C9 against P I . a n d  P l.7,16 labelled serosubtypes, with a 0.60 and a 0.85 fold 
difference observed, respectively. Increased IgG responses were determined against the  
remaining panel of PorA labelled microspheres. The maximum increase in IgG titre was
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determined against P l.5 ,2  labelled microspheres, homologous to the serosubtype of the carriage 
isolate (Table 6.6).
BCarriage £  1.5 
*5
B Cleared 2  1-0 
o
“■ 0.5
E Cleared
Microsphere serosubtype Microsphere serosubtype
■  Carriage 
H Cleared
B Carriage £  1.5 
B Cleared 2
Microsphere serosubtype Microsphere serosubtype
Figure 6.7 Fold difference between tim e points for individuals known to have cleared carriage of 
meningococcal isolates. Sera responses to specific serosubtypes was determined following 
analysis with the Liquichip assay. IgG titres were determined using a standard curve composed of 
pooled sera from healthy laboratory workers vaccinated with either the P l.7,16 or the P l.7-2 ,4  
OM V vaccine. Three samples were analysed for each individual in order to determine increases in 
serosubtype specific IgG responses both prior to and post clearance of the meningococcal isolate. 
Samples were collected over a 24 week period for each individual with the exception of C9 where 
t  = 12 weeks. Individuals C l and C2 were found to have cleared carriage of a meningococcal 
isolate with the P l.21,16 serosubtype. C6 and C9 were found to have cleared carriage of 
meningococcal isolates with the P l.5 -1 ,10-1 and P l.5,2  serosubtypes, respectively. W here the 
homologous serosubtype was not included in the Liquichip assay, sera responses were  
determined against the closest microsphere set.
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Figure 6.8 IgG titres for sera from individuals C3 and C5, known to have cleared carriage of a 
meningococcal isolate w ith a P l.21 ,16  serosubtype. Individuals were found to be carriers of 
meningococci at initial sampling, and again at t = 12 weeks, however were found to have cleared 
meningococcal carriage at t  = 24 weeks. Whilst the homologous serosubtype was not tested, IgG 
responses were expected to be directed to P l.7,16 labelled microsphere. Titres were determined 
using a standard curve composed of pooled sera from healthy laboratory workers vaccinated with 
either the P l.7,16 or the P l.7-2 ,4  OM V vaccine.
Elevated IgG concentrations, determined using the P l.7,16 labelled microspheres, preceded 
clearance of a meningococcal isolate with a P l.21,16 serosubtype for individuals C3 and C5 
(Figure 6.8). Low IgG levels were found in response to all remaining PorA labelled microspheres. 
An increased IgG response, specific to the P l.7,16 serosubtype, was observed for individual C3 
preceding clearance although this was not found to be a two fold increase. A decrease in IgG 
response was observed for C5.
Non-specific decreases in IgG concentrations were determined using the panel of PorA labelled
microspheres for three individuals (Figure 6.9). No difference in IgG response was found prior to
and post clearance of the carriage isolate for individuals C4 and C8, known to have cleared
carriage of a meningococcal isolate with a P l.21,16 and a P l.5 -1 ,10-26 serosubtype, respectively. 
Whilst C l l  was found to have elevated IgG titres following detection with the P l.7 -2 ,4  labelled 
microsphere, decreased IgG responses were observed for all other serosubtypes of PorA using the
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panel of labelled microsphere both prior to and post clearance of the carriage isolate with a P l.5 -
1,2-2 serosubtype.
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Figure 6.9 Fold difference between tim e points for individuals known to have cleared carriage of 
meningococcal isolates. Sera responses to specific serosubtypes was determined following 
analysis with the Liquichip assay. IgG titres were determined using a standard curve composed of 
pooled sera from healthy laboratory workers vaccinated with either the P l.7,16 or the P l.7-2 ,4  
OMV vaccine. Three samples were analysed for each individual in order to determine increases in 
serosubtype specific IgG responses both prior to and post clearance of the meningococcal isolate. 
Samples were collected over a 24 week period for each individual with the exception of C l l  
where t = 20 weeks. Individual C4 was found to have cleared carriage of a meningococcal isolate 
with the P l.21,16 serosubtype. C8 and C l l  were found to have cleared carriage of 
meningococcal isolates with the P l.5 -1 ,10-26 and P l.5-1 ,2-2  serosubtypes, respectively. Where  
the homologous serosubtype was not included in the Liquichip assay, sera responses were 
determined against the closest microsphere set.
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The general trends observed using this data, appear to suggest the presence of pre-existing anti- 
PorA antibodies in sera, found at a low concentration in serum from individuals not found to be 
carriers of meningococcal isolates. Acquisition of carriage was accompanied by a greater than 
two-fold increase in antibody titre directed against the serosubtype of the meningococcal isolate. 
Specificity of this increase varied between individuals, with increases in IgG titre determined 
against heterologous PorA serosubtype observed with some individuals. This may suggest cross­
reactivity of the antibody through the VR3 region or PorA, or the boosting of a pre-existing 
immune response. Increases in IgG titre were detected within eight weeks of the onset of 
carriage, with increasing titres observed as carriage was established. IgG titres of serosubtype 
specific anti-porA antibodies largely unchanged over a period of persistent meningococcal 
carriage, suggesting a maintenance level of antibody was achieved, sufficient to provide 
protection against infection, but insufficient to support clearance of the meningococcal isolate. 
As with acquisition of carriage, clearance of meningococcal isolates was found to be associated 
with a greater than two fold increase in serosubtype specific IgG titres, directed against the 
serosubtype of the meningococcal isolate immediately prior to clearance. However, it is 
important to remember the Liquichip is a measure of antibody binding, not a measure of 
functional bactericidal antibodies, and increases in IgG titres directed against heterologous PorA 
serosubtypes may not be associated with an increase in bactericidal antibodies. All sera samples 
were run in duplicate at two dilutions in order to achieve an antibody concentration within the 
linear range of the Liquichip assay.
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6.3.2 Association of circulating PorA levels w ith increases in IgG concentration in healthy 
human sera from  England and Wales over a 16 year period
To study the distribution of PorA serosubtype specific antibodies, serum from 500 randomised 
individuals, aged 15 to 19 years of age, were chosen to represent distribution of PorA specific 
antibodies across England and Wales. No information was available on the carrier status of these 
individuals and the use of randomised sera did not allow for paired samples to be analysed. 
These sera were used to study circulating PorA levels across the population, with 100 serum 
samples picked from every fourth year, from 1 9 9 0 -2 0 0 6 . Sera were analysed using the Liquichip 
assay and IgG responses were determined using the PorA-labelled microspheres. As stated 
previously, due to lack of an appropriate standard, it is not possible to make direct comparisons 
between IgG titres determined against the different PorA serosubtypes used in this assay. Trends 
can only be identified within the same microsphere sets.
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Figure 6.10 GMT in response to the panel of PorA-labelled microspheres for 500 samples from  
healthy individuals (error bars represent 95 % confidence intervals). Sera responses to specific 
serosubtypes were determined, following analysis with the Liquichip assay, using a standard curve 
composed of pooled serum from healthy laboratory workers immunised with either the P l.7,16  
or the P l.7-2 ,4  OMV vaccine.
Over a 16 year period, the lowest GMT was determined using P l._ ,_  labelled microspheres, whilst 
the highest GMT was found in response to the P l.5-2 ,10  serosubtype of PorA (Figure 6.10).
Strong correlation was observed between related protein variants, (P I.19,15 and Pl.19-1,15-11, 
r=0.71; P l.5 ,2  and P l.5-1,2-2, r =0 .69), whilst unrelated variants correlated poorly (r ~0.1).
6.3.2.1 Geometric mean titres stratified by year
To follow the distribution of circulating PorA-specific IgG from 1990 -  2006, samples were 
stratified by year, with 100 sera samples used from each fourth year. An equal number Of serum 
samples, collected from individuals from each age group, were chosen and stratified by the year 
in which sera was collected.
Table 6.8 GMT separated by year for each PorA variant. 100 samples were used for each time  
point, with sera from 20 individuals from each year of age from 15 to 19 year olds, chosen from  
the SEU collections. Sera responses to specific serosubtypes were determined, following analysis 
with the Liquichip assay, using a standard curve composed of pooled sera from healthy laboratory 
workers immunised with either the P l.7,16 or the P l.7-2 ,4  OMV vaccine.
Serosubtype 1990 1994
Year of collection 
1998 2002 2006
Pl._ ,_ 0.21 0.71 0.28 0.14 0.33
P l.5-1 ,2-2 0.68 2.29 0.51 0.54 1.39
Pl.5,2 0.91 2.79 0.69 0.80 1.42
P l.5-2 ,10 2.60 4.27 1.29 1.89 3.10
P I.19,15 2.76 3.66 1.08 . 1.70 2.91
Pl.19-1,15-11 1.16 3.42 0.88 1.41 2.30
Pl.7,16 1.15 3.53 0.96 0.87 2.12
Pl.7-2 ,4 0.97 2.39 0.58 0.68 1.06
Distribution of anti-PorA specific IgG was found to vary between 1990 and 2006 for all 
serosubtype of PorA used in this study (Table 6.8). Whilst the magnitude of the GMT varied for 
individual serosubtypes of PorA and direct comparison between serogroups cannot be made, 
increased titres of all antibodies specific to the panel of PorA labelled microspheres used in this 
study were found in 1994 and to a more limited extent in 2006. The lowest GMT observed for all 
serosubtype with the exception of P l._ ,_  in the 1998. All variants appear to show a similar
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pattern in GMT over this time period. The lowest GMT, for sera collected in every year group, 
was observed in response to the PorA mutant P l._ ,_  labelled microspheres (Figure 6.11). No 
differences were apparent between GMTs for samples collected in 1998 and 2002 for the majority 
of the PorA labelled microsphere panel.
Low GMTs were determined against P l.5-1 ,2-2  labelled microspheres for all years from which 
sera samples were chosen, with a significant increase in IgG titre observed for sera collected in 
1994. A secondary peak was observed for samples collected in 2006, although this was to a lesser 
extent than 1994, with GMTs of 1.39 and 2.29, respectively (Table 6.8). Similarly, an increase in 
GMT was determined using P l.5 ,2  labelled microspheres between 1990 and 1994, from 0.91 to 
2.79, respectively. A decrease in titre, to a minimum 0.69 was observed in 1998 prior to a second 
increase to a titre of 1.42 for sera collected in 2006. No difference was found between GMTs for 
sera collected in 1990,1994 and 2002 against either P l.5,2  or P l.5-1 ,2-2  labelled microspheres.
IgG titres raised in response to both these antigens would be expected to give a similar response, 
due to the related VR1 and VR2 regions. Disease incidence, largely attributed to the C: 2a: P l.5,2  
phenotype, continued to increase to a peak in 1998/1999 and may explain the increase in GMT 
titres observed in 1994. Introduction of the MCC vaccine in 1999 was found to result in a large 
reduction of carriage of serogroup C strains of meningococci, and would account for the decrease 
in GMT observed in 2002. Unexpectedly, the decline in GMT against these serosubtypes of PorA 
were also apparent in 1998, prior to introduction of the vaccine.
GMTs, determined using the P l.5-2 ,10 labelled microspheres, were found to increase from 2.60, 
for sera collected in 1990, to a maximum of 4.27 for sera collected in 1994. A decrease in titre  
was again found in 1998 to a minimum GMT of 1.29, followed by an upward trend in IgG titre, 
with increasing GMTs in 2002 and 2006.
Elevated IgG responses to P I.19,15 labelled microspheres were found in sera collected in 1990  
and 1994, with a GMT of 2.76 and 3.66 found, respectively. A decreased GMT was observed in 
1998 and was followed by a small increase in titre found in 2002. A further increase was observed
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in 2006, with a GMT of 2.91. Similar titres were observed for sera collected in 1990, 1994 and 
2006. A large increase in GMT was determined using P l.19 -1 ,15-11 serosubtype labelled 
microspheres between sera collected from individuals in 1990, with a GMT of 1.16, and 1994 with 
a titre of 3.42. A decrease in GMT to a minimum of a 0.88 was observed in sera collected in 1998, 
followed by a second increase in IgG concentration in 2006.
Responses determined against both P I.7,16 and P l.7-2 ,4  labelled microspheres followed a similar 
trend. The maximum GMT, observed for both serosubtypes, was found in sera collected in 1994, 
with titres of 3.53 and 2.39, respectively. High frequencies of these serosubtypes were recorded 
in the UK in 1995(340). Decreased titres were observed in 1998 and 2002, prior to a second 
increase in IgG titre in 2006, though this increase was to a more limited extent in response to 
Pl.7-2 ,4  labelled microspheres.
Disease incidence attributed to meningococcal isolates expressing the P l.7,16, P l.5-2 ,10, 
Pl.19,15 and P i .19-1,15-11 serosubtypes of PorA have been in decline since 1993 as a result of 
herd immunity(126) and may explain the increased GMT against these serosubtypes observed in 
1994. Whilst reduction of carriage with the MCC vaccine resulted in reduction in carriage of 
serogroup C meningococci, reduction in serogroup B meningococci was not observed. Serogroup 
B meningococci have shown a higher phenotypic diversity than serogroup C isolates, and may 
explain the increase GMT determined observed against all serosubtypes of PorA in 2006. The 
presence of a peak GMT observed for all serosubtype of PorA in 1994 was not expected and 
known outbreaks have not been reported for that period. As previously stated, GMT are a 
reflection of total binding activity in sera, and not restricted to functional bactericidal antibodies.
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Figure 6.11 GMTs of IgG responses separated by year for each PorA variant (error bars 
represent 95 % confidence intervals). 100 samples were used for each tim e point, with 20 
individuals from each year of age from 15 to 19 year olds, chosen from the SEU collections. Sera 
responses to specific serosubtypes were determined, following analysis with the Liquichip assay, 
using a standard curve composed of pooled sera from healthy laboratory workers vaccinated with 
either the P1.7,16 or the P l.7-2 ,4  O M V vaccine.
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6.4 Discussion
The overall aim of the studies described in this chapter was to investigate the effect of 
meningococcal carriage on the serum IgG titres in different groups of individuals and potential 
changes in exposure to meningococcal isolates overtim e.
Carriage studies are of importance in providing information about the epidemiology and 
pathogenesis of meningococcal disease, and in the identification of risk factors for carriage. 
Closed communities such as military camps and college students, with increased levels of 
meningococcal carriage provide an environment in which to study the dynamics of meningococcal 
carriage and the immune response to carriage(152). A longitudinal study was used to study the 
effect of meningococcal carriage in first year university students over a period of up to 24 weeks. 
The carriage state of each student was determined as part of a separate study and the 
serosubtype of the meningococcal carriage isolate was identified, where applicable*25*. This 
allowed analysis of developmental trends and direct comparison between serum IgG 
concentrations and known carriage states. There are several stages involved in acquisition of 
meningococci including non-carriage, first encountering organism, persistent carriage, and 
clearance of carriage, all of which occur without symptom. As described previously, an increase in 
serosubtype specific antibody response can be used as an indicator in the evaluation of vaccine 
response and can also be used to determine carriage status of individuals. Carriage of 
meningococcal isolates tend to lead to the induction of SBA, however this assay measures binding 
concentrations of both functional and non-functional antibodies. Serum IgG levels were assessed 
using the Liquichip assay developed during the earlier part of this project. The use of multiple 
samples from the same individual allowed changes in IgG titres to be measured as both arbitrary 
concentrations and as an increase from the initial tim e point.
The lowest IgG concentrations were directed towards microspheres labelled with the P l._ ,_  PorA 
mutant in which VR1 and VR2 had been removed. As observed in previous chapters, the low MFI 
values determined in the standard sera using the P l._ ,_  labelled PorA protein would have
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resulted in elevated IgG titres. This suggested that anti-PorA antibody responses are largely 
specific to the VRs and not directed to the protein backbone of PorA, in contrast to the results 
observed with vaccinated sera in chapter 5 of this thesis. However, as noted in previous chapters, 
the analysis of antibodies in normal human sera is complex, with antibodies produced in response 
to whole meningococci as opposed to specific proteins and antibody responses of different 
individuals would be expected to differ as a result of previous carriage(364>, even after clearance of 
the meningococcal isolate.
Non-carriers had low IgG responses to the panel of PorA labelled microspheres. This is consistent 
with previously published results in which individuals with a low antibody response to all 
serosubtypes o f PorA were associated with non-carriers(254'152). The presence of low IgG 
responses determined in serum from non-carriers, as opposed to a lack of response, may be 
indicative of previous carriage. Whilst carriage of meningococcal isolates was not detected at the 
tim e of sampling, it is not known whether previous carriage of meningococcal isolates has 
occurred*153*.
New carriers were shown to exhibit a greater than two fold increase in serosubtype specific 
antibody concentration. This increase in antibody production was likely to have been stimulated 
by the presence of carriage isolates(152) in agreement with previously published data whereby 
meningococcal carriage is an immunising event resulting in the development of specific 
antibodies, homologous to the carriage strain(133). For the individuals in this study, an increase in 
titre of serosubtype specific antibodies was observed within eight weeks of the onset of carriage, 
whilst increases in antibody titre as early as two weeks following the acquisition of a 
meningococcal carriage isolate have previously been reported*114* Direct correlation was found 
between the amount of time that had elapsed between the gain of carriage and the tim e at which 
sera was collected, and the extent to which antibody responses were increased. The highest 
antibody titres were recorded at the furthest time point, up to 24 weeks following acquisition of 
carriage as shown by Individuals N3 and N5 (Figure 6.2). An increase in IgG concentration in 
response to all panel PorA serosubtypes was observed for individual N5, in particular the P I .19,15
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labelled microspheres. This may have been a result of previous carriage and clearance of 
meningococcal isolates with this serosubtype immediately prior to collection of the initial sera 
sample or the presence of antibodies binding to parts of the PorA protein other than the VR1 and 
VR2. This was demonstrated with the use of the PorA mutant (P l._ ,_). This protein was 
expressed as a PorA protein lacking VR1 and VR2, and pre-inhibition with this protein may prevent 
binding to epitopes other than the VR1 and VR2 of PorA. Some activity has been demonstrated 
against the VR3 region of PorA, and variants of the P l._ ,_  protein expressing differing VR3 
epitopes would have to be cloned. Elevated levels of PorA antibodies, produced in response to 
carriage are likely to play a role in the development of natural immunity to meningococcal 
disease*152*.
Specific IgG concentrations were found to be largely unaffected over the 12 - 24 week reporting 
period where persistent carriage was observed. Persistent carriage was not found to have a 
serosubtype specific effect on antibody titres with increases or decreases in IgG titres observed 
against many of the PorA IgG serosubtypes tested. In contrast to new carriers of meningococci, 
longevity of meningococcal carriage in persistent carriers was hot found be associated with IgG 
titres and little difference was observed against anti-PorA antibody titres in sera collected at 
t  = 12 weeks and t  = 24 weeks This suggested that this concentration of antibody acted as a 
maintenance level sufficient to protect against infection, but insufficient to support clearance of 
the carriage isolate *133* and carriage may persist over many months*8*.
Clearance of carriage isolates, as with acquisition of the meningococcus, was associated with a 
large increase in serosubtype specific IgG titre. This was found to be in the form of a greater than 
two fold increase in titre (Figure 6.6 and Figure 6.7), or elevated IgG titres (Figure 6.8) observed 
immediately prior to clearance followed by a reduced titre once the carriage isolate could no 
longer be detected. This suggests that these largely elevated levels of serosubtype specific 
antibodies resulted in an antibody concentration sufficient to clear meningococcal carriage, with 
responses to the remaining serotypes remaining largely unaffected. As the Liquichip multiplex
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assay is an antibody binding assay, a functional antibody assay, such as the SBA assay would be 
needed to determine whether this increase was due to the production of bactericidal antibodies.
Priming of the immune system through the use of vaccination would have a direct effect on the 
rate at which meningococcal carriage is cleared and the presence of circulating antibodies has 
been suggested as a more appropriate correlate of protection against meningococcal disease*33* 
than the ability to generate a memory response*14*. However the impacts of meningococcal 
vaccines on carriage rates have been varied. Polysaccharide vaccines were found to have little 
effect on carriage rates due to the rapid decline of antibody titres raised in response to these 
vaccines and insufficient antibody titres to prevent colonisation*135*. Introduction of the MCC 
vaccine was found to induce herd protection and a 66 % reduction was observed in 
nasopharyngeal carriage, in students aged 15 to 18 years of age, specific to both serogroup and 
clonal complex within the first year*187*. However the vaccine was not found to have an effect on 
the other serogroups, in particular, the prevalence of carriage of meningococci most commonly 
associated with serogroup B disease (members of the ST-41/44 complex) was unaffected by the 
introduction of the MCC vaccine*186*. W ith a lower prevalence of disease and carriage in 
vaccinated compared to unvaccinated individuals, benefits to older age groups have been 
observed with a significant herd immunity effect in those that have not been vaccinated with 
conjugate vaccines*187*. The use of OM V vaccines was found to result in reduced carriage rates 
and correlation has been demonstrated between anti-PorA antibody responses in sera from  
individuals vaccinated with an OMV vaccine and bactericidal activity*346*. Although vaccination can 
be used to prime the immune system, the rapid development and progression of meningococcal 
disease, means the stimulated response from immune memory may not occur quickly enough to  
protect against infection*228*. Therefore the presence of circulating antibodies may be critical for 
clinical protection against disease*33'82*.
Analysis o f Seroepidemiology samples
A seroepidemiology study was carried out using sera obtained from the HPA SEU to study the 
prevalence of serum anti-PorA antibodies in sera collected from 15 -  19 years olds around 
England and Wales over a 16 year period. These samples had been collected as part of clinical 
investigations for medical conditions other than Meningococcal disease and carriage status was 
unknown.
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Figure 6.12 Incidence of invasive meningococcal infection in 15 -  19 year olds in England and 
Wales (cases per 100,000 population). Data adapted from the epidemiological data reported by 
the HPA. The years from which sera samples were selected are shown by the arrows.
A peak in GMT was seen against all PorA serosubtype used in this assay, in 1994, with a smaller 
peak observed in 2006 and show inverse correlation with the incidence of meningococcal disease 
reported in this age range (Figure 6.12), with high GMT detected during periods of low disease 
incidence. Similar patterns in the GMT were detected in all the serogroups and may have 
occurred as a result of using geometric mean titres whereby data was pooled and the results were 
homogenised. The use of such methods, whilst allowing determinations in trend, can also result 
in the loss of ability to resolve individual responses to specific serosubtypes. In particular, with a 
25 % carriage rate estimated in 15 -  19 year olds(43,49) it is possible that high titres of anti-PorA 
serum antibodies present in few individuals show results determined within the overall group. 
Increased titre of anti-PorA antibodies detected in 1994 may have preceded an increase in disease
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association in 1995 and proportionately more disease cases were found to occur in the 15 -  19 
year age group following an age shift between 1994/95 and 1995/96(12G). The GMTs detected 
using the Liquichip assay were found to have declined for all anti-PorA antibodies in the 1998 sera 
samples, corresponding with an increase in disease incidence that continued to a peak in 
1998/1999(126). The increase in disease was largely attributed to the Serogroup C cases, due to  
the C: 2a: P l.5 ,2  phenotype however this is not reflected in GMT determined using the P l.5,2  and 
the P I.5-1,2-2 PorA labelled microspheres. Decreased antibody titres specific for the P l.5,2  and 
Pl.5-1 ,2-2  proteins observed in 1998 and 2002 reflect the decline in disease association resulting 
from introduction of the MCC vaccine(359'246'126,282). Whilst introduction of the serogroup C 
conjugate vaccine was found to result in a large reduction in carriage of meningococcal serogroup 
C strains, this effect was not observed for other serogroups(187), and may go some way to explain 
the secondary peak in 2006 with increased carriage of non-serogroup C meningococcal strains. A 
slight increase in meningococcal disease attributed to serogroup Y has been reported since 2007, 
and again may have been preceded by an increase in IgG titres to specific PorA serosubtypes 
detected using this assay.
The most common cause of meningococcal disease are Serogroup B meningococci, representing 
up to 69 % of disease cases in 1993/94, 46 % in 1996/97 and increasing to 87 % following 
introduction of the MCC vaccine. Serogroup B isolates have shown higher phenotypic diversity of 
serogroups than serogroup C isolates and a number of changes in strain population have been 
recorded over the assay period(126>. GMT titres in response to the P I.7,16, P I.5-2,10 P I .19,15 and 
P l.19 -1 ,15-11 PorA labelled microspheres were determined to have a similar GMT profile as 
observed with the P l.5,2  serosubtype PorA protein. Disease incidence attributed to 
meningococcal isolates expressing each of these serosubtypes have been shown to be in decline 
since 1993 possibly due to an increase in host/herd immunity(126). This natural immunity may 
account for the increase in GMT detected for sera samples collected in 1994 and in 2006, as 
previously stated, the Liquichip assay measures binding antibodies and not just bactericidal 
antibodies. This was further supported by the gradual accumulation of immunity to the
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meningococci expressing the P l.7-2 ,4  serosubtype of PorA following the predominance of strains 
expressing the P1.4 serosubtype.
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Chapter 7. G eneral Discussion 
7.1. Discussion
The most straightforward method of assessing immune responses against vaccines is the 
measurement of serum IgG titres directed against the vaccine. These methods alone are not a 
good measurement for the effect of vaccination alone and whilst IgG titres are a measure of 
antigen binding antibodies, the production of bactericidal antibodies cannot be conferred. 
Methods such as the SBA would also need to be performed for vaccine assessment, and the ability 
of the vaccine to produce a protective response. Whilst current ELISA based methods are well 
suited for the detection and quantification of serum IgG antibody titres against single analytes, 
the same cannot be said for multiple analytes. This requirement for multiple ELISA is both time 
consuming and costly in terms of serum volume for multiple analytes(167). A microsphere based 
multiplex immunoassay assay, such as the one described here, has several advantages over 
standard ELISA. In theory, antibodies raised against 100 different antigens can be measured 
simultaneously due to the unique fluorescent signature of each microsphere set. The ability to 
multiplex the measurement of antibodies to multiple antigens within a single reaction resulted in 
a decrease in processing time, and a reduction in the volume of reagents and sera required for 
analysis in comparison to the standard ELISA(169). This is of particular importance in instances such 
as with the use of infant sera which may only be available in minute quantities. With the 
introduction of multivalent vaccines, such as Hexamen and Nonamen, the detection of multiple 
antigens within a single assay is advantageous. These vaccines have been found to be safe and 
immunogenic with responses to all of the vaccine serosubtypes detected. A new generation of 
vaccine has been produced based on Nonamen, utilising the detergent free extraction of OMVs, 
used to preserve the native (attenuated) LPS content and retains protective lipoproteins(154). As 
with Nonamen, this vaccine is based on three trivalent OMVs and has been shown to induce high 
SBA titres against all PorA serosubtypes included in the vaccine strain, and also elicited cross 
protection against meningococcal B strains with non-vaccine PorA serosubtype in pre-clinical 
trials(315'154).
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Although no comparison was made between the multiplex PorA assay and ELISA in this thesis, 
previous studies have shown strong correlation between multiplex immunoassays and ELISA using 
both meningococcal and pneumococcal capsular polysaccharides(229'230'78'167'168'242'94,67'194>. Studies 
have also been performed to evaluate the use of a microsphere based multiplex assay for 
antibody response to organisms including: Hib bacteria; measles virus, mumps virus and rubella 
virus; Diphtheria toxin; pertussis bacterium; Clostridium tetani (the Tetanus causing bacteria); and 
Hepatitis C virus^66'96'285'326'278), j h e small volumes of serum required along with the time and cost 
effectiveness of a multiplex assay in relation to the more traditionally used detection methods are 
highlighted in each case.
In this thesis a multiplex immunoassay, based on Luminex technology was developed and 
validated for the simultaneous detection and quantification of serum IgG responses to a panel of 
seven serosubtypes of PorA along with a VR1/VR2 deleted mutant. Assay suitability was 
determined using pre-clinical trial sera; clinical trial sera; and sera from carriage studies. The 
developed assay was found to be specific, sensitive and reproducible. Several variants of target 
antigens were amplified, cloned and used to express of protein resulting in the purification of 
eight PorA proteins, three PorB proteins and five FetA proteins as described in Chapter 3. Four 
variants of the fHbp  were also cloned but were not used for protein expression as a result of time 
constraints. All of these proteins can be used as antigens within the liquichip assay, but only the 
PorA proteins have been used in this study.
For the purpose for this study, highly purified PorA proteins, established to include the PorA 
serosubtype expressed by the most commonly circulating meningococcal isolates were used to 
create a panel of PorA-labelled microspheres for use in the development of the microsphere 
based immunoassay described in this thesis. A VR1/VR2 (P l._,_) deleted mutant was also 
included in this panel to detect the presence of antibodies binding to regions of PorA other than 
VR1/VR2. His-tagged PorA proteins were conjugated to nickel coated microspheres ensuring that 
the proteins immunogenic epitopes were accessible to serum antibodies, this was confirmed 
using monoclonal antibodies, specific to the VR1 and VR2 epitopes of PorA. An important
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consideration for multiplex assays is the possibility of interference or cross-reactivity (167). 
However, the use of mouse monoclonal antibodies demonstrated no evidence of cross-reactivity 
or interference was found to exist between the microsphere sets and the assay was found to be 
equally sensitive whether used for the detection of a single or multiple analytes. This was 
consistent with other studies on the multiplex immunoassay(167,67). Minimal intra- and interassay 
variation was found when repeat samples were analysed and the resulting CVs were comparable 
to those previously reported for multiplex immunoassays(40'167). Assay specificity is of particular 
importance in the development of any multiplex assay as this may result in the reporting of false 
negative, or false positive results. Specificity of the multiplex PorA immunoassay assay was 
demonstrated with the use of MAbs and cross-reactivity was only observed between related PorA 
variants. This was further supported by inhibition experiments using MAbs incubated with 
purified proteins. The assay was not found to be as specific using human adult serum and a 
reduction in the reactivity of human serum was observed following inhibition studies with 
recombinant proteins, on both homologous and unrelated serosubtypes. However, this cross- 
reactivity can be explained by the presence of pre-existing antibodies in human sera. Since 
humans are carriers of meningococci, the presence of anti-meningococcal antibodies in adult sera 
will influence the immune response initiated in response to a new infection or vaccination(113). 
Non-specific binding of human serum antibodies directly to the beads has previously been 
suggested(339), however, the use of the VR1/VR2 deleted mutant labelled microspheres showed 
this was not the case in this study.
As described in this thesis, the multiplex PorA assay was successfully used for the detection of 
increases in serum IgG titres against specific PorA serosubtypes following vaccination with one of 
four different OM V vaccines in preclinical and clinical trial sera. Increased GMTs were determined 
against all PorA serosubtypes included in the multiplex assay panel using murine and human 
toddler/child sera following vaccination with either HexaMen or Nonamen(316). Low antibody titres 
were detected in pre-vaccination and unvaccinated control sera confirming the absence of pre­
existing anti-PorA antibodies. Antibody responses detected in the post-vaccination sera are
therefore likely to have been produced in response to vaccination. The highest GMT was 
detected in sera following the booster dose of the vaccine, with similar responses determined 
following vaccination with three doses of either the HexaMen or the NonaMen vaccine. Although 
only a small number of samples were analysed, the vaccine response was variable between 
individuals, with high antibody titres determined against all PorA serosubtypes in one serum 
sample following one dose of the HexaMen, and titres lower than pre-vaccination sera titres in 
another. This highlighted the need for analysis of pre- and post-vaccination sera from the same 
individual, to allow for the vaccine response to be determined particularly where sample size is 
small.
Increased IgG titres were also determined against specific PorA serosubtypes in human adult sera 
immunised with both the P l.7,16 or the P l.7-2 ,4  OM V vaccines as previously reported(267). 
However, as previously mentioned, immune responses were found to be dependent on the 
individual rather than the vaccine with the presence of high and low responders to the OMV  
vaccines. The use of monoclonal antibodies found the assay to be specific with no cross reactivity 
observed between microsphere sets. Inhibition with the P l._ ,_  protein was not found to affect 
the antibody responses determined against the heterologous PorA labelled microspheres, with 
the exception of the P l.7,16 and P l.7-2 ,4  serosubtypes of PorA, where a slight decrease was 
observed, and is likely to be due to the VR3 epitope of PorA homologous to these proteins. This 
confirmed the majority of antibody binding was directed against VR1 and VR2 epitopes. As with 
the inhibition study, the presence of pre-existing antibodies in adult sera, detected using the PorA 
assay, may have appeared as non-specific responses to the vaccine, or may have been boosted 
following vaccination. It is likely that increasing the scale of this study would have resulted in 
findings similar to those previously reported(92<267).
This assay is likely to be useful in the evaluation of complex vaccine formulations containing a 
number of different PorA serosubtypes. The Liquichip assay can therefore be tailored for the  
assessment of individual vaccines, with only the serosubtypes of interest included in the protein 
labelled microsphere panel. The multiplex assay can easily be adapted for use in any number of
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studies with flexibility in the number of PorA serosubtypes to be tested and the serosubtype 
variants used within the assay. Use of an assay such as this has a valuable role in determining the 
effects of vaccination, not only on the PorA serosubtype homologous to the vaccine strain(s) but 
also on heterologous PorA antigens within a single reaction thereby allowing determination of the 
cross-protective effect of vaccination on any number of PorA serosubtypes.
An alternative use for this assay in addition to vaccine evaluation, would be of use for 
immunological studies of meningococcal carriage with antigenic variants of interest included in 
the microsphere panel. Due to the high genetic diversity of PorA, and the changing serosubtype 
prevalence of meningococci, it is necessary to monitor circulating strains, particularly in regions 
where the vaccine strain may need to be adapted*9*. However the current method for 
determining meningococcal carriage is time, reagent and labour intensive and may explain why 
current carriage studies in Europe are limited, particularly at a serosubtype level. The ability to 
adapt the PorA multiplex immunoassay to include up to a 100 variants of interest can be of 
benefit both for longitudinal and cross-sectional carriage studies resulting in the high throughput 
of sera in a time and cost effective manner with a reduction in the volume of sera required. This 
was shown through the use of the PorA multiplex assay to perform immunological analysis on 
carriage samples collected as part of a study to evaluate the effect of meningococcal carriage in 
first year university students over a period of up to 24 weeks*25*. Differences in sera immune 
response determined against the panel of PorA serosubtypes highlighted, the known carrier state 
of individuals, with direct comparisons able to be made between IgG titres and known carrier 
states. Low IgG titres were found in sera from individuals determined to be non-carriers of 
meningococcal isolates consistent with previously published results*254'152*. New carriers were 
shown to exhibit a greater than two fold increase in serosubtype specific antibody concentration, 
possibly stimulated by the presence of carriage isolates(152). Increased IgG titres were found to  
correlate with the amount of time that had elapsed between gain of carriage and the tim e at with 
sera was collected. Elevated levels of PorA antibodies, produced in response to carriage are likely 
to play a role in the development of natural immunity to meningococcal disease*152*. Persistent
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carriers of the same meningococcal isolate were not found to have a correlation between 
longevity of carriage and IgG, with little difference observed in IgG titre over time. It has been 
suggested that this concentration of antibodies acted as a maintenance level*133*. The highest 
increase in serosubtype specific IgG titres was determined in individuals preceding cleared 
carriage of meningococci with a reduced IgG titre following clearance, with IgG titres to the other 
PorA serosubtypes largely unaffected. The Liquichip is a binding assay and as such was not able to 
determine the presence of functional antibodies following a period of carriage.
Suitability of the PorA multiplex assay for seroepidemiology studies was demonstrated using sera 
samples collected over a 16 year period across England and Wales, however mixed results were 
obtained from this study. Increases in specific anti-PorA antibody titres were found to correlate 
well with increased disease incidence*126*. In particular a peak in disease incidence in 1998 was 
largely attributed to the Serogroup C meningococci, with the C: 2a: P l.5,2  phenotype and was 
reflected in the increased GMT determined using the P l.5 ,2  and the P I.5-1,2-2 PorA labelled 
microspheres. Decreased antibody titres specific for the P l.5,2  and P l.5-1 ,2-2  proteins observed 
in 1998 and 2002 reflect the decline in disease incidence reported in England and Wales over this 
period (Figure 6.12) this is particularly evident following introduction of the MCC vaccine in 
1999*126'282*. Similar trends were observed in the IgG titres against all serosubtypes of PorA, 
however with a decline in disease incidence attributed to meningococcal isolates expressing each 
of these serosubtypes*126*, natural immunity may account for the increase in GMT detected for 
sera samples collected in 1994 and in 2006 corresponding to a decrease in disease incidence, 
however as previously stated, the Liquichip assay measures binding antibodies and these may not 
be bactericidal antibodies.
There are many advantages of Liquichip assay in comparison to use of the ELISA, not least of 
which is the reduction in the amount of time, reagents, and sera required for the analysis of IgG 
responses to multiple antigens within a single serum sample. Flexibility of the Luminex system 
has allowed for the conjugation of different types of biological molecules to the microsphere 
including capsular polysaccharides, lipopolysaccharides, cytokines and nucleic acids and assays
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developed using this molecules have been the subject of many studies(229'230,78'167'168'242'94'67'194'53,. 
Whilst the majority of meningococcal studies performed using the multiplex assay have been 
based on the capsular polysaccharides*167'168'67*, the assay described in this thesis focused on the 
detection of serum antibodies specific to the outer membrane protein, PorA. This is of particular 
importance following the development of vaccines based on components of the meningococcal 
outer membrane as opposed to capsular polysaccharides. Use of the multiplex assay ensures the 
immune response to multivalent vaccines can be determined without the need for large volumes 
of serum and therefore well suited for the evaluation of vaccine immunogenicity in infants and 
small children. The main advantage over a multiplex assay such as this over the more traditionally 
used ELISA is adaptability of this system to evaluation response to any number of antigens 
without increasing specimen volume or processing time*168* and a multiplex immunoassay has 
been developed to evaluate serum response to 14 capsular polysaccharides*30*.
The liquichip assay was found to be a useful tool in the evaluation of vaccine, however it cannot 
be used as a functional assay, and the effect of vaccination on bactericidal antibodies would have 
to be measured using a SBA assay. SBA values have long been used as a measure of vaccine 
efficacy however good correlation between antibody titres determined using ELISA and functional 
activity determined using SBA has not always been reported. Good correlation between SBA and 
ELISA in sera from adults, toddlers and infants was reported following immunisation with the MCC 
vaccine*277*. However poor correlation was reported in infant sera following vaccination with a 
polysaccharide vaccine, with no bactericidal activity detected despite high serum antibody 
responses*176'197*. Whilst antibody dependant bactericidal activity will be reflected in the 
responses determined using the Liquichip assay, antibody independent activity will not. IgM 
antibodies may also contribute to SBA activity, and again cannot be not quantified using the assay 
develop in this study. SBA values for the sera used in this study would have been useful in the 
evaluation of non-specific responses in sera for both vaccine, and carriage studies, and provided a 
useful link between vaccine response and non-protective antibodies. Whilst the vaccines used in 
this study are largely based on the immunogenicity of PorA, the effect of vaccination on IgG titres
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to other meningococcal antigens would be advantageous, particularly with the OM V vaccines. 
Addition of the PorB and FetA antigens to the panel of protein labelled microspheres would allow 
further evaluation of the vaccines on individual IgG responses, and alongside SBA would be useful 
for determining the effectiveness of a vaccine to produce a broadly protective response. In 
England and Wales, peaks in meningococcal disease have been associated with meningococcal 
isolates expressing either the PorB 2b or the 2a serotype in 1973-75(240), isolates expressing the 
PorB 15 serosubtype in the 1980s(240), and more recently meningococci isolates expressing the 
serotype 4 of PorB(48). Use of the Liquichip to determine IgG titres against these serotypes could 
be a useful tool for the determination of trends in the prevalence of meningococci isolates 
expressing different serotypes of PorB
The high sensitivity and specificity of the assay has allowed for the discrimination of antibody 
responses to several antigenic variants of the PorA protein. The use of pooled mouse monoclonal 
antibodies can be used for the quantification of antibodies in murine serum. However, 
comparison of immune responses to the different serosubtypes is hindered by the lack of a 
suitable human reference serum and known antibody levels within the reference serum. For the 
purpose of this thesis, sera collected from healthy laboratory workers immunised with three 
doses of the P l.7 ,16  or the P l.7-2 ,4  OM V vaccine were pooled for use as a human standard. Sera 
from these individuals were assumed to contain high levels of IgG antibodies against a wide range 
of PorA serosubtypes, as a result of both vaccination and routine exposure to meningococcal 
isolates within the laboratory. This was confirmed using the PorA assay with the detection of 
specific anti-PorA antibodies against all PorA serosubtypes included in the microsphere panel. 
However, due to the lack of an appropriate standard the concentration of serosubtype specific 
anti-PorA antibodies could not be quantified. An arbitrary antibody concentration was assigned 
for the level of IgG antibodies determined against each PorA serosubtype in the pooled sera. All 
human sera antibody responses determined using this assay were quantified in relation to this 
standard. As a result, direct comparison between the IgG concentrations determined against 
each of the PorA serosubtype could not be made. Where available, the use of sera collected both
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prior to and post vaccination or episode of carriage helped to overcome this issue with 
differences in pre- and post-sera IgG responses used to compare the effect on serosubtype 
specific anti-PorA IgG concentrations. However the effect of vaccination or carriage on an 
individual could not be made where pre- and post- serum was not available.
The lack of commercially available antigen coated microspheres and the high cost of reagents 
required for assay development are limitations to this assay. Production and subsequent 
validation of both specificity and sensitivity must be performed both in the capacity o f a 
monoplex and multiplex assay prior to use of the assay*285*. However, the advantages of an assay 
such as this outweigh the limitations with significant savings both in time, reagents and sera once 
the assay has been established.
Protein refolding could not be analysed, due to use of Triton X-100 in the purification process, 
however the correct conformation of the VR1 and VR2 epitopes were assumed with the use of 
monoclonal antibodies specific to these regions of the PorA protein. In order to analyse this more 
fully, proteins would need to be purified using an alternative solubilisation reagent, such as Octyl 
glucoside, octyl thioglucoside or 3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate 
(CHAPS) all of which can easily be removed from final purified protein extracts using dialysis*11,12*.
Further developm ent
The first step in using the assay to its full potential would be the development of an extended 
panel of antigen labelled microsphere sets which can be selected for use in the assay. W ith the  
high antigenic diversity of PorA, and the availability of 100 different microsphere types, all of 
which can be included within a single assay, expansion of the protein labelled microsphere panel 
to include further serosubtypes of PorA would be of benefit. The production of such a diverse 
panel of PorA labelled microspheres would allow for the development of tailor-made assays to be 
used for seroepidemiology studies of meningococcal carriage and the evaluation of vaccines 
containing multiple serosubtypes of PorA. Determination of vaccine induced sera IgG responses 
could be limited to vaccines strains, or expanded to include other serosubtypes of interest in
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order to determine the cross-protectiveness of the vaccine without the need for extra sample 
volume or tim e. The use of synthetic peptides corresponding to the variants of PorA VR1 or 
VR2 (1" ) to label microspheres would allow more detailed analysis of immune responses induced 
as a result of vaccination or carriage. In addition to PorA, further development of this assay can 
be performed to include the use of alternative antigens including PorB, FetA fHbp and other 
vaccine antigens either in combination with the PorA multiplex assay or as a separate assay. As 
previously described, the detection of immune responses against multiple antigens has not been 
found to affect the outcome of the assay. IgG concentrations determined against pneumococcal 
and meningococcal capsular polysaccharides were not affected following the addition of 
meningococcal polysaccharide labelled microsphere sets into a multiplex assay for detection of 
immune responses directed towards pneumococcal capsular polysaccharides*168*.
Further development of the work presented would include expression and characterisation of the 
fHBP proteins cloned in Chapter 3, preferably in the absence of Triton X, in order to allow protein 
refolding studies, such as to be performed. These proteins along with recombinant his-tagged 
proteins produced using five antigenic variants of FetA, and three variants of PorB could be used 
to label microsphere beads for use in the Liquichip assay. These variants are representative of 
those that are commonly found in the UK (FetA F l-5, F3-3, F3-6, F3-9, F5-1, and PorB 2a, 4 and 15) 
and those that are representative of hyper invasive lineages*314*. Following validation, this assay 
could be used in a similar experiment to the PorA assay, to determine the contribution of 
different antigenic variants to the immune response and used to expand the work described in 
thesis to include greater sample numbers for the evaluation of HexaMen, NonaMen, MenBvac 
and MeNZB and Seroepidemiology studies.
Further work in the development of this study, would also include production of highly purified 
his-tagged proteins to be used as antigens in the Liquichip assay and would include the use o f 
surface membrane proteins including those identified using reverse vaccinology, such as IMadA, 
NHBA and other components of the OMV. These proteins are currently in use as vaccine antigens 
and development of an assay to determine immune responses following vaccination with these
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antigens could be used in combination with SBA to determine vaccine efficacy. If the project was 
started now, these would be the antigen targets selected, due to their inclusion in the 4CMenB 
vaccine. Priority for the selection of antigens used in this assay must be given to the antigen 
includes in vaccines currently in development as this is where the assay is most likely to be of use. 
Production of a library of protein labelled microsphere could then be used to develop a vaccine 
specific assay, with the inclusion of vaccine strains or non-vaccine strains for each antigen 
included as required.
Expansion of the experiments performed in this study to include larger sizes for both carriage and 
vaccine studies could be performed. These would include the use of pre- and post-vaccination 
sera as vaccine responses were found to vary between individuals, and low vaccine responses 
observed particular where high IgG titres were determined in pre-vaccination samples.
Correlation between IgG titres determined using the liquichip assay and ELISA would need to be 
performed, as this is the accepted method used for the measurement of vaccine induced IgG 
responses. Additional correlation between the Liquichip and SBA would need to be established.
In conclusion, a meningococcal PorA multiplex immunoassay described in this thesis was found to  
be a rapid, specific and reproducible method in which IgG responses to seven serosubtypes of 
PorA can be determined. These responses can be determined simultaneously with the 
requirement for only a very small volume of sera. Advantages of small sera volumes, high 
throughput of sera and simplicity of this assay/make the PorA multiplex assay a viable alternative 
to the standard ELISA. The ease with which additional serosubtypes and novel antigens can be 
introduced into the multiplex will help to speed up in determining the complete immune 
response to vaccination or carriage of meningococcal isolates. The optimal study population of 
and vaccine for the Liquichip assay described in this thesis, would be infant sera following 
immunisation with a multivalent PorA vaccine, such as Hexamen and Nonamen. The ultimate 
goal would be the use of an extended assay used for the evaluation of responses to a multi- 
component vaccine.
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Appendices
Appendix 1. Alignment of deduced amino acid sequences of the Neisserial OMP genes porA, 
porB, FetA and fHbp. The alignm ents were carried ou t using Vector NTi software.
Alignment of deduced amino acid sequences encoding seven PorA serosubtypes and a VR1 and 
VR2 deleted m utant (P l._ ,_)
PI.19,15 
PI. 19-1,15 
PI.5-1,2-2 
PI.5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4
PI.19,15 
PI. 19-1,15- 
PI.5-1,2-2 
PI .5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4 
p l - _ ' _
PI.19,15 
PI. 19-1,15- 
PI.5-1,2-2 
PI.5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4 
p l - _ ' _
PI.19,15 
PI .19-1,15- 
PI.5-1,2-2 
PI.5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4 
p l - _ ' _
PI.19,15 
PI.19-1,15- 
PI.5-1,2-2 
PI.5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4
p l - _ ' _
PI.19,15 
PI.19-1,15- 
Pl.5-1,2-2 
PI.5,2 
PI.5-2,10 
PI.7,16 
PI.7-2,4 
PI. ,
-11
DVSLYGEIKAGVEGRN|Q^^^Jp(KS|PQ------V^^^JSRIRTKISDFGSFIGFKGSED
d vs ly g ei k ag ve g rn|q^ ^ ^ J p|ks|s q------V | ^ J H SRIRTKISDFGSFIGFKGSED
d vs ly g ei k ag ve g rn iq^ ^ ^ J lqni|q ------- pq^ J r| s ri rt k is d fg sf i gf kg s ed
d vsly g ei k ag ve g rn iq^ ^ ^ J lqni|-------- pq^ J r| s ri rt k is d fg sf i gf kg s ed
DVSLYGEIKAGVEGRNIQ|^|BlpniI-------- POj^pjSRIRTKISDFGSFIGFKGSED
DVS L YGEIKAGVE G R N l Q ^ H ^ Q ^ N 13^ 5 GQVKVT| ^ H | S R1RTK1S D FG S F1GFKG S E D 
DVSLYGEIKAGVEGRNIq^ ^ H ^ I ^ 66^ ^ ---V ^ 1 SRIRTKISDFGSFIGFKGSED
DVSLYGEIKAGVEGRN|Q--------------------------- SRIRTKISDFGSFIGFKGSED
LG|GLKAVWQLEQDVSVAGGGA§|WGNRESFfGLAGEFGTLRAGRVANQFDDAS|AIDPWDSNNi
■ii lg|g lk av w ql e qd vs v ag gg aH wgnresfS g l a g e f g t l ra gr v an qf d da s|aidpwdsnn| 
lg|glkav w ql e qd vs v ag gg a|rwgnresf|gla ge f gt l r a g r v a n q f d d a s k a i d p w d s n n v 
lg|glkav w ql e qd vs v ag gg aB w g n r e sf|gla ge f gt l ra gr v an qf d da s|aid pwdsnn| 
lg|glkavwqleqdvsvagggasc]wgnresfS gla ge f gt l ra gr v an qf d da s|aid pw d sn n|
LGDGLKAVWQLEQDVSVAGGGAHWGNRESF|GLAGEFGTLRAGRVANQFDDAS|AIDPWDSNNi
lg|glkav w ql e qd vs v ag gg aB w g n r e sf|gla ge f gt l ra gr v an qf d da s|a id pwdsnn|
lg|glkav w ql e qd vs v ag gg aB w g n r e sf|gla ge f gt l ra gr v an qf d da s|a id pwdsnn|
vas ql g if k rh dd m|vsv ry d sp|fsg fs g sv q fv p|
■11 VASQLGIFKRHDDM|VSVRYDSP|FSGFSGSVQFVpj
5KS ■ TRI- B advf^ a w  
B i d v p B a w
V A S Q L G IF K R H D D M lv S V R Y D S llF S G F S G S V Q F V P ^ ^ ^ ^ ^ H Q irE iS Q E ^ B A W
V A S Q L GIFKRH D DM|VS VR Y D S p| F S G F S G S VQ F VP PK s Q pH B A W
vas q l g i f k r h d d m s v s v r y d s p|f sgfsgsvqfvpa^ ^ B a y ' PA F';q| K Q H rpH H aW  
VA S Q L GIFKRH D DM|VS VR Y D S P|F S G F S G S VQ kdt _H nl^ H a w
VASQLGIFKRHDDMlvSVRYDSPlFSGFSGSVQFVP^^^^^^HBvlvi— |KVA|hB a w  
vasqlgifkrhddmsvsvrydsp|fsgfsgsvqfvp--------------------------- A W
g k p g s d v y y ag ln y kn gg f ag sy a fk y a|hanvgr|a fe lf l|g s-tsd|a kg td p lk n hq vh r l 
■ii g k p g s d v y y ag ln y kn gg f ag sy a fk y a|h anvgr|afe lf l|g s-tsd|a kg td p lk n hq vh r l 
gkp gs d vy y ag ln y kn gg f ag|yafkya|h anvgr|a felfl|gs|-sd|a k g td p lk n hq vh r l 
gkp gs d vy y ag ln y kn gg f ag|yafkya|hanvgr|afelfl|gs|-sd|a kg td p lk n hq vh r l 
gkpgs d vy y ag ln y kn gg f ag|yafkya|hanvgr|afelfi ]|gs|tsd|a kg td p lk n hq vh r l
GKPGSDVYYAGLNYKNGGFAG|YAFKYA|HANVGRNAFELFL(GS(-SDQAKGTDPLKNHQVHRL
gkpgs d vy y ag ln y kn gg f ag| yafkyaShan vg r na f el fl|gs|t s d q a k gt d pl kn h qv hr l
gkp gs d vy y ag ln y kn gg f ag|yafkya|kanvgr|afe lf l|gs|tsd|a kg td p lk n hq vh r l
tgg ye e gg l nl al a aq ld l se n|nk a k t k n s t t e i a a t a s y r f g n a v p r i s y a h g f d| iergkkg 
■ii tggyeegg l nl al a aq ld l se nB kak tk n s t t e i a a t a s y r f g n a v p r i s y a h g f d| iergkkg 
TGGYEEGGLNLALAAQLDLSENB— k tk ns t t e i a a t a s y r f g n a v p r i s y a h g f d f i e r g k k g 
tgg ye e gg l nl al a aq ld l se nB — k tk ns t t e i a a t a s y r f g n a v p r i s y a h g f d f i e r g k k g 
t gg ye e gg l nl al a aq ld l se nB kak t k n s t t e i a a t a s y r f g n a v p r i s y a h g f d|:ergkkg 
TGGYEEGGLNLALAAQLDLSENB— k tk ns t t e i a a t a s y r f g n a v p r i s y a h g f d f i e r g k k g 
TGGYEEGGLNLALAAQLDLSENB— k tk ns t te i a a t a s y r f g n a v p r i s y a h g f d| iergkkg 
tgg ye e gg l nl al a aq ld l se nB — ktk n s t t e i a a t a s y r f g n a v p r i s y a h g f d f i e r g k k g
ent sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
■11 e n t s y d q i i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
e nt sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
e nt sy d qi i a g v d y d f s k r t s a i v s g a w l k c n t g i g n y t q i n a a s v g l r h k f 
e nt sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
e nt sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
e nt sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f 
e nt sy d qi i ag vd y df sk r ts ai v sg a wl k|ntg ig n y t q i n a a s v g l r h k f
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Alignment of deduced amino acid sequences encoding three subtypes of PorB
PorB 2a v t l y g t i k a g v e v s r v k|agtyk§q gg ks k t|t q i a d f g s k ig fk g qe dl g ng|kai wq|eqkasiagtn
PorB 15 vtl y g t i k a g v eIsrB fHI— n|q|te|tt(t| i|d|g s k ig f kg q ed lg n g|kaiwq(eqkasiagt| 
PorB 4 VTLYGTIKAGVE|SRBHi— g|qBvs|et|t| i|d|gSKIGFKGQEDLGNg|k a IWq|eQKASIAGt|
PorB 2a sgw gn r qs f ig lk g gf gt|ragnln|vlk d|gdn|naw| sgsntedvlg|gti|rve|reisvrydspvf 
PorB 15 s gw gn r qs f ig lk g gf gB rIgI lnIvlk dIg d-InIwI sI s— d|lg^ J i^ B e|r| isvrydsp|f 
PorB 4 sgwgn r qs f ig lk g gf gB kI gIlnIv lk dIg d-InIwI sIs— d|lg^ B i||Be|r| isvrydsp|f
PorB 2a AGFSGSVQYVPRDNANDVDKYKHBKSSRESYHAGLKYENBGFFGQYBGBA|pA^BTDAERVAVNTANA
PorB 15 AG|SGSVQY^DNA|  ESYHAGBy|n|gff|Qy|g^ ^ M hQ B B g l n---------
PorB 4 ag| s gsvqy^ | dna|  esyhagB ^ I nI gffIqyIg^ ^ B qM 0! ^ 1---------
PorB 2a HPg|jDYQ|H gydandl|v s v a g q y e a a k n n|vgs|k g k k h e q t q v a at a ay rf g nv tp r vs y ah gf 
PorB 15 — |eky q|hr|v|gyd^ B lB sva|q^ J akBt|asn^ B — |qt|vaa t|a y r fg n vt p rv sy a hg f 
PorB 4 — e|-yq|hr|v|gydB ^ B sva|q^ B akBvB dny^ B — |qt|vaa t|a y r fg n vt p rv sy a hg f
PorB 2a k|k|n gv kd|n yqydqv|vgaB y df sk r ts a lv sa g wl kq g kg ag k ve q ta sm v gl rh k f 
PorB 15 K | L | H  B gn _Iy dQvIvgaI ydfsk r ts a lv sa g wlH gkgH k^ H taH v glrhkf
PorB 4 k| S F ^ ^ ^ B n _|YDQVBv GA|YDFSKRTSALVSAGWLBgkgM k^ H taM v GLRHKF
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Alignment of deduced amino acid sequences encoding four variants of the FetA protein
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
Fl-5
F3-3
F3-6
F5-1
aen na k v| l d t vt v kg d rq gs k ir tn i vt lq q kd e st at d mr el l ke e ps id f gg gn g ts q fl tl r gm gq n sv
aen na k v| ldt vt v kg d rq gs k ir tn i v t l q q k d e s t a t d m r e l l k e e p s i d f g g g n g t s q f l t l r g m g q n s v
a en na k va l d t v t v k g d r q g s k i r t n i v t l q q k d e s t a t d m r e l l k e e p s i d f g g g n g t s q f l t l r g m g q n s v
a e n na k v|ldt vt v kg d rq gs k ir tn i v t l q q k d e s t a t d m r e l l k e e p s i d f g g g n g t s q f l t l r g m g q n s v
d i k v d n a y s d s q i l y h q g r f i v d p a l v k w s v q k g a g|asa gi g at n ga ii a kt vd|qdl lk g ld k nw gv r ln
d i k v d n a y s d s q i l y h q g r f i v d p a l v k w s v q k g a g|a sa gi g at n ga ii a kt vd|qdllk g ld k nw gv r ln
d i k v d n a y s d s q i l y h q g r f i v d p a l v k w s v q k g a g f a s a g i g a t n g a i i a k t v d|qdl lk g ld k nw gv r ln
d i k v d n a y s d s q i l y h q g r f i v d p a l v k w s v q k g a g|a sa gi g at n ga ii a kt vd|qdllk g ld k nw gv r ln
s ps ds n eg v sy ga s vf gk e gn fd g lf s yn rn n ek|y eagkgfrnn|n gg kt v py s al dk r sy la k ig t|fgd|
sB B s n e g v s yg a sv fg k eg nf d gl fs y nr n|ek|y e a g k g f r n-v ng gk t v p y s a l d k r s y l a k i g t|fgdd
s | B SNEGVSYGASVFGKEGNFDGLFSYNRNl EKl YEAGKGFRN-DNGGKTVPYSALDKRSYLAKIGTl FGDD
s^ B s n e g v s yg a sv fg k eg nf d gl fs y nr n|ek|y e a g k g f r n-|ngg kt v py s al dk r sy la k ig t|fgd|
DHRIVLSHMKDQHRGIRTVREEF|vBa| D S R B i|rQvp|y r e t tQsntnlaytgi^ lgfve k ld a na yv l ek
d h r i v l sh m kd qh r gi rt v re ef|v|g d k|srB idrQ|pIy re ttQSn tn la y tg k|l gf ve k ld a na yv l ek
DHRIVLSHMKDQHRGIRTVREEFAVSBNSRlTIlRQ|plYRETTQSNTNLAYTGKDLGFVEKLDANAYVLEK
DHRIVLSHMKDQHRGIRTVREEFlvB^SRTllTRQlpiYRETTQSNTNLAYTGKDLGFVEKLDANAYVLEK
erysadd^ J gyagnv|g pn ht r it t rg an f n f d s r l a e q t l l k y g i n y r h q e i k p q a f l nB fkiedkH at
ery sa d ds g|gyagnv|g pn ht r it t rg an f n f d s r l a e q t l l k y g i n y r h q e i k p q a f l n|kf| i|t t: -n
|rys ad d kdngyagnv|gpnht r it t rgBnfn fd s r l a e q t l l k y g i n y r h q e i k p q a f l nB fI p|k^ M d
|rys ad d kd n gy ag n vv gp n ht ri t tr g§nfn fd s r l a e q t l l k y g i n y r h q e i k p q a f l n g e f e i s g k k| dp
d|  EKNKNBenBkBakBy|l|NPTKTDAG|y|EAIH|iB ftltgglr y dr fk v kt hd g kt vs s
|q— k^ H pmH H mkB a^ B t^ H yI lI nptktd I gvyI e a ih I igdftltgglrydrfkvkthdgktvss  
|k— B Al is ^ B T K ^ ^ B ,I' ^ H Yl Ll NPTKTDl Gl Yl EAIHl I H FTLTGGLRYDRFKVKTHDGKTVSS 
K |P K K ^ B Di EKAK^ H MB M Yi Li NpTKTDi Gi Yi EAiHi i H FTLTGGLRYDRFKvKTHDGKTvss
s n l np s fg v iw qp h eh ws f s|shn ya s rs p rl yd a lq th g kr gi i si a dg tk a er ar n te i gf ny n dg tf a an
SNLNPSFGVIWQPHEHWSFsjsHNYASRSPRLYDALQTHGKRGIISIADGTKAERARNTEIGFNYNDGTFAAN 
SNLNPSFGVIWQPHEHWSFsjsHNYASRSPRLYDALQTHGKRGIISIADGTKAERARNTEIGFNYNDGTFAAN 
SNLNPSFGVIWQPHEHWSFS(SHNYASRSPRLYDALQTHGKRGIISIADGTKAERARNTEIGFNYNDGTFAAN
gsy fw q ti k da la n pq nr h ds1avr ea v na g y i k n h g y e l g a s y r t g g l t a k v g v s h s k p r f y d t hB kll sa
GSYFWQTIKDALANPQNRHDS|AVREAVNAGYIKNHGYELGASYRTGGLTAKVGVSHSKPRFYDTHBkllSA
g s y f w q ti k da la n pq nr h| s aa vr e av n ag yi k nh gy e lg as y rt g gl ta k vg vs h sk p rf yd t hB kllsa
g sy fw q ti k da la n pq nr h( saa vr e av n ag yi k n h g y e l g a s y r t g g l t a k v g v s h s k p r f y d t h p k k l l s a
n p e f g a qv g rt wt a sl ay r f|n p n l e i gw r gr yv q ka|gsilB gQkdrI gIlenwrkgfgwi: ifanwkpl
n p e f g a qv g rt wt a sl ay r f|n pn le i gw r gr yv q ka tg s il a| g q k d r k g n l e n w r k g f g v n d B fanwkpl
NPE FGAQVGRTWTASLAYRFKNPNLEIGWRGRYVQKAEGSI lB gQKDR1g|LENWRKGFGVND|FANWKPL
n pe fg a qv g rt wt a sl ay r f|n p n l e i gw r gr yv q kaBg si lv|gqkdr| g|l e n w r k g f g v n d | fanwkpl
gkdtl n vn l sv nn v fn|fyyphsq|w t n t l p d v g r d v r l g v n y k f-
g k d t l n vn l sv nn v fn kf y yp hs q|wtn tl p|v g r d v r l g v n y k f-
gkdtl n vn l sv nn v fn|f y y p h s q h w t n t l?|v g r d v r l g v n y k f-
gkdtl n vn l sv nn v fn|fyyphsq|w t n t l p d v g r d v r l g v n y k f-
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Alignment of the amino acid sequences of fHbp variants used in this study.
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
fHbp
ox pep 13
ox pep 4
ox pep 19
ox pep 45
ox pep 13
ox pep 4
ox pep 19
ox pep 45
ox pep 13
ox pep 4
ox pep 19
ox pep 45
ox pep 13
ox pep 4
ox pep 19
ox pep 45
ox pep 13
ox pep 4
ox pep 19
ox pep 45
CSSG GGGVAADIG|GLADALTAPLDHKD k|l|
I I
, | s^ | n| l| l| aqgaekt| 
s ltl|s^Bn|l|l|aggaekt| 
SLTLHsB|NHL|L|AQGAEKTj
GD— slntgklkndk| srfdi
|ievdgk|itl|sgefq|ykq|hsa|talq|eqvq s | d 
ji evdgH i tl|s gefq|ykq|h sa|yalq| qvq se
J ievdgH itl|sgefq|ykqdhsaH alqiek^ B pH
)kievdg|tit la s ge f q|ykqdhsaH a lQiekM 1 pM
 d KB AKR(2FH GDB IGEHTl FDKLPKGl SAl Yl Gl AFGSdda|gkltytIDFAAKQGHGKIE
SG MVAKRQFR|GI Ii|GEH 
IYSLINQ S LVSGLG 
IP S LINQ S LVS G^GE H
FDKLPEGGR |Y|G|AFGSDDASGKLTYTIDFAAKQGHGKIE
lp|g-|a ey hg k af| sdda| gklty t id f aa kq g hg ki e
|l P|G-|AEYHGKAF|S DDA|GKLTYTI DFAAKQGHGK IE
HLK|PELNV|LAHY|K |D |K R H A V l|G H |L Y H iE K G |Y |L H FG|Q AQE!
hlk| pelnv| la^ H kI dkkrhaviI gH lyH aekgI yI l H
|peq :v|l 
hlk|pe|nv|
■  I I
|r| ig|a|k q-
| eig|a|k q-
H Ie i g| a| kq-
kad|k|hav il g dt|ygg|ekg| yhl| 
kad|k|hav il g dt|ygs|ekg|yhl|
fg|qaqe|
f geryqe|
fgd|aqe|
vgsaeve|a|g 
^gsaeve|a|g 
g^sa|v|i|r: k 
^gsa|v|i|r k
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